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ABSTRACT
Fe(II) localized on DNA can reduce hydrogen peroxide (H2O2) to form hydroxyl
radical, resulting in oxidative DNA damage. This oxidative DNA damage is an
underlying leading cause of cardiovascular diseases, neurodegenerative diseases, and
cancer. Sulfur and selenium antioxidants have been investigated for their prevention of
metal-mediated oxidative DNA damage, and sulfur- and especially selenium-containing
antioxidants prevent metal-mediated oxidative DNA damage, likely by radical
scavenging and sacrificial oxidation via metal coordination.
To determine how iron coordination results in DNA damage inhibition, Fe(II)
complexes with imidazole-thione and –selone ligands were synthesized to examine their
iron coordination modes (Chapter 2), electrochemistry (Chapter 2), and reactivity with
H2O2 (Chapter 3). N,N’-dimethylimdiazole thione (dmit) and –selone (dmise) ligands
were used since they resemble ergothioneine and selenoneine, thione and selonecontaining antioxidants naturally found in plants and animals. Dmit and dmise
coordination to Fe(II) increases the zwitterionic character of these ligands, and binding
occurs primarily through σ and π donation. Fe(II)-thione and selone complexes of the
formulae Fe(L)2Cl2, [Fe(L)2(NCCH3)2]2+, and [Fe(L)4]2+ complexes (L = dmit or dmise)
have ligand-based oxidation potentials ranging from 0.36 - 0.69 V, significantly higher
than their observed Fe(III/II) oxidation potentials. Thus, the thione and selone ligands
should undergo oxidation prior to Fe(II), possibly preventing iron-mediated oxidative
DNA damage.
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The oxidation of Fe(dmit)2Cl2 and Fe(dmise)2Cl2 complexes by H2O2 was
examined to determine potential antioxidant mechanisms (Chapter 3). Treatment of
Fe(dmit/dmise)2Cl2 with H2O2 showed sacrificial oxidation of the thione and selone
ligands; however, only dmise significantly protected Fe(II) from oxidation to Fe(III). If
similar iron-thione and –selone complexes form in vivo, these complexes may similarly
scavenge H2O2 to inhibit iron-mediated oxidative DNA damage.
A comparative mechanistic study required synthesis and characterization of
Zn(L)2Cl2 and [Zn(L)4]2+ complexes (L = dmit or dmise) as well as H2O2 oxidation
studies of Zn(dmit/dmise)2Cl2 complexes (Chapter 4). Dmit and dmise coordination to
non-redox-active Zn(II) occurs thorough σ and π binding, similar to their Fe(II) analogs.
However, the dmit and dmise ligand oxidation potentials decrease compared to unbound
dmit and dmise, indicating stabilization of the chalcogenones, opposite the effect
observed upon Fe(II) coordination. Treatment of Zn(dmit)2Cl2 with H2O2 showed dmit
oxidation; however, dmit does not undergo complete oxidation, since dmit-OH species
were observed by mass spectrometry. Unlike dmit, when Zn(dmise)2Cl2 was treated with
H2O2 complete oxidation of dmise was observed, similar to that observed for its Fe(II)
complex analog. These results indicate dmit oxidation is dependent upon the redoxactivity of the coordinated metal ion, whereas dmise oxidation is not metal dependent.
Novel thione- and selone-containing imidazoles were synthesized and
characterized with various substituents on the imidazole ring (Chapter 5). A novel
synthetic approach was also implemented for the synthesis of thione derivatives to avoid
the use of air-sensitive techniques. Addition of chlorine atoms in place of the imidazole
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ring hydrogen atoms in dmit increases its zwitterionic character compared to dmit;
however, no similar difference in zwitterionic character is observed for its selenium
analog compared to dmise. This difference suggests that the nucleophilicity of the Se
compared to the S in these chloro-substituted imidazole thiones is significant, with a
larger partially negative charge on the Se atom compared to its S analog even when not
bound to a metal. Use of trityl as a thione sulfur protecting group is a novel synthetic
route that allows facile synthesis of novel thione derivatives. Addition of a methyl-keto
substituent on an imidazole nitrogen atom may increase metal binding affinity of the
resulting thione due to an increase in zwitterionic character and a possible an increase in
ligand denticity through the available S and O atoms compared to methimazole and dmit.
Methimazole and its derivatives were also investigated for their ability to
coordinate Fe(II) and Zn(II) (Chapter 6). Since methimazole and 2-mercaptoimidazole
oxidize to their respective disulfides, the synthesis of Fe(II) and Zn(II) complexes with
these oxidized ligands was also investigated. When bound to Fe(II) and Zn(II),
methimazole and 2-mercaptoimdazole increase in zwitterionic character and bind solely
through the S atom via σ and π donation. The oxidized thione and selones bind through
their available nitrogen atom, forming seven-membered ring systems. These studies have
enhanced our understanding of the possible antioxidant mechanisms of thiones and
selones as well as provided proof that iron coordination is a major mechanism in
prevention of metal-mediated DNA damage.
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CHAPTER ONE
THIONE- AND SELONE-CONTAINING COMPOUNDS, THEIR LATE
FIRST ROW TRANSITION METAL COORDINATION CHEMISTRY,
AND THEIR BIOLOGICAL POTENTIAL

1.1 Biological components of sulfur and selenium
Sulfur and selenium are essential elements and are incorporated into amino acids
and enzymes.1-7 Sulfur has been very widely studied for its biological importance as well
as its excess and deficiency.8 Although the recommended dietary allowance for selenium
is low, 55-350 μg/day,9 selenium deficiency can lead to Keshan, Keshan-Beck, and
numerous neurodegenerative diseases.10 An excess of selenium, however, can also have
malnutritional effects such as garlic breath, selenosis, and selenium poisoning.10 Humans
obtain their nutritional needs for sulfur and selenium from milk, cheeses, garlic, eggs,
fruits, vegetables, Brazil nuts, grains, legumes, and meats.7 The main biological form of
selenium in humans is selenocysteine, which is synthesized in the body from dietary
selenium sources.8,10,11
Common sulfur and selenium compounds in biological systems include the amino
acids cysteine, selenocysteine, methionine, and selenomethionine (Figure 1.1).
Selenocysteine differs from cysteine by replacement of a single selenium atom in place of
sulfur, and has similar chemical properties; however selenocysteine has a lower pKa and
is a stronger nucleophile, making it much more reactive.12 Selenoproteins, including
thioredoxin reductases and glutathione peroxidases (GPx), are involved in redox
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Figure 1.1. Common biological sulfur and selenium compounds and antithyroid drugs.

reactions, electron transfer, and the synthesis of thyroid hormones; however, many of the
selenoproteins’ functions are not well elucidated. Cysteine and selenocysteine are often
found in proteins and enzymes bound to late-transition metal centers such as iron, copper,
and zinc.12
In contrast to the thiol and selenol functional groups of cysteine and
selenocysteine, the amino acids ergothioneine and selenoneine (Figure 1.1) feature either
a sulfur-carbon double bond (S=C, the thione functional group) or a selenium-carbon
double bond (Se=C, the selone functional group). These thione- and selone-containing
amino acids have the resonance forms shown in Figure 1.2, and belong to a class of
pharmacologically active N,S ligands widely used in treating thyroid disorders.13,14
Thione and selone compounds bind to metal ions through the sulfur or selenium atom as
well as any unsubstituted NH groups of the imidazole ring. Imidazole thiones and selones
have neutral and zwitterionic resonance forms; upon metal binding, spectroscopic data
are consistent with stabilization of the zwitterionic resonance form with more negative
charge on the sulfur or selenium atom,13,14 similar to thiolate and selenolate ligands.
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Figure 1.2. Resonance structures of an example imidazole thione (E = S) and selone (E = Se) compound.

Thione-metal coordination has been widely examined, but reviews do not
specifically discuss late-transition-metal complexes of these ligands. General
coordination chemistry of thione ligands was reviewed more than ten years ago by
Raper15 and Akrivos16, but significant advances have since been made in this field.
Reviews of multidentate (scorpionate) thione ligands and their coordination chemistry
were recently published by Spicer and Reglinski17 and Pettinari,18 but do not primarily
focus on late transition metal coordination chemistry. Selone-containing compounds are
scarce, and their metal complexes are correspondingly rare, so this area has not been
previously reviewed. This review focuses on describing the coordination chemistry of
thione- and selone-containing compounds with the late-first-row-transition metals,
especially studies that have been published in the past decade, and the biological
implications of this chalcogenone-metal binding.

1.2 Thione and selone compounds
Recently, thione- and selone-containing compounds have been primarily
examined for their antioxidant behavior and their metal coordination abilities1,14,19,20.
Antioxidant behavior of thione and selone compounds arises from several different
mechanisms, including reactive oxygen species (ROS) scavenging, GPx-like activity to
scavenge hydrogen peroxide, and binding of ROS-generating metal ions.1,21 Because
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ROS damage cells and can result in disease development, it is important to understand
how naturally occurring thione- and selone-containing compounds, as well as thione- and
selone-containing drugs, neutralize ROS and prevent oxidative damage that leads to
disease. Since the antioxidant activity of these compounds is also linked to prevention of
ROS formation by metal coordination, it is essential to understand how these compounds
bind metals and how they might react in vivo.

1.3 Thione and selone antioxidant drugs
The thione-containing amino acid ergothioneine is found in plants and animals (13 mM22,23), including humans. Ergothioneine is synthesized only in bacteria and various
fungi, and it is thought that humans obtain ergothioneine in the diet.24 Although a specific
transport system for ergothioneine has been identified in humans, no definite molecular
pathway that involves ergothioneine has been reported.24 Franzoni, et al.5 demonstrated
in vitro that ergothioneine scavenges peroxyl, hydroxyl, and peroxynitrite radicals more
effectively than glutathione. In addition, several studies have determined that
ergothioneine is a potent biological antioxidant, preventing many different types of
oxidative damage, including lipid peroxidation oxidative DNA damage, and apoptosis, in
cells or in animals.25-31 Metal coordination as an antioxidant mechanism has also been
examined using density functional theory methods,32 and ergothioneine-copper
coordination was found to prevent copper-mediated oxidative DNA and protein damage
by inhibiting copper redox cycling.33
Selenoneine, the selenium-containing analog of ergothioneine, has not been as
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extensively studied due to its very recent discovery in the blood of bluefin tuna.4 Since
then, selenoneine has been identified in humans in very low concentrations (5-10 nM34);
similar to ergothioneine, selenoneine is taken up from the diet. It is thought that
selenoneine may be metabolized through selenium methylation, and this metabolic
product was identified from human urine by mass spectrometry.35 Selenoneine’s
biological function is not known, but Yamishita, et al.34 reported that selenoneine is a
more potent radical scavenger than ergothioneine, as determined by in vitro DPPH
radical scavenging studies, and hence may play an important role in the redox cycle in
animals.
Many of the drugs used to treat hyperthyroidism have thione functional groups,
the most common of which is methimazole (Figure 1.1).36,37 In addition to its anti-thyroid
activity, methimazole prevents oxidative DNA damage by hydrogen peroxide
scavenging.38,39 Other compounds that fall into this thione-containing class of
hyperthyroid inhibitors are the thiourea drugs 6-n-propyl-2-thiouracil (PTU) and 6methyl-2-thiouracil (MTU; Figure 1.1), but these drugs have not been studied as potential
antioxidants. Although these compounds are the most commonly employed drugs for
treating hyperthyroidism, their detailed mechanism of action is still unproven.26 It has
been proposed that these drugs may block thyroid hormone synthesis by coordinating to
the iron center of thyroid peroxidase.37

1.4 Imidazole thione compounds
The

heterocyclic

N,N’-dimethylimidazole
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thione

(dmit)

and

(N,N’-

dimethylimidazole selone (dmise) compounds (Figure 1.3) synthesized by Roy, et al.37
resemble methimazole and are structurally similar to ergothioneine24 and selenoneine,4
respectively. Similar compounds 1,1’-(1,2-ethanediyl)-bis(3-methyl-imidazole-2-thione)

Figure 1.3. Thione- and selone-containing ligands discussed in this chapter.
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(ebit) and 1,1’-(1,2-ethanediyl)bis(3-methyl-imidazole-2-selone) (ebis; Figure 1.3) also
have been synthesized by Jia, et al.40 to provide bidentate thione and selone ligands for
metal coordination. These heterocyclic chalcogenones are strong σ- and π-donors, and
similar compounds, such as the class of imidazoline-2-thione ligands (Figure 1.3), display
a diversity of metal binding modes.41
Trithiocyanuric acid (2,4,6-trimercaptotriazine, ttcH3; Figure 1.3) and its
trisodium salt have a wide range of applications: they can be used to precipitate heavy
metals,42-44 and the acid shows anti-toxoplasmal activity more effective than the presently
used drugs 5-fluorouracil and emimicin.45 The protonation state and solubility of
trithiocyanuric acid depends strongly on pH. At pH values below 5, only the water-

insoluble ttcH3 exists, whereas increasingly soluble ttcH2 , ttcH2-, and ttc3- anions are
formed as the pH increases. Unsurprisingly, the different protonation states of this
compound greatly affect its metal binding abilities.46 Depending on the extent of ttcH3
deprotonation, different metal coordination modes are possible, and transition metal
complexes with various nuclearities can be formed.46

1.5 Scorpionate-thione compounds
The so-called scorpionate compounds have become a hugely popular class of
ligands in coordination chemistry since they mimic biological coordination sites.17,47-53
This perceived analogy, coupled with their ease of synthesis and their remarkable
versatility in transition-metal complexation, rapidly established them as a widely used
class of ligands. One of the first examples, tris(pyrazolyl)borate, was described by
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Trofimenko in 1966.54 These are tripodal, anionic ligands with an N3 donor set that caps
one face of a coordination polyhedron. The ability to synthesize a wide range of
substituted pyrazolyl ligands facilitates tuning of their steric, and to some degree,
electronic properties.18,55
The

thione-containing

hydrobis(methimazolyl)borate

hydrotris(methimazolyl)borate

(BmR),

hydrotris(thioxotriazolyl)borate

bis(thioimidazolyl)(pyrazolyl)borate (BmMepz), and

(TmR),
(TrR,R’),

bis(mercaptoimidazolyl)borate

(BmR) ligands (Figure 1.3), like the pyrazolyl borates, have great potential for
modification. The N-methyl group can be readily replaced by a range of alkyl (methyl,
ethyl, tert-butyl, benzyl, and cyclohexyl) or aryl (phenyl, p-tolyl, o-tolyl, mesityl,
cumenyl, 2-biphenyl, 2,6-xylyl, and 2,6-diisopropylphenyl) groups. In keeping with
Trofimenko’s synthesis of the pyrazolyl borate ligands, Spicer and Armstrong17,56,57
synthesized TmR and BmR by reaction of methimazole with sodium borohydride in a
solvent-free system.54 Hydrogen evolves as the methimazole melts, forming sodium
hydrotris(methimazolyl)-borate in 73-88% yields. Both lithium58 and potassium59-61
borohydrides have also been used successfully in these syntheses. Coordination
complexes of these soft scorpionate ligands have been used as structural enzyme models
for nickel-containing hydrogenases 62 and zinc-containing alcohol dehydrogenases.63,64

1.6 Thione compounds as ligands
Thiones and selones readily bind transition metals such as Fe(II), Co(II/III),
Ni(II), Cu(I/II), and Zn(II). Recently, there has been increased interest in the chemistry of
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soft Lewis base donors such as thiolates, thioamides, selenolates, and selenoamides for
use in catalysis65 and in bioinorganic chemistry for the study of copper metallothioneins,
metallochaperones, and methinobactin.66-68 Metal-thione complexes also have been
studied for a broad range of biological activities, including applications as antitumor,
antibacterial, antifungal, and antiviral agents.69-72
Many publications describe metal-thione complexes and, in a few cases, the
structures and properties of these complexes have been compared to analogous metalselone complexes. Unsurprisingly given the polarizability of the sulfur donor atoms,
thione complexes have been largely reported only for the late first-row d-block metal
ions, typically only in lower oxidation states.

1.7 Iron-thione complexes
Iron-thione complexes have not been extensively studied, likely because Fe(II) is
unstable to oxidation and, thus, these complexes must be synthesized using air-free
conditions. Iron-thione complexes are of interest as model complexes to study sulfur-rich
metal centers in proteins and to determine potential biological behavior of ergothioneine
and thione-containing drugs. Sanina, et al.73 reported the synthesis of [Fe(1,2,4-triazole3-thione)2(NO)2]∙0.5H2O (Figure 1.4A) by combining 3-mercapto-1,2,4-triazole (Figure
1.3) with [Na2Fe2(S2O3)2(NO)4]∙2H2O and Na2S2O3∙5H2O in a 10:1:2 molar ratio in
aqueous alkaline solution. The heterocyclic thione ligands coordinate iron through the
sulfur atom, rather than through the available nitrogen atoms, with Fe–S bond distances
of 2.298(1) and 2.318(1) Å.73
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The infrared spectrum of Fe(1,2,4-triazole-3-thione)2(NO)2∙0.5H2O has a single
band at 702 cm–1 due to the iron-bound C=S that shifts to lower energy compared to the
unbound 1,2,4-triazole-3-thione (750 or 745 cm–1).73 This shift upon complex formation
indicates significant weakening of the C=S bond, and iron backbonding to the thione
sulfur. Sanina, et al.73 reported that one of the sulfur atoms, S(1), is negatively charged
and covalently binds to iron, whereas the other sulfur atom, S(2), is formally neutral and
forms a donor–acceptor bond with iron. This description of the bonding is not supported
by the single infrared C=S band and the very similar Fe-S bond lengths reported for this
complex.
A similar complex was synthesized using 4-amino-3-methyl-1,2,4-triazole-5thione (amt; Figure 1.3) and iron(II)perchlorate to yield [Fe(amt)2(H2O)2][ClO4]2 (Figure
1.4B).73 This iron compound decomposed during X-ray structural analysis as
demonstrated by a ~30% decrease in the intensity of the standard reflections over the
course of data collection. As expected, the symmetrically equivalent Fe-S bond distances
of 2.474(1) Å73 in this octahedral iron complex are significantly longer than the Fe-S
bonds

in

the

tetrahedral

Fe(1,2,4-triazole-3-thione)2(NO)2∙0.5H2O.

Crystals

of

[Fe(amt)2(H2O)2][ClO4]2, initially pale green and transparent, slowly become yellowish/
brown and cloudy within a few days of exposure to air, characteristic of Fe(II) to Fe(III)

Figure 1.4. Crystal structures of A) Fe(1,2,4-triazole-3-thione)2(NO)2]∙0.5H2O,73
Fe(amt)2(H2O)2][ClO4]2.69 Hydrogen atoms, solvent, and counterions are omitted for clarity.
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and

B)

oxidation.69
The

monodentate

iron-thione

complexes

Fe(dmit)2Cl2

(Figure

1.5A),

[Fe(dmit)4][BF4]2, and [Fe(dmit)4][OTf]2 (Figure 1.5B), were synthesized by addition of
dmit (Figure 1.3) to FeCl2∙H2O, Fe(BF4)2, or Fe(OTf)2, respectively.74 These distorted
tetrahedral Fe(II) complexes bind though the sulfur atom of the monodentate thione
ligand, with bond distances ranging from 2.3395(9) to 2.395(2) Å.
When dmit is bound to iron(II), the infrared stretches for the S=C bonds shift very
slightly to lower energies (3 to 5 cm-1) compared to unbound dmit (1181 cm-1; Table 1.1),
indicating primarily σ and π bond donation. The 1H NMR spectra of these three
complexes show a prevalent paramagnetic effects from the iron metal center. X-ray
crystallography, IR spectroscopy and DFT calculations suggest an increase in aromaticity
favoring the zwitterion structure with increased negative charge on the thione sulfur atom
(Figure 2), promoting metal coordination. This effect has been observed previously with
copper- and platinum-thione complexes.13,14,19
The electrochemistry of the dmit ligand also changes when bound to iron, with the
Epa shifting by 99 mV compared to unbound dmit (455 mV), indicating that the Fe(II)-

Figure 1.5. Crystal structures of A) Fe(dmit)2Cl2,74 B) [Fe(dmit)4][BF4]2,74 and C) TmtBuFeCl.75 Hydrogen
atoms and counterions are omitted for clarity.
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Table 1.1. Infrared bands for C=S and C=Se bond vibrations in thione and selone compounds.

Metal Complex
Fe-Thiones
Fe(dmit)2Cl2
[Fe(dmit)4][BF4]2
[Fe(dmit)4][OTf]2
Fe-Selones
Fe(dmise)2Cl2
[Fe(dmise)4][BF4]2
[Fe(dmise)4][OTf]2
Co-Thiones
TmtBu2Co2(μ-TmtBu)2Cl2
Co-Selones
[Co(mbis)Cl2]n
[Co(ebis)Cl2]n
Ni-Thiones
Ni(mbit)Br2
Ni(ebit)Br2
Ni(SRN)Br2
Ni-Selones
Ni(mbis)Br2
Ni(ebis)Br2
Cu-Thiones
trans-Cu(dmit)2Cl
trans-Cu(dmit)2Br
trans-Cu(dmit)2I
cis-Cu(dmit)2I
[TpmCu(dmit)][BF4]
[Tpm*Cu(dmit)][BF4]
[TpmiPrCu(dmit)][BF4]
Tp*Cu(dmit)
[Cu(dmit)3][OTf]
[Cu(dtucH2)(PPh3)Cl]n
[Cu(dtucH2)(PPh3)Br]n
[Cu(dtucH2)(PPh3)I]n
Cu-Selones
trans-Cu(dmise)2Cl
cis-Cu(dmise)2Br

Change From
C=S/Se Infrared
Unbound Ligand Ref.
Band (cm-1)
(cm-1)
1176
1178
1177

-5
-3
-4

74
74
74

1149
1155
1151

1
7
3

74
74
74

1087

-30

78

1096
1135

-32
9

82
82

1153
1146
1156

15
10
2

82
82
83

1133
1128

5
2

82
82

1173
1173
1171
1171
1174
1171
1180
1175
1147
1090
1105
1125

-8
-8
-10
-10
-7
-10
-1
-6
-34
-45
-30
-10

19
19
19
19
14
14
14
14
20
103
103
103

1149
1150

1
2

19
19
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Table 1.1(cont.). Infrared bands for C=S and C=Se bond vibrations in thione and selone compounds.

Change From
C=S/Se Infrared
Metal Complex
Unbound Ligand Ref.
Band (cm-1)
(cm-1)
cis-Cu(dmise)2I
1148
0
19
Cu4(μ-dmise)4(μ-Br)2Br2
1150
2
19
Cu4(μ-dmise)4(μ-I)2I2
1144
-4
19
[TpmCu(dmise)][BF4]
1150
2
14
[Tpm*Cu(dmise)][BF4]
1150
2
14
iPr
[Tpm Cu(dmise)][BF4]
1150
2
14
Tp*Cu(dmise)
1146
-2
14
[Cu(dmise)4][OTf]
1146
-2
20

bound thione becomes more readily oxidizable.74 This increase in oxidation potential
suggests that the bound dmit may protect Fe(II) from oxidation.
Scorpionate-thione complexes with iron. Treatment of FeCl2 and LiTmR at room
temperature over four days yields the scorpionate-thione complexes TmRFeCl (R = Me,
t

Bu, Ph, and 2,6-iPrC6H3; Figure 1.3); the structure of the t-butyl derivative, TmtBuFeCl, is

shown in Figure 1.4C.75 These Fe(II) complexes adopt distorted tetrahedral geometry
with Fe-S bond distances ranging from 2.366(1) to 2.3881(1) Å.75 As observed for the
monodentate thione complexes, these chelating thione complexes are moderately air- and
moisture-stable in the solid state but unstable in solution.
The reported iron–thione complexes are only found as Fe(II) and adopt tetrahedral
or octahedral geometry around the Fe(II) metal center. They are easily synthesized,
binding through the sulfur atom rather than an available nitrogen atom, as observed for
Fe(1,2,4-triazole-3-thione)2(NO)2]∙0.5H2O.73 Fe(II)-thione complexes oxidize when
exposed to oxygen, but these oxidized products have not been characterized. Because of
iron’s importance in generating ROS such as hydroxyl radical, and the demonstrated
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ability of biological thiones to prevent oxidative damage from these species, further
studies of the relationship between iron-thione binding and reactivity of these complexes
with ROS will help elucidate the mechanisms for thione antioxidant activity.

1.8 Cobalt-thione complexes
In the only report of a monodentate thione complex with cobalt, Castro, et al.76
synthesized Co(C6H12N2S)2Cl2 with the heterocyclic thione 1-propylimidazolidine-2thione-S (Figure 1.6A). Similar to the Fe(dmit)Cl2 complex, the Co(II) center adopts
distorted tetrahedral geometry with the two thione ligands bound through the S atoms and
Co-S bond distances of 2.341(2) and 2.330(2) Å.76
Scorpionate-thione complexes with cobalt. The scorpionate-thione ligand
hydrotris(1-methylimidazol-2-ylthio)borate (HBmit3, Figure 1.3) was treated with CoF3
to afford the cobalt complexes [Co(III)(HBmit3)2][HBmit3] (Figure 1.6B) and
[Co(II)(HBmit3)2]∙4H2O.77 X-ray structural analysis indicated that these complexes have
octahedral and tetrahedral geometries, respectively, with the cobalt bound to all three
thione sulfur atoms. In [Co(III)(HBmit3)2][HBmit3], the Co-S distances range from
2.293(6) to 2.321(5) Å, and in [Co(II)(HBmit3)2]∙4H2O, the Co-S bond distances are
somewhat longer, ranging from 2.34(2) to 2.391(4) Å.77 As expected with the change in
oxidation state, the geometry of the cobalt metal center also changes: Co(III) adopts the
expected octahedral geometry, whereas Co(II) adopts tetrahedral geometry. Interestingly,
coordination of the HBmit ligand does not favor a single cobalt oxidation state, the only
example of a thione ligand to do so.
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Similar to the synthesis of the TmR Fe(II) complexes, treatment of CoCl2 with
LiTmR (Figure 1.3) at room temperature over four days yielded the TmRCoCl complexes
(R = Me, tBu, Ph, and 2,6-iPrC6H3). The tetrahedral TmtBuCoCl complex (Figure 1.6C)
has Co-S bond distances of 2.312(1) to 2.331(1) Å.75 The reaction of cobalt(II) chloride
hexahydrate with N-tert-butyl-2-thioimidazole (TmtBu) yields both [κ2-(TmtBu)2] CoCl2
and TmtBu2Co2(μ-TmtBu)2Cl2∙CH3CN (Figure 1.6D) depending on the reaction time. In
both complexes, each cobalt(II) center is four-coordinate with distorted tetrahedral
geometry.78 Unexpectedly, two of the sulfur atoms of the TmtBu ligand in[κ2(TmtBu)2]CoCl2 do not coordinate cobalt, but instead form a S–S bond with a typical bond
distance of 2.050(4) Å, while the available nitrogen atoms on the imidazole coordinate
Co(II). The infrared spectrum of this complex shows a weak absorption band at 472 cm-1,
confirming disulfide bond formation, with no observable band at 1117 cm-1 for the C=S
stretch of free thioimidazole.78

Figure 1.6. Crystal structures of A) Co(C6H12N2S)2Cl2,76 B) [Co(III)(HBmit3)2][HBmit3],77 C)
TmtBuCoCl,75 and D) TmtBu2Co2(μ-TmtBu)2Cl2.78 Hydrogen atoms and counterions are omitted for clarity.
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The TmtBu2Co2(μ-TmtBu)2Cl2 complex is a sulfur-bridged dimer where four TmtBu
ligands are coordinated to both Co(II) centers.75 Two of the tridentate thione ligands bind
in a bidentate fashion through nitrogen as well as the sulfur atoms, with the other two
thione ligands coordinate only through the sulfur atoms. The infrared spectrum of
TmtBu2Co2(μ-TmtBu)2Cl2∙CH3CN exhibits a lower energy C=S stretching band at 1087
cm-1 compared to the unbound ligand (1117 cm-1), indicative of cobalt backbonding to
the sulfur atoms.78
The majority of cobalt-thione complexes form with Co(II) in tetrahedral structures
similar to Fe(II)-thione complexes, but thione ligands bind both Co(II) and Co(III)
oxidation states, a feature not observed for iron complexes. In addition, the TmtBu ligand
in [κ2-(TmtBu)]2CoCl2 does not bind through the sulfur atoms, but through the available
nitrogen donors of the ligand, with concomitant formation of a diselenide bond from the
thione sulfur atoms. No reactivity studies have been reported for these cobalt-thione
complexes.

1.9 Nickel-thione complexes
Ni-thiolate/thione chemistry is of significant interest because of its relevance to
hydrogenase chemistry.79-81 In addition, since ergothioneine coordination chemistry is not
well established, a recent study utilized a simpler version of this thione to investigate its
nickel binding.79 Mononuclear Ni(II) dithione complexes with the bidentate ligands mbit
or ebit (Figure 1.3) were synthesized by thione addition to Ni(PPh3)Br2 under nitrogen for
10 h to yield Ni(mbit)Br2 or Ni(ebit)Br2 (Figure 1.7A).82 Both Ni(II)-thione complexes
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are air- and moisture-stable and adopt distorted tetrahedral geometry with symmetrically
equivalent Ni-S bond distances of 2.283(1) and 2.286(2) Å, respectively. Ni(mbit)Br2
and Ni(ebit)Br2 infrared spectra show C=S stretches at 1153 and 1146 cm-1, respectively,
stretches that are shifted to higher energy compared to the unbound ligands (1138 and
1136 cm-1, respectively), indicating primarily donor bond formation.82
The tetrakis(1-tert-butyl-imidazole-2-thione) nickel complex [Ni(HmimtBu)4][I]2
(Figure 1.7B) is readily synthesized by treating HmimtBu (Figure 1.3) with NiI2 in
acetonitrile.83 The Ni(II) adopts square planar geometry, coordinated to four thione
ligands with symmetrically equivalent Ni-S bond distances of 2.220(2) and 2.236(3) Å.
Two iodide ions bridge the deprotonated nitrogen atoms from separate HmimtBu ligands.
When the coordinated HmimtBu ligands are deprotonated by KH in the presence of a
second equivalent of NiI2, the dinuclear complex Ni2(mimtBu)4 is formed. Each of the four
mimtBu ligands bridge the two Ni centers through N and S atoms, forming N2S2 Ni(II)

Figure 1.7. Crystal structures of A) Ni(ebit)Br2,82 B) [Ni(HmimtBu)4][I]2,79 and C) Ni(SRN)Br2 (SRN = 1pyridyl-(3-(2,6-diisopropylphenylimidazole)-2-thione)).83 Hydrogen atoms and counterions are omitted for
clarity.
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coordination with symmetrically equivalent Ni-S bond distances of 2.218(1) Å and
2.238(1) Å,79 similar to Ni-S distances from the monomeric [Ni(HmimtBu)4][I]2.
Mixed thione/nitrogen and thione/oxygen donor ligands have also been used to
synthesize Ni(II) complexes. Reaction of Ni(DME)Br2 (DME = dimethoxyethane) with
1-pyridyl-(3-tert-butylimidazole-2-thione)

or

1-pyridyl-(3-(2,6-

diisopropylphenylimidazole)-2-thione) yields Ni(SRN)Br2 complexes.83 The structure of
Ni(SRN)Br2 (SRN = 1-pyridyl-(3-(2,6-diisopropylphenylimidazole)-2-thione) is shown in
Figure 1.7C. Both complexes adopt tetrahedral geometry, with a Ni-S bond distance of
2.282(3) Å. The infrared C=S stretching frequencies for both complexes (1156 cm -1)
show little change compared to the unbound ligand (1154 cm-1), indicating primarily
donor Ni-S interactions.83
A separate crystallographic study used the 1-hydroxy-3-methylpyridine-2(1H)thione ligand (3-Me-HPT, Figure 1.3), a compound widely investigated for its antifungal
and antibacterial properties84 as well as its potential as a ligand for metalloenzyme

Figure 1.8. Crystal structures of A) Ni(3-Me-HPT)2,86 B) Ni(BmMe)2,62 and C) TmtBuNiI.75 Hydrogen atoms
and t-butyl groups are omitted for clarity.
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modeling.85 Addition of 3-Me-HPT to NiCl2∙6H2O affords Ni(3-Me-HPT)2 (Figure 1.8A),
a complex with distorted square-planar geometry, O2S2 coordination, and an Ni-S bond
distance of 2.131(1) Å for the symmetrically equivalent sulfur atoms.86
Scorpionate-thione complexes with nickel. Seeking to investigate new structural
and functional model compounds for nickel hydrogenases, the scorpionate-thione ligand
bis(2-mercapto-1-methylimidazolyl)borate (BmMe, Figure 1.3) was treated with
NiCl2∙6H2O to afford Ni(BmMe)2 (Figure 1.8B). This air-stable complex adopts octahedral
geometry around Ni(II) with Ni-S bond distances of 2.362(2) and 2.389(1).62 The S4H2
coordination around the Ni(II) center is unique among nickel complexes and provides a
structural model for the active form of NiFe hydrogenase enzymes.
Scorpionate thione complexes of Ni(II) also have been synthesized from NiX2 (X
= Cl, Br, or I) and LiTmR to give a series of TmRNiX (R = Me, tBu, Ph, and 2,6-iPrC6H3)
complexes. The structure of TmtBuNiI is provided in Figure 1.8C. Each complex adopts
distorted tetrahedral geometry with Ni-S bond distances ranging from 2.278 to 2.300 Å,
shorter than the M-S bond distances in the analogous Fe(II) (2.366-2.388 Å) and Co(II)
(2.298-2.333 Å) complexes.75
As observed for Fe(II)- and Co(II)-thione complexes, the few reported Ni(II)thione complexes adopt primarily tetrahedral geometry, with similar Ni-S bond distances
ranging from 2.130 to 2.300 Å. All of these Ni-thione complexes were studied only for
their structural characteristics, so additional reactivity and electrochemical studies to
understand properties of these Ni(II)-thione complexes still remain to be performed.
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1.10 Copper-thione complexes
Coordination of heterocyclic thiones to copper results in diverse architectures
ranging from mononuclear complexes to polynuclear networks with monodentate or
bidentate coordination of the sulfur atoms. Mono-alkylated heterocyclic thiones can also
bind metals via the non-alkylated nitrogen atom. Many different types of copper-thione
complexes have been synthesized and characterized to study the sulfur-rich environments
of copper coordination in proteins.17
The biological coordination chemistry of methimazole (Figure 1.1) is of particular
interest, due to its use as an anti-thyroid drug. One structural study reported addition of
CuI, methimazole, and PPh3 to form Cu(methimazole)(PPh3)2I (Figure 1.9A). In this
complex, Cu(I) is tetrahedrally coordinated with a Cu-S bond distance of 2.369(1) Å,87
consistent with similar copper(I) thione complexes.88,89
Heterocyclic thioamides are also of interest for their potential luminescence

Figure 1.9. Crystal structures of A) Cu(methimazole)(PPh3)2I,87 B) Cu(pymSH)(PPh3)2Br,90 and
[Cu(phen)2(dmit)][ClO4]2. 91 Hydrogen atoms and counterions are omitted for clarity.
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properties 92 as well as their medicinal purposes,93,94 and complexes of these ligands have
been studied with numerous metals, including copper, mercury, silver, and palladium.90
One example of this diversity of heterocyclic thioamide complexes was reported
when pyrimidine-2-thione (pymSH, Figure 1.3) was treated with CuX (X = I, Br, or Cl)
and PPh3, resulting in synthesis of the unusual dimer Cu2(pymSH)(PPh3)2I2, where the
two copper ions are bridged by N and S atoms of pymSH and two iodide ions, as well the
monomers Cu(pymSH)(PPh3)2Br (Figure 1.9B) and Cu(pymSH)(PPh3)2Cl.90 Changing
the halide from I to Cl or Br results in formation of monomeric rather than dimeric
complexes; however, all three complexes have the expected tetrahedral Cu(I)
coordination and similar Cu-S bond distances (2.3530(3), 2.3340(6), and 2.3720(3) Å,
respectively).90
Cu(II) phenanthroline (phen) complexes have been widely examined in vivo and
in vitro for their cytotoxic,95 genotoxic,96 and antitumor effects.97 Pivetta, et al.91
synthesized

and

characterized

four

penta-coordinate

copper(II)

complexes

[Cu(phen)2(L)][ClO4]2 (L = disubstituted imidazolidine-2-thione ligands with mixed H,
Me, and Et substituents; Figure 1.3) to study their formation constants, cytotoxicity, and
antiprion activity. In all four complexes, copper(II) adopts distorted trigonal–bipyramidal
geometry, as seen for [Cu(phen)2(dmit)][ClO4]2 (Figure 1.9C), with similar but fairly
long Cu-S bond distances ranging from 2.385(2) to 2.427(1) Å. Although at least one
imidazole nitrogen is unsubstituted in three of the four compounds, Cu(I) binds
exclusively through the thione sulfur atoms. In the first study to quantify thione ligand
binding, formation constants (log K values) for these copper-thione complexes in
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acetonitrile were measured between 1.75 and 3.20, following the same trend as the Cu-S
bond lengths.91 From these data, Pivetta, et al.91 concluded that alkyl substitution of the
thione ligand, even if increasing thione nucleophilicity, did not improve the donor ability
of the thione ligand.
No antiprion activity was observed when these [Cu(phen)2(L)][ClO4]2 complexes
were tested in scrapie-prion-protein-infected mouse neuroblastoma cells at non-cytotoxic
levels; however, these compounds exhibited significant cytotoxicity, with cytostatic
concentrations (CC50 values) between 0.41 and 0.54 µM.91 These effects were consistent
with the cytotoxicity of other Cu-phen complexes and proposed to occur through
oxidative damage to DNA and other cellular targets.
In addition to phenanthroline-thione copper complexes, complexes of the
formulae Cu(dmit)2X (X = I, Br, and Cl) were synthesized and characterized by Kimani,
et al.19 Changes in the halide ligand have little effect on Cu–S bond distances:
2.2376(6) Å for trans-Cu(dmit)2Cl, 2.2298(9) Å for trans-Cu(dmit)2Br, 2.234(1) Å for
trans-Cu(dmit)2I (Figure 1.10A), and 2.240(1) Å for cis-Cu(dmit)2I (Figure 1.10B). All
of these Cu(I) complexes are unstable to copper oxidation in air. Only the iodide complex
has both trans and cis structural isomers, with pi-stacking of the dmit imidazolium rings
in the cis conformer observed in the solid state and confirmed by density functional
theory calculations.19 Infrared spectra of these complexes show C=S stretching
frequencies 8-10 cm-1 lower than unbound dmit (1181 cm-1), indicating weak Cu-S
backbonding.19 The 1H NMR resonance for the olefinic protons of the copper- bound
dmit ligand (δ 7.27-7.32) shift downfield relative to unbound dmit (δ 6.64), and the
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Figure 1.10. Crystal structures of A) trans-Cu(dmit)2I,19 B) cis-Cu(dmit)2I,19 C) Tp*Cu(dmit),14 and D)
[Cu(dmit)3][OTf].20 Hydrogen atoms and counterions are omitted for clarity.
13

C{1H} resonance of the C=S carbon also shifts downfield by δ 3 to 8 upon copper

complexation, characteristic increasing the zwitterionic form of the thione ligand (Figure
1.2) upon metal binding.19
The same thione ligand was also used to synthesize the copper-thione complexes
[TpmCu(dmit)][BF4],

[Tpm*Cu(dmit)][BF4],

and

Tp*Cu(dmit)

(Tpm

=

tris(pyrazolyl)methane, Tpm* = tris(3,5-dimethylpyrazolyl)methane, and Tp* =
hydrotris(3,5-dimethylpyrazolyl)borate; Figure 1.10D) with trinitrogen donor scorpionate
ligands to determine how thione coordination alters the redox potentials of the copper
center.14 In these complexes, the Cu(I) ion is in a distorted tetrahedral environment with
Cu-S bond lengths ranging from 2.191(8) to 2.202(7) Å.14 Thione C=S infrared stretching
frequencies in these complexes range from 1172 to 1178 cm-1 (Table 1), and the olefinic
1

H NMR and C=S

C{1H} NMR resonances shift downfield by  0.18-0.40 and 

13

2.3-7.8, respectively, relative to unbound dmit,14 similar to coordination effects observed
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for the Cu(dmit)2X complexes.19
Electrochemical studies of these tris(pyrazolyl) copper-thione complexes in
acetonitrile showed Cu(II/I) potentials between 70 and -160 mV, lowered by 374 to 617
mV compared to the non-thione-coordinated [TpmCu(NCCH3)]+ complex.14 In addition,
increasing steric bulk on the tris(pyrazolyl) ligand stabilizes Cu(II) relative to Cu(I).
Although this represents a significant shift in this copper potential upon thione binding,
the resulting potentials are well above that of the cellular reductant NADH (-324 mV98),
indicating that similar Cu(I) compounds in vivo still may be capable of redox cycling and
generation of damaging reactive oxygen species.
Adding four equivalents of dmit to Cu(OTf)2 yields the reduced [Cu(dmit)3][OTf]
complex (Figure 1.10D) with concomitant oxidation of the thione to the imidazolium
disulfide,20 the first imidazolium disulfide synthesized by Cu(II) reduction. The
[Cu(dmit)3]+ cation adopts distorted trigonal-planar geometry with Cu-S bond distances
ranging from 2.226(1) to 2.260(1) Å. Kinetic studies were performed in acetonitrile,
demonstrating that dmit reduces Cu(II) to Cu(I) at a rate of 0.18 s-1,20 and establishing
that these thione ligands are capable of promoting copper redox cycling under these
conditions.
Only a few structurally characterized complexes of 2,4-dithiouracil (dtucH2;
Figure 1.3) coordinated to Cu(I), Ti(III), and Ru(III) have been reported.99-102 Cu(I)
halides combined with this ligand form [Cu(dtucH2)(PPh3)X]n (X = Cl, Br, and I; Figure
1.11A with X = Br), with tetrahedral Cu(I) geometry and an average Cu–S bond length of
2.332 Å.103 The two sulfur atoms of the 2,4-dithiouracil ligands are coordinated to
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Figure 1.11. Crystal structures of A) [Cu(l-S,S-dtucH2)(PPh3)Br]n,103 B) Cu(PPh3)2(pmtH)(SH),104 C)
Cu(PPh3)2(pmt),104 D) Cu2(PPh3)2(pmt)2∙0.5CH3OH,104 and E) [Cu2(tsac)2(sbim)2(CH3CN)].105 Hydrogen
atoms are omitted for clarity.

separate copper ions, forming a polymeric chain. The infrared spectra of the
[Cu(dtucH2)(PPh3)X]n complexes display a γ(C=S) band between 1090 and 1125 cm-1,
significantly shifted from that of the unbound ligand at 1135 cm-1, and consistent with
copper coordination through the sulfur rather than through the nitrogen atoms as well as
backbonding of copper to the thione.103
The

structural

and

antioxidant
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properties

of

Cu(PPh3)2(pmtH)Cl,

Cu(PPh3)2(pmtH)(SH)

(Figure

1.11B),

Cu(PPh3)2(pmt)

(Figure

1.11C),

and

Cu2(PPh3)2(pmt)2.0.5CH3OH (Figure 1.11D; pmtH = 2-mercaptopyrimidine; Figure 1.3)
have also been reported.104 2-Mercaptopyrimidine readily binds copper(I) chloride in the
presence of PPh3 to form the monomeric complex Cu(PPh3)2(pmtH)Cl. The acidic nature
of the H(N) proton on the pmtH ligand in Cu(PPh3)2(pmtH)Cl was established by treating
this complex with sodium hydroxide to form the dimeric Cu(PPh3)(pmt)2∙0.5CH3OH
(Figure 1.11D).104 In this complex of the deprotonated ligand, pmt binds each tetrahedral
Cu(I) through the nitrogen atom and a bridging sulfur atom from the thione (Cu-S bond
distances of 2.67(1) and 2.31(1) Å. A terminal PPh3 ligand completes the tetrahedral
copper coordination. The thione-bridged copper ions are close enough (2.699(2) Å) to
form a Cu-Cu bond. In contrast, treatment of pmtH with Cu(CH3COO) and PPh3 in
ethanol results in the formation of the monomeric Cu(PPh3)2(pmt) (Figure 1.11C), with
the tetrahedral Cu(I) terminally bound through the nitrogen and sulfur atoms of the
deprotonated pmt ligand.104 As expected, the Cu-N distance in this complex (2.144(1) Å)
is similar to the Cu-N distance in the dimeric complex (2.052(1) Å), but the terminal CuS bond (2.400(1) Å) is significantly shorter.104
Reaction of copper(II) sulfate or nitrate with pmtH and PPh3 in refluxing
methanol/acetonitrile solution forms the unusual Cu(PPh3)2(pmtH)(SH) complex (Figure
1.11B) with two PPh3 ligands and the sulfur atom of the pmtH ligand (Cu-S 2.3652(6) Å)
coordinated to Cu(I).104 Tetrahedral geometry around Cu(I) is completed by a terminal
thiol group, with a Cu-S bond distance of 2.3718(5) Å.
These Cu(I) pmtH and pmt complexes were tested for their ability to inhibit
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linoleic acid peroxidation by lipogenase (LOX), an enzyme that controls cancer cell
proliferation. Although all four complexes prevent LOX activity with 50% inhibitory
concentrations of 7 to 47 µM, the dimeric Cu2(PPh3)2(pmt)2 was the most effective.104
Direct LOX binding by these complexes was observed using 1H NMR spectroscopy, and
computational studies suggested that the most effective inhibitors interact close to the
LOX active site but not in a single binding pocket.104
Dennehy, et al.105 report the synthesis of copper complexes of the ternary
thiosaccharin (tsac) and 1H-benzimidazole-2(3H)-thione (sbim; Figure 1.3) to form
Cu2(tsac)2(sbim)2(NCCH3) (Figure 1.11E) and Cu2(tsac)2(sbim)3. In both these
complexes, the tsac and the sbim ligands have monodentate and bidentate coordination.
In Cu2(tsac)2(sbim)2(NCCH3), the two copper ions are bridged by the N atom and thione
S of one tsac ligand as well as through the sulfur of the second tsac ligand. The two sbim
ligands are bound only through the sulfur atoms, in monodentate and bidentate fashion, to
give an NS3 core around one Cu(I) and an S3 core around the second Cu(I). Distorted
tetrahedral geometry around the second Cu(I) is completed by coordinated acetonitrile.
The Cu-S bond distance for the terminal sbim is 2.209(1) Å, somewhat shorter than for
the bridging sbim ligand (2.238 Å).105 The Cu-S bond distances for the tsac ligand vary
more significantly, with a µ-N,S-Cu distance of 2.2799(9) compared to the average Cu-S
distance of 2.523 Å for the tsac bridging through only the sulfur atom.105
Monodentate thione ligands bind to Cu(I) in trigonal planar tetrahedral geometries
and to Cu(II) in trigonal planar geometry. The majority of the monodentate thione-copper
complexes contain Cu(I), as expected for polarizable sulfur donor ligands, but
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electrochemistry of the tris(pyrazolyl) Cu(I) thione complexes indicate that thione
coordination destabilizes Cu(I) relative to acetonitrile coordination.14 In all cases, the
thiones predominantly bind through the sulfur atom rather than other available nitrogen
atoms as observed with the pmt, a characteristic also observed for both iron and cobalt
complexes. Although these complexes are relatively easy to synthesize, the reactions to
synthesize Cu(I) complexes typically require air-free techniques and the products oxidize
over time. Similar to iron-thione complexes, copper-bound thione ligands favor the
zwitterionic resonance structure (Figure 1.2), as determined by NMR spectroscopy
showing increased aromaticity within the ring upon metal binding.
Scorpionate-thione complexes with copper. Many copper coordination studies
have used tridentate thione-containing scorpionate ligands that permit tetrahedral Cu(I)
coordination with a substitutable binding site. One example of this type of complex is
TrR,R’Cu(PPh3) (TrR,R’ = tris(mercaptoimidazoyl)borate; Figure 1.12A), where the Cu(I) is
bound to the three thiones of the TrR,R’ ligand (Figure 1.3), with average Cu-S bond
distances of 2.367 Å, and a PPh3 ligand.106 Further characterization, including infrared
and electrochemical studies, would be useful to determine details of the thione-copper
interactions and how coordination of these chelating ligands affects copper redox
behavior.
A similar study was conducted by Rabinovich, et al.107 to study the effects on
bonding and structure of the sterically bulkier thione chelating ligand TmtBu (Figure 1.3).
TmtBuCu(PPh3) was prepared by combining equimolar amounts of NaTmtBu, PPh3, and
CuCl. In contrast to Cu(I) complexes of monodentate thione ligands, the Tm tBuCu(PPh3)

28

complex is air and light stable, a feature typical of these thione-scorpionate complexes.
The symmetry equivalent Cu–S bond distance of 2.3435(7) Å in TmtBuCu(PPh3) (Figure
1.12B) is similar to those in TmMeCu(PAr3) (2.357(2) and 2.332(1) Å for Ar = m-tolyl
and p-tolyl groups, respectively), suggesting that the steric bulk of the secondary ligand
does not affect the binding modes of the scorpionate TmR ligand.107
In some cases thione-scorpionate ligands bridge multiple metal centers. The
dimeric

Cu(I)

complexes

TrMes,Me2Cu2

and

TrMes,o-Py2Cu2

(TrR

=

hydrotris(thioxotriazolyl)borate; Figure 1.12C), are air stable and exhibit similar
coordination geometries in the solid state,108 where every copper ion is surrounded by
three thione groups from two TrR ligands in a trigonal arrangement. The presence of a [BH-Cu] three-center-two-electron interaction in both compounds causes the overall
coordination to become tetrahedrally distorted (with S3H coordination for each copper
center). In TrMes,Me2Cu2, the symmetrically equivalent non-bridging Cu-S distances are
2.265(1) and 2.355(1) Å, and the bridging Cu-S distance is 2.253(2) Å.108 Similarly, the
TrMe,o-Py2Cu2 complex has symmetrically equivalent, non-bridging Cu-S bond distances
of 2.285(1) and 2.305(1) Å and bridging Cu-S bond lengths of 2.252(1) Å. The tridentate
ligand hydro[bis(thioxotriazolyl)-3-(2-pyridyl)pyrazolyl]borate (BrMespzo-Py; Figure 1.3)
with only two thione groups also forms a dimeric complex, (BrMespzo-Py)2Cu2, with
trigonal copper(I) coordination from a bridging pyrazolyl nitrogen atom and two terminal
thione sulfur atoms.108 The symmetrically equivalent Cu-S distances in (BrMespzo-Py)2Cu2
are 2.245(2) and 2.268(3) Å, significantly shorter than the terminal Cu-S bonds in TrMe,oPy
2Cu2

with the tridentate thione ligand TrMe,o-Py.
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Figure 1.12. Crystal structures of A) TrR,R’Cu(PPh3),106 B) TmtBuCu(PPh3),107 and C) TrMe,o-Py2Cu2.108
Hydrogen atoms, t-butyl groups, o-pyridyl groups, and phenyl groups are omitted for clarity.

To examine the stability of these dinuclear complexes and to determine relative
formation constants of monodentate and scorpionate ligands bound to Cu(I), NMR
titrations of TrMes,Me2Cu2, TrMes,o-Py2Cu2, and (BrMespzo-Py)2Cu2 with PPh3, thiourea, and
pyridine were performed.106 Addition of two equivalents of PPh3 ligand to each of the
dinuclear complexes was sufficient to give the corresponding monomeric Cu(I) PPh3
complexes, whereas thiourea titrations reached completion only at a much higher ligand
to complex ratios. Pyridine titrations showed no reactivity with any dimeric complexes
even upon addition of 40-64 equivalents,106 indicating that these Cu(I) complexes have a
much greater affinity for phosphorus- and sulfur-donor ligands compared to nitrogendonor ligands.
Al-Harbi and Parkin109 treated the [BmMeBenz]- and [TmMeBenz]- ligands (Figure
1.3) with [Me3PCuCl]4 to yield [BmMeBenz]Cu(PMe3) (Figure 1.13A) and
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Figure 1.13. Crystal structures of A) [BmMeBenz]Cu(PMe3),109 B) [TmMeBenz]Cu(PMe3),109 and C) [PnBm]Cu
(PPh3).110 Hydrogen atoms are omitted for clarity.

[TmMeBenz]Cu(PMe3), (Figure 1.13B), the first structurally related bis- and
tris(mercaptoimidazolyl)hydroborato copper(I) compounds. [TmMeBenz]Cu(PMe3) has
an approximately tetrahedral [S3P] motif with a four-coordinate τ4 geometry.109 In
contrast, the [BmMeBenz]Cu(PMe3) complex adopts a trigonal planar [S2P] coordination
motif.109
There are very few ligands which feature a mix of heterocycles, so in an attempt
to further develop and explore this ligand class, Owen et al.111 synthesized the first hybrid
version of the flexible S scorpionates,

mp

Bm (Figure 1.3). The addition of 1 equiv of

[mpBm] to CuCl in methanol with the corresponding phosphine ligand resulted in the
formation of [(mpBm)]Cu(PR3)] complexes (where R = Ph and Cy). 1H and

13

C NMR

spectra were consistent with only one chemical environment for the two methyl-2mercaptoimidazole arms.112 Each Cu metal center adopts a highly distorted trigonal
pyramidal with average Cu-S bond distances of 2.303(1) Å.112
Mösch-Zanetti110 reported a second such ligand,

Pn

Bm (Figure 1.3), and its Cu

complexes. Addition of CuCl to a solution of PR3 in methanol yielded complexes with
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the formula [Cu{PnBm}(PR3)] (R = cyclohexyl, phenyl; Figure 13C).110 From the X-ray
diffraction structure of Cu{PnBm}(PPh3), the average Cu-S bond distance was
2.278(5).110 In absence of phosphine, the reaction of the hybrid scorpionate ligand
with

CuCl

in

methanol

yielded

[Cu{PnBm}]2.110

Variable-temperature

Pn

Bm

NMR

spectroscopic data of this complex provided evidence for a dimeric structure in solution
with fluxionality between the two coordination isomers.110
The TrR, TmR, BmR, and BrRpzR ligands bind Cu(I) in two coordination
environments: mononuclear complexes with tetrahedral geometry and dinuclear
complexes with trigonal planar geometry. In contrast to the majority of mononuclear
Cu(I) complexes, Cu(I) complexes with these tridentate thione ligands are substantially
more air stable. Since most reports of copper-thione complexes are entirely structural,
there is a great need for characterizing the reactivity of these complexes, to determine
how thione coordination affects copper oxidation and redox cycling, a major factor in
ergothioneine antioxidant behavior, and how well these copper-thione complexes model
sulfur-rich copper sites in metalloproteins.

1.11 Zinc-thione complexes
A large number of zinc enzymes perform thiolate alkylations for various
purposes,50 the most prominent of which are cobalamin-independent methionine
synthase113 and the Ada DNA repair protein.114 In these enzymes, zinc is bound to
histidine and cysteine residues in N2S, NS2, or S3 donor environments, and it is
generally believed that thiolate alkylation is facilitated by zinc binding.115 Although thiols
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and thiones do not behave identically, synthesis of zinc-thione complexes allows the
study of sulfur-rich zinc sites in these metalloproteins.115
The [Zn(diap)2(OAc)2]∙H2O complex (Figure 1.14A) was synthesized with 1,3diazepane-2-thione (Figure 1.3), a ligand similar to thiourea but with sufficient steric bulk
to restrict the coordination number. The distorted tetrahedral coordination around the zinc
ion in [Zn(diap)2(OAc)2] consists of two terminal S-donating thione ligands and one
oxygen atom from each of two acetate anions. The Zn–S bond distances (2.322(1) and
2.340(1) Å) are very similar to Zn–S bond distances in other reported pseudo-tetrahedral
zinc–thiolate complexes.116
A similar coordination study of N,N’-bis(3-aminopropyl)ethylene-diamine
(bapen)

was

performed

by

the

synthesis

of

the

mononuclear

[Zn(bapen)(ttcH)]∙CH3CH2OH complex (Figure 1.14B) (ttcH3 = trithiocyanurate dianion,
Figure 1.3), where ttcH is bound to the zinc as a bidentate ligand in the cis configuration
through N and S donors. The Zn(II) ion in this complex adopts a substantially distorted
octahedral geometry, coordinated to the four N atoms of the bapen ligand (Zn-N =

Figure 1.14. Crystal structures of A) Zn(diap)2(OAc)2,116 and B) Zn(bapen)(ttcH).46 Hydrogen atoms are
omitted for clarity.
.
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2.104(2) Å) and the two S and N atoms of the ttcH2- anion (Zn-S = 2.5700(7) Å and ZnN = 2.313(2) Å) in the cis configuration.46
Scorpionate complexes with zinc. The tripodal sulfur ligand hydrotris(tbutylthioimidazolyl)borate (TtitBu) was also reported to coordinate zinc to form
TtitBuZn(OClO3). Recrystallization of TtitBuZn(OClO3) from methanol in the presence of
2-butylmercaptan forms the cationic zinc tetramer [TtitBuZn]4[ClO4]4 (Figure 1.15A) as
determined by X-ray structural analysis.117 In this tetramer, each TtitBu ligand is
coordinated through one of its sulfur atoms to each of two neighboring zinc ions, with the
third sulfur atom bridging them. The bridging Zn–S bonds (2.402(3) - 2.479(2) Å) are
approximately 0.15 Å longer than those to the terminal sulfur atoms (2.291(5) - 2.342 (2)
Å), and the intraring S–Zn–S angles of 91.90(6) to 105.16(7)o are among the smallest of
all S–Zn–S angles in the molecule.117
The tris(thioimidazolyl)borate scorpionate ligands (TtiR; Figure 1.3) provide a S3
donor set and were used to synthesize 11 new complexes of the formula TtiRZn(SR’) (R
= xylene, t-butyl, tolyl, cumenyl; SR’ = Et, iPr, tolyl, Ph, C6H4(p-NO2), C6H3(o-OCH3)2,
C6F5, and others) to understand why unusual sulfur-rich donor environments are common
for zinc-containing enzymes.115 To synthesize these zinc-thione-thiolate complexes,
KTtiR was combined with zinc nitrate or zinc perchlorate to generate Tti RZn(ONO2) or
TtiRZn(OClO3) in situ, and then the desired sodium thiolate was added. The structure of
an example thione-thiolate complex, TtiXylZn(SEt), is shown in Figure 1.15B. TtiR ligand
conformation in this series of Zn(II) complexes varies little, with the Zn-S distances of
2.33(1) to 2.39(1) Å.115 The terminal Zn-S thiolate bond lengths range from 2.252(6) to
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Figure 1.15. Crystal structures of A) [TtitBuZn]4[ClO4],117 B) TtiXylZn(SEt),115 and C) L1Zn(SEt).118 Xylyl
groups, t-butyl groups, and hydrogen atoms are omitted for clarity.

2.305(3) Å in these complexes, with a slight tendency for the aliphatic thiolates to have
shorter Zn-S bonds than the aromatic thiolates.115
The

tripodal

thione

ligands

bis(pyrazolyl)(3-tert-butyl-2-thioimidazol-1-

yl)hydroborate) (L1) and bis(pyrazolyl)(3-isopropyl-2-thioimidazol-1-yl)hydroborate (L2,
Figure 1.3) are similar to the tris(thioimidazolyl)borates, but provide N2S coordination.
Combined with zinc nitrate or zinc chloride and the corresponding thiolate, these ligands
yielded a total of 17 (L1)Zn(SR) and (L2)Zn(SR) complexes (R = Et, CH2CF3, tolyl, Ph,
C6H4(p-NO2), C6H3(o-OCH3)2, C6F5, and others).118 X-ray structural analysis of
(L1)Zn(SEt) (Figure 1.15C) confirmed tetrahedral N2S2 coordination of zinc, with Znthione and Zn-SEt bond distances of 2.349(3) and 2.228(3) Å, respectively.118 There is a
remarkable similarity between all 17 structures; the comparable bond lengths vary not
more than 0.02 Å, and the Zn-S thiolate bonds are characteristically shorter than the Zn-S
thione bonds by 0.132 Å.118
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To understand why sulfur-rich coordination environments are necessary for zinccatalyzed thiolate alkylations, methylation reactions were performed with Zn(II)scorpionate complexes. Effects of systematic variation on the zinc coordination
environment

were

determined

using

zinc-thiolate

complexes

of

tris(3,5-

dimethylpyrazolyl)borate (Tp*) ligands as N3 donors,119 L1 and L2 ligands as N2S
donors,118 and the TtiR ligands as S3 donors.115 Methyl iodide in chloroform solution was
used as the methylating agent instead of the biological methyltetrahydrofolate, a
methylammonium species. Methylammonium salts and trimethyl phosphate were not
reactive enough for efficient alkylation of the model zinc-thiolate complexes.119
Methylation reactions of the TtiRZn(SR’) complexes to yield TtiRZnI and MeSR’, were
the fastest of the tested model complexes, several orders of magnitude faster (10 min to
several hours for complete methylation)115 than methylation of the Tp*Zn-thiolate
complexes,119 and significantly faster than the L1 and L2 copper complexes (one day to
two weeks).118 These methylation studies indicate that zinc coordination by sulfur donors
is the most effective way to increase zinc-thiolate electron density and nucleophilicity,
and support the zinc-bound thiolate mechanism of alkylation, but methylation rates for
these model complexes are far lower than those observed in enzymes.115,118 Thus, these
methylation studies complexes have established mechanistic details for this reaction, but
researchers are still far from understanding the factors controlling alkylation efficiency in
zinc enzymes.
Unsurprisingly, thione ligands typically bind zinc(II) though the sulfur atom in a
tetrahedral

geometry;

however

the

six-coordinate
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Zn(bapen)(ttcH)

complex46

demonstrates that thione ligands may also bind through available nitrogen atoms, similar
to a few reported Fe(II), Ni(II), and Cu(I) thione complexes.69,104 Synthesis of Zn(II)
complexes with scorpionate thione ligands to study thiolate methylation reactions has
resulted in a multitude of structurally characterized, tetrahedral Zn(II) thione/thiolate
complexes. Zinc-thione complexes with the TtiR ligands are the most promising models
for zinc-containing thiolate alkylation enzymes, but their slow alkylation rates
demonstrate the need to adjust the electronic properties of the thione scorpionate ligands
to better model these reactions.
The bidentate [S2]-donor bis(mercaptoimidazolyl) ligands, [BmMe]- and [BmMes]-,
(Figure 1.3) were treated with ZnX2 (X = Me, I, NO3) to yield [BmMe]ZnMe (Figure
1.16A), [BmMe]ZnI and [BmMes]Zn(NO3).120 The [BmMe] ligand is insufficiently bulky to
prevent formation of the tetrahedral homoleptic complex, [BmMe]2Zn, (Figure 1.16B)
formed from a redistribution reaction of [BmMe]ZnMe in CHCl3.120 The average Zn-S
bond distances were 2.310 Å for the 1:1 complexes [BmMe]ZnX and 2.340 Å for the
homoleptic [BmMe]2Zn complex.120
Parkin et al. 120 have investigated coordination chemistry of the

Figure 1.16. Crystal structures of A) [BmMe]ZnMe
for clarity.

120

and B) [BmMe]2Zn.
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120

Hydrogen atoms are omitted

bis(thioimidazolyl)(pyrazolyl) hydroborato (BmMepz) ligand to model active sites of zinc
enzymes that are closely related to liver alcohol dehydrogenase (LADH). [BmMepz]treated with ZnI2 forms [BmMepz]CuI, adoping a distorted tetrahedral geometry about the
Zn(II) metal center with an average Zn-S bond distance of 2.335(2) Å.120 Most
importantly, [BmMepz]CuI closely resembles the active site of LADH by bonding Zn(II)
via the N and S donors of [BmMepz]-. Thus, these ligands may also be useful for the
investigating other Zn enzymes with a [ZnNSS] coordination environment.64

1.12 Selone compounds as ligands
Reports of metal-selone complexes are rare and primarily limited to structural
studies, likely because biological selone compounds were not identified until
recently.4,12,34,121 Selone compounds are expected to be more nucleophilic than their
thione analogs, resulting in stronger coordination bonds,122-124 although formation
constants of these ligands have never been measured for comparison. Metal-selone
complexes are more readily oxidizable than their thione counterparts, resulting in
increased air sensitivity, but their synthesis is no more difficult than that of the airsensitive thione complexes.

1.13 Iron-selone complexes
Very few iron-selone complexes have been reported, possibly due to the facile
oxidation of Fe(II) or the selone ligand, and the need for air-free synthesis. The only
report of iron-selone complexes is the synthesis and characterization of the mononuclear
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complexes Fe(dmise)2Cl2, [Fe(dmise)4][OTf]2, and [Fe(dmise)4][BF4]2 (dmise = 1,3-N,Ndimethylimidazole selone; Figure 1.3).74 These selone compounds are synthesized by
addition of dmise (Figure 1.3) to FeCl2∙H2O, Fe(OTf)2, and Fe(BF4)2, respectively,74 and
are analogous to the previously discussed iron-thione compounds. The selone complexes
Fe(dmise)2Cl2 (Figure 1.17A) and [Fe(dmise)4][BF4]2 (Figure 1.17B) crystallize in
distorted tetrahedral geometry with Fe-Se bond distances ranging from 2.455(2) to
2.510(1) Å. When dmise coordinates Fe(II), the infrared stretches for the Se=C bonds
shift very slightly to higher energies (1149-1155 cm-1) compared to unbound dmise (1148
cm-1), indicating primarily σ and π donor bonding.74 This strengthening of the Se=C bond
in Fe(II) selone complexes upon dmise binding is similarly observed for the Fe-thione
complexes Fe(dmit)2Cl2, [Fe(dmit)4][OTf]2, and [Fe(dmit)4][BF4]2.74
The 1H NMR spectra of these three Fe(II)-selone complexes show imidazole
proton resonances shifting downfield by δ 0.4-0.5 compared to the unbound ligand (δ
6.77), indicating increased aromaticity of the selone imidazole ring (Figure 1.2) upon
coordination, similar to analogous Fe-thione complexes.74 As observed for the analogous
thione complexes, the electrochemistry of these iron-bound selone ligands also change

Figure 1.17. Crystal structures of A) Fe(dmise)2Cl2 and B) [Fe(dmise)4][BF4]2.74 Hydrogen atoms and
counterions are omitted for clarity.
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when bound to iron, with the Epa of dmise shifting by 40 mV compared to unbound
dmise (372 mV), indicating that iron-bound selones are more readily oxidizable.74

1.14 Cobalt-selone complexes
In 1997, Williams, et al. synthesized Co(dmise)2C12 (Figure 1.18A), the first
metal halide complex to be prepared with the dmise ligand, by combining CoCl 2 and
dmise in methanol and heating. Upon cooling, blue-green crystals of Co(dmise)2C12
(Figure 1.18A) precipitated.125 In this complex, the Co(II) center adopts distorted
tetrahedral geometry with Co-Se distances of 2.277(3) and 2.456(3) Å.126 No further
characterization was reported; thus, additional infrared and electrochemical studies are
required to understand cobalt-selone binding and for comparison with selone complexes
of other metal ions.
Similar reactions were also carried out with the ethyl- and methyl-bridged selone
ligands, ebis and mbis (Figure 1.3). Treating CoCl2 with mbis or ebis (Figure 1.3) in
tetrahydrofuran forms the polymeric [Co(mbis)Cl2]n (Figure 1.18B) or [Co(ebis)Cl2]n
complexes.82 In both complexes, the Co(II) metal center adopts distorted tetrahedral
geometry, bound to two terminal chloride ligands and two Se atoms from different

Figure 1.18. Crystal structures of A) Co(dmise)2C12125 and B) [Co(mbis)Cl2]n.82 Hydrogen atoms are
omitted for clarity.
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bidentate selone ligands to form diselone-Co(II) chains. In these mbis and ebis
complexes, the symmetrically equivalent Co–Se bond distances are 2.447(4) and
2.423(5) Å, respectively. The most unusual structural feature in [Co(mbis)Cl2]n is the
formation of infinite helical chains that are of different chiralities (right and left handed),
despite the fact that they contain the same components and linking sequence.82 In
contrast, the [Co(ebis)Cl2] molecules form zigzag chains. The infrared spectrum of
[Co(mbis)Cl2]n shows a shift of the C=Se stretching frequency to lower energy (1096
cm-1) compared to unbound mbit (1128 cm-1), indicating weak backbonding of Co(II) to
mbis.82 In [Co(ebis)Cl2]n, however, the C=Se stretching frequency is shifted to higher
energy (1135 cm-1) relative to unbound ebis (1126 cm-1; Table 1), indicating donor bond
formation.82
As expected, the few structurally characterized cobalt-selone complexes
demonstrate that selone ligands bind primarily to Co(II) through the selenium atom with
distorted tetrahedral geometry. Similar to their thione analoges mbit and ebit, the
bidentate ligands mbis and ebis form polymeric complexes with Co(II). The shifts in
C=Se stretching frequencies observed for [Co(mbis)Cl2]n and [Co(ebis)Cl2]n indicate that
there is no single binding mode of these multidentate ligands to Co(II). Further synthesis
and structural characterization of Co(II)-selone complexes as well as infrared and
electrochemical studies are required for a comprehensive understanding of cobalt-selone
binding.
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1.15 Nickel-selone complexes
Reports of Ni-selone complexes are limited to structural studies. A single paper
investigates the substitution reaction of [NiL(MeCN)][BF4]2 (L = 2,5,8-trithia(2,9)-1,10phenanthrolinophane) with dmise to yield [NiL(dmise)][BF4]2 (Figure 1.19A).127 This
Ni(II) complex has octahedral geometry, with a Ni-Se bond distance of 2.592(1) Å.
Mononuclear Ni(II) diselone complexes were also synthesized by addition of
mbis or ebis to Ni(PPh3)2Br2 under nitrogen to afford Ni(mbis)Br2 (Figure 1.19B) and
Ni(ebis)Br2.82 Unlike the analogous thione complexes, these selone complexes are very
sensitive to air and moisture. Ni(mbis)Br2 has distorted tetrahedral geometry around the
Ni(II), with symmetry equivalent Ni-Se bond distances of 2.394(1)Å. Infrared C=Se
stretches for nickel-bound mbis and ebis are at 1133 and 1128 cm-1, respectively, very
slightly shifted to higher energies compared to the unbound ligands (Table 1.1),
indicating no Ni(II)-selone backbonding.82
Nickel-selone complexes have not been widely investigated; however, the few
complexes that have been synthesized demonstrate both octahedral and distorted

Figure 1.19. Crystal structures of A) [NiL(dmise)][BF4]2 (L = 2,5,8-trithia(2,9)-1,10phenanthrolinophane)127 and Ni(mbis)Br2. 82 Hydrogen atoms are omitted for clarity.

42

tetrahedral geometry around Ni(II). In contrast to their polymeric complexes with Co(II),
the bidentate selone ligands mbis and ebis form monodentate complexes with Ni(II). The
infrared C=Se stretching frequencies for Ni(mbis)Br2 and Ni(ebis)Br2 are similar to that
of [Co(ebis)Cl2]n, Fe(dmise)2Cl2, and [Fe(dmise)4]2+ indicating primarily donor bond
formation in these complexes. In contrast, weak backbonding is observed for the Co(II)selone bond in [Co(mbis)Cl2]n.

Since so little is known, any additional synthetic,

computational modeling, or reactivity studies would greatly elucidate metal-selone
bonding in these complexes.

1.16 Copper-selone complexes
In the only reported example of a Cu(II) selone complex, the distorted trigonalbipyramidal Cu(II) center in [Cu(phen)2(dmise)][ClO4]2 (phen = 1,10-phenanthroline;
Figure 1.20A) is coordinated by four nitrogen donors from the two phenanthroline
ligands and by the selenium atom from the dmise ligand. In this complex, the Cu-Se
distance of 2.491(3) Å is slightly longer than expected for a Cu(II)-selone complex, likely
due to the strong π-conjugation properties of the phenanthroline ligands.128 Trigonalbipyramidal coordination geometry is not common for Cu(II) complexes, particularly
when they contain ligands with reducing properties.129
Using the same dmise ligand, the distorted-trigonal-planar copper-selone
complexes trans-Cu(dmise)2Cl, cis-Cu(dmise)2Br (Figure 1.20B), and cis-Cu(dmise)2I
were synthesized by combining the respective Cu(I) halides with two equivalents of
dmise.19 Similarly to their thione counterparts, these copper selone complexes have

43

Figure 1.20. Crystal structures of A) [Cu(phen)2(dmise)](ClO4)2,128 B) cis-Cu(dmise)2Br,19 C) Cu(μdmise)4(μ-Br)2Br2,19 D) Tp*Cu(dmise),14 and E) [Cu(dmise)4](OTf)2.20 Hydrogen atoms and counterions
are omitted for clarity.

identical Cu–Se bond distances of 2.34 Å, but unlike the thione analogs, cis geometry is
favored upon selone coordination, likely due to the greater polarizability of the selenium
atom in addition to the polarizable halides. When CuI and CuBr are treated with only
one equivalent of dmise,

the tetrameric Cu4(μ-dmise)4(μ-Br)2Br2·0.5CH3CN (Figure

1.20C) and Cu4(μ-dmise)4(μ-I)2I2·1.5CH3CN complexes are formed.19 The structures of
both these complexes are similar, and notable for the two different coordination
geometries around the copper(I) ions. In Cu4(μ-dmise)4(μ-Br)2Br2, two selenium atoms
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and one bromide ion each coordinate the Cu(2) and Cu(2A) ions in a distorted trigonal
planar geometry, with average Cu–Se bond distances of 2.41 Å. The two additional
copper centers (Cu(1) and Cu(1A)) adopt distorted tetrahedral geometries, with a Cu2(μBr)2 core, two bridging selenium atoms from the dmise ligand, and an average Cu–Cu
distance of 2.631(2) Å.19
In contrast to the backbonding observed for their thione analogs, the infrared
spectra of trans-Cu(dmise)2Cl, cis-Cu(dmise)2Br (Figure 1.20B), and cis-Cu(dmise)2I,
Cu4(μ-dmise)4(μ-Br)2Br2·0.5CH3CN, and Cu4(μ-dmise)4(μ-I)2I2·1.5CH3CN show copperbound C=Se bond stretching frequencies (1149-1163 cm-1) shifting to higher energies
relative to unbound dmise (1148 cm-1), indicating Cu-Se donor bonding.19

77

Se{1H}

NMR spectra of these complexes show significant upfield shifts for the copper-bound
dmise resonance, ranging from δ -13.4 to -75.0 compared to unbound dmise (δ 21.8).19
Cu(II/I) reduction potentials for these Cu(I) selone complexes range from -340 to -360
mV, significantly lower than their thione counterparts (-177 to -284 mV).19
In an effort to understand the role of copper-selenium coordination in metalmediated DNA damage prevention, Kimani, et al.14 synthesized biologically relevant
Cu(I) dmise complexes with trinitrogen donor ligands. For each of the complexes,
[TpmCu(dmise)][BF4],
Tp*Cu(dmise)

(Tpm

[Tpm*Cu(dmise)][BF4],
=

[TpmiPrCu(dmise)][BF4],

tris(pyrazolyl)methane,

Tpm*

=

and
tris(3,5-

dimethylpyrazolyl)methane, TpmiPr = tris(3,5-isopropylpyrazolyl)methane, Tp* =
hydrotris(3,5-dimethylpyrazolyl)borate),14 each copper ion adopts distorted tetrahedral
coordination with similar Cu-Se bond lengths ranging from 2.294(6) to 2.33(8) Å. The
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short Cu-Se bond distances for all four complexes suggest strong donor interactions
between the soft selenium ligand and the soft copper metal ion, consistent with slight
shifts to higher C=S bond stretching energies in the infrared spectra (2-3 cm-1; Table
1.1),14 but only a limited number of non-bridging copper selone complexes are available
for structural comparison. As is the case with Fe(II) selone complexes, 1H NMR
resonances of the imidazole protons and

13

C{1H} NMR resonances of the C=S carbon

atom shift downfield by δ 0.20-0.41 and δ 2.4-8.0 compared to unbound dmise,
comparable to NMR shifts observed for the analogous Cu(I)-thione complexes.14 Thus,
both copper-bound dmit and dmise favor the zwitterionic resonance form of the
chalcogenone ligand (Figure 1.2) in these complexes, despite the slight backbonding
observed for Cu-S interactions and primarily donor interactions for the Cu-Se bonding as
determined by infrared spectroscopy.
Electrochemical studies of [TpmCu(dmise)][BF4], [Tpm*Cu(dmise)][BF4],
[TpmiPrCu(dmise)][BF4], and Tp*Cu(dmise) in acetonitrile showed very low Cu(II/I)
redox potentials for these complexes (-283 to 390 V), lower by 0.635 to 0.874 V relative
to the analogous complexes with acetonitrile ligands in place of dmise, and an average of
0.224 V lower than their thione analogs.17 Thus, selone binding to Cu(I) stabilizes Cu(II)
in these complexes much more effectively than analogous thione binding. In fact, the
very low potentials for these copper-selone complexes are near or below the potential of
NADH (-324 mV98), suggesting that similar Cu(I)-selone binding in vivo may prevent
copper redox cycling and generation of damaging reactive oxygen species.
Additional studies to determine the ability of selone coordination to reduce Cu(II)
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to Cu(I) were carried out by the addition of 5.5 equiv dmise to Cu(OTf) 2 to afford the
reduced [Cu(dmise)4][OTf] complex (Figure 1.20E) and the oxidized [(dmise)3][OTf)2].20
This reaction represents the first synthesis of an imidazolium triselenide by Cu(II)
reduction. The Cu(I) center of the [Cu(dmise)4]+ cation has tetrahedral geometry with
symmetrically equivalent Cu-Se bond distances of 2.454(1) Å.20 A similar reaction with
the analogous thione dmit results in formation of the trigonal planar complex
[Cu(dmit)3][OTf],20 illustrating the significant differences in binding and coordination
chemistry that can exist between similar ligands. This difference is also observed in the
infrared spectra of the two complexes, with the C=Se stretching vibration shifting much
less to lower energy than the C=S stretching vibration (2 cm-1 vs. 34 cm-1) upon
chalcogenone binding,20 indicating significantly more backbonding interactions in the
Cu-S bond.
Dmise was also added to Cu(OTf)2 in acetonitrile, and the increasing absorbance
of [Cu(NCCH3)4]+ was monitored to determine the kinetics of copper reduction by this
selone. Initial rates indicated that dmise reduces Cu(II) to Cu(I) three times faster than
dmit (0.50 vs. 0.18 s-1) in a first-order reaction with respect to ligand concentration.20
Under oxygen-free conditions, this reduction was four orders of magnitude slower,
indicating the involvement of O2 in this reaction. Thus, biological selone coordination to
Cu(II) in the presence of oxygen may promote reduction to ROS-generating Cu(I) faster
than thione binding.
Only a few copper-selone complexes have been reported, but these complexes
display a wide variety of coordination environments, ranging from tetrahedral and
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trigonal geometry with Cu(I) to trigonal bipyramidal geometry with Cu(II). Similar to the
thiones, selone ligands can be terminal and bridging ligands, although so few complexes
have been reported that it is difficult to compare the prevalence of selone binding modes
with their thione analogs. Copper-selone complexes behave similarly to other latetransition-metal-selone complexes in that infrared spectroscopy indicates little or no
backbonding in the metal-selone interaction, in contrast to their thione analogs that can
show significant weakening of the C=S bond due to Cu-S backbonding (Table 1.1). In
the few electrochemical studies conducted, copper-selone binding significantly lowers the
Cu(II/I) redox potential compared to thione binding, a result that may indicate increased
antioxidant ability of selones relative to analogous thione compounds.

1.17 Zinc-selone complexes
Very few zinc-selone complexes have been reported, with the first being
Zn(dmise)2Cl2 (Figure 1.21), prepared by combining ZnCl2 and dmise in boiling
acetonitrile. X-ray crystallographic studies of this complex show the expected tetrahedral
geometry about the zinc(II) center with Zn-Se bond distances of 2.4691(4) Å and
2.4873(4) Å.130 Although this is the only example of a zinc-selone complex with
monodentate selone ligands, this and future complexes may be of interest in the

Figure 1.21. Crystal structure of Zn(dmise)2Cl2.130 Hydrogen atoms are omitted for clarity.
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development of precursors for zinc selenide-based materials used in optical electronics,
laser technology, semiconductor research, and blue-green light emitting diode
materials.131-133
Parkin et al.123 have synthesized a novel bidentate ligand featuring two selenium
donor atoms [BseMe] (BseMe = bis(2-seleno-1-methylimidazolyl)hydroborato)) and
reported its reactions with ZnX2 (X = Cl and I) in 1:1 and 2:1 ratios, resulting in
{[BseMe]ZnX}2 ({[BseMe]ZnCl}2; Figure 1.22A) and [BseMe]2Zn (Figure 1.22B),
respectively. X-ray diffraction structures show that BseMe can act as both a monomer and
a bridging ligand, and in {[BseMe]ZnX}2, the bridging ligand is one of the 2-seleno-1methylimidazolyl selenium atoms rather than a halide.123 For {[BseMe]ZnX}2 complexes,
the Se,Se,X geometry about the Zn(II) is trigonal planar with Zn-Se bond distances
averaging 2.441 Å.123 The monomer [BmMe]ZnX exhibits tetrahedral geometry with bond
lengths averaging 2.445 Å, similar to the dimeric complexes.123 Although [BseMe] is an
analog of the mercapto ligand [BmMe], structural comparison of the analogous zinc iodide
compounds, {[BseMe]ZnI}2 and [BmMe]ZnI, demonstrated that the seleno ligand exhibits
a greater tendency to bridge metal centers than the mercapto ligand.123

Figure 1.22. Crystal structures of A) {[BseMe]ZnCl}2 and B) [BseMe]2Zn.123 Hydrogen atoms are omitted
for clarity.
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Metal-selone complexes are rare; however, they have become more investigated
in the past few years due to the recent discovery of selenoneine and other biological
selones.10,11 The few reported metal-selone complexes are easily synthesized with a
variety of late-transition-metal ions, including Fe(II), Co(II), Ni(II), Cu(I), Cu(II), and
Zn(II). Typical metal thione interactions involve significant backbonding from the metal
center, but most metal-selone complexes interact primarily through donor bonds with
little or no evidence of metal backbonding. Selone complexes are often similar to
analogous thione complexes, but seemingly minor M-S and M-Se bonding differences
can result in different coordination numbers and binding modes. Drawing wide-ranging
conclusions about selone coordination or comparisons to analogous thione complexes is
difficult, however, due to the paucity of well-characterized complexes and lack of
reactivity studies.
The metal coordination properties of thione- and selone-containing ligands have
been investigated for multiple applications, including antitumor and antioxidant
properties, protein active-site models, and optical materials. The wide structural diversity
exhibited by thione and selone donor ligands upon binding to first-row-transition metals
explains the considerable recent interest in their coordination chemistry. Many studies of
thione and selone complexes with these metal ions demonstrate rich coordination
chemistry with varying coordination numbers and geometries, reinforcing the fact that
subtle differences in both metal and ligand properties can have significant consequences
for resulting structure and reactivity.
Although electrochemical studies of metal-thione and -selone complexes are still
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uncommon, they indicate that both ligand and metal redox properties are altered upon
coordination. Copper-selone complexes have lower Cu(II/I) reduction potentials
compared to their thione analogs, and this difference might be at least partly responsible
for the greater antioxidant activity observed for selones. The thione-scorpionate classes of
ligands have provided a facile system for modeling sulfur-rich metalloenzyme active
sites, including nickel-containing hydrogenases and zinc-containing thiolate alkylation
enzymes. Despite the utility of thione-scorpionate ligands, a limited number of
selone-scorpionate metal complexes have been reported. Reactivity studies of thione- and
selone-metal complexes are also scarce, and such studies related to antioxidant activity
and functional metalloenzyme modeling would be particularly relevant.
Sulfur and selenium should behave similarly due to their near-identical
electronegativities; however, their different atomic radii (1.04 and 1.17 Å,
respectively)134 result in increased bond distances and polarizability for selenium
compared to sulfur. Selenium’s longer bond distances and greater polarizability may
reduce backbonding and result in the observed differences in analogous thione- and
selone-metal coordination, but current studies of these ligands do not provide decisive
conclusions as to the specific properties that account for differences in their coordination
chemistry.

Irrespective of the specific cause, these differences between sulfur and

selenium as well as differences in the properties of thione and selone ligands result in
varied coordination complexes. This is not surprising, since organisms go to significant
lengths to include selenium in place of sulfur in amino acids. In large part, it remains to
be determined how much of the rich coordination chemistry demonstrated by both
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thiones and selones impacts the biological functions of naturally occurring thione and
selone compounds.
The review in this introductory Chapter is reprinted with permission from
Stadelman, B. S.; Brumaghim, J. L. In Biochalcogen Chemistry: The Biological
Chemistry of Sulfur, Selenium, and Tellurium; American Chemical Society: Washington,
2013, p 33-70. Copyright 2013 American Chemical Society; appropriate permissions can
be found in Appendix A.) The research presented in this dissertation involves
understanding the interactions of chalcogenone-containing compounds similar to
ergothioneine, selenoneine, and methimazole with iron(II) and Zn(II) as well as an
investigation into their antioxidant mechanisms when bound to to these metal ions.
The work presented in Chapter 2 investigates the effects of N,N’-1,3dimethylimidazole thione (dmit) and selone (dmise), bis(thioimidazolyl)ethane (ebit), and
bis(selenoimidazolyl)ethane (ebis) ligand coordination on the redox properties of the
thiones and selones as well as the effects on the redox properties of Fe(II). Experimental
results and DFT calculations both demonstrate that when bound to Fe(II), the thiones and
selones favor their zwitterionic resonance structures. Thione and selone coordination to
Fe(II) lowers the Fe(II/III) reduction potentials with a greater decrease for Fe(II)-dmise
than Fe(II)-bound dmit. Also, bound thione and selone oxidation potentials increase
significantly, indicating that iron-bound thione and selone ligands should undergo
oxidation prior to Fe(II).
The research described in Chapter 3 describes the reactivity of dmit, dmise and
their Fe(L)2Cl2 (L= N,N’-1,3-dimethylimidazole thione (dmit) and selone (dmise))
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complexes with H2O2. 1H NMR titrations and mass spectrometry studies demonstrate that
Fe(II)-bound dmit and dmise undergoes oxidation, forming the imidazolium cation and
S/Se oxide species. Fe(dmise)2Cl2 requires 4 equiv of H2O2 for complete oxidation, while
dmit required 6 equiv of H2O2. While dmit undergo oxidation, it does not protect Fe(II)
from oxidation, however dmise significantly protects iron Fe(II) from oxidation.
Chapter 4 discusses the synthesis of Zn(II)-dmit and –dmise complexes and their
reactivity towards H2O2 to understand what role the metal center plays in the redox and
antioxidant properties of dmit and dmise. Upon coordination to Zn(II), dmit and dmise
reduction potentials decrease, indicating that oxidation becomes more difficult. Oxidation
studies of Zn(L)2Cl2 (L= N,N’-1,3-dimethylimidazole thione and selone) complexes
indicate that Zn(II) binding decreases ease of oxidation of the thiones and selones in
which dmise requires 4 equiv of H2O2, while upon treatment with 6 equiv of H2O2 dmit
bound to Zn(II) does not undergo C=S bond cleavage forming the imidazolium cation but
instead oxidizes to a hydroxy bound thione.
Work described in Chapter 5 investigates the synthesis of novel thione and selone
compounds. Chapter 5 also introduces a novel synthetic route for the synthesis of novel
thione compounds. Testing these novel thiones and selones for their ability to bind iron
and copper and to prevent metal-mediated DNA damage will allow us to better
understand and tune the antioxidant properties of these compounds.
Chapter 6 describes the synthesis of novel Fe(II)-thione and –selone complexes
and demonstrates that altering the electronic structure of the coordinated thione and
selone ligands affects their binding properties towards Fe(II). Fe(II) and Zn(II) complexes
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of the formula M(L)2Cl2 and M(L’)Cl2 (L = methimazole or 2-mercaptoimidazole and L’
= (mimR)2 or (seimMe)2 (R = H or Me) were synthesized and characterized to see how the
altered aromaticity of the thiones and selones effects the binding mechanisms. The work
presented in Chapters 2, 3, 4, 5, and 6 will promote our understanding of sulfur and
selenium antioxidant activity and metal coordination properties as well as their ability to
scavenge reactive oxygen species such as H2O2.
ABREVIATION LIST
DNA = deoxyribonucleic acid
ROS = reactive oxygen species
NMR = nuclear magnetic resonance
GPx = glutathione peroxidase
DPPH = 2,2-diphenyl-1-picrylhydrazyl
PTU = 6-n-propyl-2-thiouracil
MTU = 6-methyl-2-thiouracil
amt = 4-amino-3-methyl-1,2,4-triazole-5-thione
dmit = N,N’-dimethylimidazole thione
dmise = N,N’-dimethylimidazole selone
mbit = 1,1’-methylenebis(1,3-dihydro-3-methyl-2H-imidazole-2-thione)
mbis = 1,1’-methylenebis(1,3-dihydro-3-methyl-2H-imidazole-2-selone)
ebit = 1,1’-(1,2-ethanediyl)bis(3-methyl-imidazole-2-thione)
ebis = 1,1’-(1,2-ethanediyl)bis(3-methyl-imidazole-2-selone)
ttcH3 = 2,4,6-trimercaptotriazine
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sbim = 1H-benzimidazole-2(3H)-thione
tsacH = thiosaccharinate
diap = 1,3-diazepane-2-thione
3-Me-HPT = l-hydroxy-3-methylpyridine-2(1H)-thione
TpR = tris(pyrazolyl)borate
TmR = hydrotris(methimazolyl)borate
BmR = hydrobis(methimazolyl)borate
TrR = hydrotris(thioxotriazolyl)borate
BrR = hydrobis(thioxobiazolyl)borate
HBmit3 = hydrotris(1-methylimidazol-2-ylthio)borate
Epa = anodic (oxidation) potential
LOX = lipogenase
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CHAPTER TWO
SYNTHESIS, CHARACTERIZATION, DFT CALCULATIONS, AND
ELECTROCHEMICAL COMPARISON OF NOVEL IRON(II)
COMPLEXES WITH THIONE AND SELONE LIGANDS

2.1 Introduction
Reactive oxygen species (ROS) are byproducts of cellular respiration that damage
lipids, proteins, and DNA.1-7 Iron(II) and copper(I) generate damaging hydroxyl radical
(Reaction 2.1)8-10 and this reaction becomes catalytic in vivo when cellular reductants
such as NADH reduce Fe(III)/Cu(II) to Fe(II)/Cu(I). This metal-mediated oxidative
damage to cells is an underlying cause of cardiovascular diseases, neurodegenerative
diseases, and cancer.3-7
Fe2+/Cu+ + H2O2  Fe3+/Cu2+ + •OH + OH-

(2.1)

Biological functions of the naturally occurring thione- (C=S) and selone- (C=Se)
containing compounds ergothioneine and selenoneine (Figure 2.1) are not well
established, but several studies indicate that they are antioxidants.11-17 Because
ergothioneine and selenoneine are not biosynthesized by humans, ergothioneine
concentrations in the blood serum of middle-aged and older adults vary between 1 and
9 μM due to differences in dietary consumption.18,19 Concentrations of recently
discovered selenoneine are much lower, with blood concentrations up to 9 nM in a
Japanese population with high bluefin tuna consumption.17
Ergothioneine and selenoneine are potent radical-scavenging antioxidants.13,17,20
In addition, ergothioneine is an established metal-binding antioxidant, and selenoneine
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may also act as an antioxidant through metal coordination.17,21,22 Ergothioneine binding
prevents Cu(I)-mediated oxidative DNA damage,22 and ergothioneine-Cu(I) coordination
has been investigated using DFT methods.21,22 Selenoneine prevents iron auto-oxidation
by binding iron(II) in hemoglobin and myoglobin.17 Methimazole (Figure 2.1) is a
hyperthyroidism drug structurally similar to ergothioneine.23 In hyperthyroidism patients,
methimazole blood concentrations range from 4-13 μM,24,25 and it also scavenges ROS to
prevent oxidative DNA damage.26,27 Although ergothioneine, selenoneine, and
methimazole have at least one NH group potentially available for metal binding, these
ligands universally bind at the S/Se atoms in preference to the NH site.28
Although iron concentrations in humans are difficult to measure and vary by
tissue, blood serum iron concentrations in healthy human adults range from 20-30 μM,29
and much higher concentrations of iron (0.1 – 17 mM) have been found in liver tissues of
men that died of natural causes.30 Non-protein-bound iron pools in human cells also vary
from 30 μM in the cytoplasm to over 200 μM in mitochondria.31 Since both iron and
thione- and selone-containing molecules are present in humans, iron-thione, and to a
lesser extent iron-selone, interactions are likely, warranting their thorough investigation.

Figure 2.1. Biologically relevant chalcogenone compounds and selone and thione ligands.
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Metal-thione complexes are widely studied and have been previously
reviewed.32-37 Rabinovich et al.38 determined the coordination chemistry of Cu(I), Ag(I),
and Au(I) with heterocyclic thiones and selones, and the coordination chemistry of
Hg(II)39-42 and Cd(II)43,44 with heterocyclic thiones is also reported. In addition, a few
Fe(II) complexes with tris(mercaptoimidazolyl)borate -type ligands are characterized
have been also been reported.45-48 Co(II) and Zn(II) complexes of the formula
M(dmise)2Cl2 (dmise = N,N’-dimethylimidazole selone; Fig. 1),49,50 as well as tetrakis
Cd(dmise)451 and Zn(dmit)452 (dmit = N,N’-dimethylimidazole thione; Fig. 1) also are
reported. Devillanova et al.53 investigated the Cu(I) coordination chemistry of 2pyrrolidineselone, 2-imidazolidineselone, and 2-thiazolidineselone ligands. Other Cu(I)thione complexes of the formula Cu(L)2Cl (L = 1,3-dimethylimidazoline-2-thione, N,N’dimethylimidazolidine-2-thione, N,N’-diethylimidazolidine-2-thione, and N-ethyl-1,3imidazolidine-2-thione)54-56 and a Cu(II)-thione complex of the formula Cu(L)2Cl2 (L =
1,3-diisopropyl-4,5-dimethylimidazoline-2-thione)57 are also known.
Dmit and dmise bind Cu(I) and Cu(II) in a variety of coordination modes.58-61
Dmise-copper

binding

significantly

lowers

the

Cu(II/I)

redox

potential

in

[TpmRCu(dmise)]+ complexes (TpmR = tris(3,5-di-R-pyrazolyl)methane; R = H, CH3,
and iPr) compared to analogous acetonitrile-coordinated complexes, resulting in Cu(II/I)
potentials that occur at or below -0.32 V, the potential at which NADH cannot reduce
Cu(II) to Cu(I).10,62 If NADH cannot reduce Cu(II), copper-mediated catalytic generation
of hydroxyl radical (Reaction 1) may be prevented.59 However, copper-thione
coordination may not be similarly effective at preventing catalytic radical formation,
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since the analogous dmit-Cu(I) complexes have Cu(II/I) reduction potentials significantly
higher than their selone counterparts.58,59,61
Although several sulfur- and seleno-amino acids and related compounds prevent
iron-mediated DNA damage by coordinating Fe(II),63-65 there are few biologically
relevant studies of thione-Fe(II) coordination66-68 and no reports of isolated selone-Fe(II)
complexes. However, selenoneine binds iron(II) in heme proteins and prevents its
oxidation.17 The recent discovery of selenoneine in tuna and human blood,16,17 has
spurred examination of selones to determine their antioxidant behavior and ability to bind
biologically common metals such as iron,69 copper,58,59,61,70,71 and zinc.72 We report the
synthesis and characterization of novel, mononuclear Fe(II) complexes of the formulae
FeL2Cl2, [FeL2(CH3CN)2]2+, [FeL4]2+ (L = dmit or dmise), and {Fe(ebit/ebis)Cl2}n (ebit =
bis(thioimidazolyl)ethane; ebis = bis(selenoimidazolyl)ethane; Figure 2.1) and an
investigation of how thione and selone binding alters Fe(II) redox potentials.
Understanding the coordination and electrochemical properties of these complexes may
elucidate possible iron-binding mechanisms for biological selone and thione antioxidants.

2.2 Results and Discussion
Synthesis of Fe(II)-thione and -selone complexes. Treating FeCl2·4H2O with two
equivalents of dmit or dmise in a mixture of dichloromethane and triethylorthoformate (to
remove water from the Fe(II) starting material) forms four-coordinate Fe(L)2Cl2 (L =
dmit (1) or dmise (2)) complexes (Scheme 2.1A). Both complexes decompose in air
within a few hours in the solid state and in 10-20 min in solution.
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To understand how labile solvato ligands affect the binding properties of Fe(II)thione and -selone complexes, Fe(II)-dmit and –dmise acetonitrile compounds were also
synthesized. Treating Fe(BF4)2∙6H2O with two equiv of dmit or dmise (Scheme 2.1B)
afforded

peach

and

yellow

powders

of

[Fe(dmit)2(CH3CN)2]2+

(3)

and

[Fe(dmise)2(CH3CN)2]2+ (4), respectively. The air stability of 3 and 4 is far less than the
Scheme 2.1
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chloride complexes 1 and 2, with decomposition in solution and solid states occurring
within 5 to 10 min. To compare homoleptic complexes of dmise and dmit, [Fe(dmit)4]2+
(5) and [Fe(dmise)4]2+ (6) were synthesized. Similar to 3 and 4, treating Fe(OTf)2 or
Fe(BF4)2 with 4 equivalents of dmit or dmise affords green and yellow powders of
[Fe(dmit)4]2+ (5) and [Fe(dmise)4]2+ (6) (Scheme 2.1C).
Under similar conditions, bidentate ebit and ebis ligands afford the polymeric
Fe(II) complexes {Fe(ebit)Cl2}n and {Fe(ebis)Cl2}n, similar to previously reported
{FeLCl2}n complexes (L = bis(3-tert-butyl-2-thione-imidazolyl)methane).68

Treating

FeCl2·4H2O with one molar equivalent of ebit or ebis in triethylorthoformate and
dichloromethane solution and filtration of the resulting precipitate yields tan
{Fe(ebit)Cl2}n (7) or pale yellow {Fe(ebis)Cl2}n (8; Scheme 2.1D). After 24 h, these solid
iron(II) complexes decompose in air. Solubility of complexes 7 and 8 are significantly
lower than for complexes 1 - 6, similar to that of the polymeric {Fe(L1/L2)Cl2}n
complexes (L1 = 1,1’-methylenebis(3-methylimidazole-2-thione) and L2 = 1,1’methylenebis(3-tert-butyl- imidazole-2-thione).68 MALDI mass spectrometry of 7 and 8
also suggests formation of a polymeric structure with fragmentation patterns different
from monomeric complexes 1 - 6, and polymeric complex formation for 7 is confirmed
by X-ray crystallography (vide infra).
Structural analysis of iron-thione and -selone complexes. Single crystals of
Fe(dmit)2Cl2 (1; Figure 2.2A), Fe(dmise)2Cl2 (2; Figure 2.2B), [Fe(dmit)4][BF4]2 (5b;
Figure 2.2C), and [Fe(dmise)4][BF4]2 (6b; Figure 2.2D) were grown via slow diffusion of
ether into acetonitrile solutions of the corresponding complexes, and their structures
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determined by X-ray diffraction. Similar compounds such as Co(dmise)2Cl249 and
Zn(dmise)2Cl250 have been synthesized, but compounds 2 and 6b represent the first
structurally characterized iron-selone complexes. Selected bond distances and angles are
summarized in Table 1, and their structures are shown in Fig. 2. Complexes 1 and 2 are
an isomorphous pair containing Fe(II) bound to two Cl atoms and two S/Se atoms from a
heterocyclic chalcogenone (Figure 2.2; crystal packing diagrams for 1 and 2 are shown in
Figures. 2.8 and 2.9, respectively). In 5b and 6b, Fe is coordinated to four S (5b) or Se
(6b) atoms to form the tetrakis [Fe(dmit/dmise)4]2+ complexes (Figure 2.2; crystal
packing diagrams for 5b and 6b are shown in Figures 2.10 and 2.11, respectively),
likewise forming an isomorphous pair. The Fe(II) valence was confirmed by the two
coordinated Cl- ions in 1 and 2, and the presence of uncoordinated [BF4]- counterions in a
2:1 ratio with Fe in 5b and 6b.
Table 2.1. Selected bond lengths and angles for Fe(dmit)2Cl2 (1), Fe(dmise)2Cl2 (2), [Fe(dmit)4][BF4]2 (5b),
[Fe(dmise)4][BF4]2 (6b).
1
Fe1—S1

2
2.3687 (18)

Fe1—Se1

5b
2.4882 (7)

Fe1—S1

Fe1—S2

2.3950 (19)

Fe1—Se2

2.5140 (10)

Fe1—S1

Fe1—Cl1

2.2977 (18)

Fe1—Cl1

2.2977 (8)

Fe1—Cl2

2.2887 (19)

Fe1—Cl2

2.2877 (8)

S1—C2

1.719 (6)

Se1—C2

S2—C7

1.715 (6)

Cl1—Fe1—S1

110.36 (7)

6b
2.3395 (9)

i

Fe1—Se1

2.4533 (9)
i

2.3395 (9)

Fe1—Se1

2.4533 (9)

Fe1—S2

2.3495 (8)

Fe1—Se2

2.4566 (8)

Fe1—S2i

2.3495 (8)

Fe1—Se2i

2.4566 (8)

1.873 (3)

S1—C1

1.711 (3)

Se1—C1

1.861 (5)

Se2—C7

1.869 (3)

S2—C6

1.715 (3)

Se2—C6

1.864 (6)

Cl1—Fe1—Se1

109.71 (3)

S1i—Fe1—S1

120.14 (6)

Se1i—Fe1—Se1

122.83 (6)

Cl1—Fe1—S2

109.32 (7)

Cl1—Fe1—Se2

109.42 (3)

S1 —Fe1—S2

105.20 (3)

Se1 —Fe1—Se2

104.77 (2)

Cl2—Fe1—S1

118.62 (7)

Cl2—Fe1—Se1

118.34 (2)

S1i—Fe1—S2i

105.62 (3)

Se1i—Fe1—Se2i

103.80 (2)

Cl2—Fe1—S2

106.82 (7)

Cl2—Fe1—Se2

106.89 (2)

S1—Fe1—S2

105.62 (3)

Se1—Fe1—Se2

103.80 (2)

S1—Fe1—S2

100.01 (7)

Se1—Fe1—Se2

99.09 (2)

i

S1—Fe1—S2

i
i

105.20 (3)

i

Se1—Fe1—Se2

i

104.77 (2)

i

117.91 (5)

Cl2—Fe1—Cl1

110.83 (7)

Cl2—Fe1—Cl1

112.29 (3)

S2—Fe1—S2

115.64 (5)

Se2—Fe1—Se2

C2—S1—Fe1

104.9 (2)

C2—Se1—Fe1

101.67 (8)

C1—S1—Fe1

101.33 (9)

C1—Se1—Fe1

98.64 (15)

C7—S2—Fe1

101.3 (2)

C7—Se2—Fe1

98.24 (8)

C6—S2—Fe1

99.68 (9)

C6—Se2—Fe1

98.13 (15)

i symmetry operator for symmetrically equivalent atoms: -x, y, -z+3/2
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Figure 2.2. Crystal structure diagrams with 50% probability density ellipsoids for A) Fe(dmit)2Cl2 (1), B)
Fe(dmise)2Cl2 (2), C) [Fe(dmit)4][BF4]2 (5b), and D) [Fe(dmise)4][BF4]2 (6b). Hydrogen atoms and
counterions are omitted for clarity.

All the Fe(II) centers in these complexes adopt a distorted tetrahedral
coordination geometry with bond angles ranging from 99.09(2) to 122.83(6)°, possibly
due to ligand steric bulk. The angular distortion about Fe in 6b is comparable to that
observed in 1 and 2, whereas complex 5b is distorted to a somewhat lesser degree. Using
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the τ4 geometry index of Yang and coworkers,73 four-coordinate geometry indices of
0.93, 0.92, 0.90, and 0.85 are calculated for complexes 1, 2, 5b, and 6b, respectively.
Thus, complexes 1, 2, and 5b appear to be intermediates of tetrahedral and trigonal
pyramidal geometries, while 6b closely approaches the trigonal pyramidal threshold. The
observed Fe-S-C (99.68(9) to 104.9(2)°) and Fe-Se-C (98.13(15) to 101.67(8)°) bond
angles fall within the expected ranges.66,67 Average Fe-S bond distances for 1 and 5b
(2.382(2) and 2.345(1) Å, respectively) are similar to previously reported Fe(II)-thione
complexes (2.298 - 2.474 Å).66,67 The mean Fe-Se bond distances for 2 and 6b (2.501(1)
and 2.454(1) Å, respectively) are slightly longer than other reported iron(II)-selenolate
bond distances (2.443(1) Å in an iron tetrakis phenyl selenolate),74 an expected result for
these Fe(II)-selones, since the number of available electrons and greater negative charge
on the Se atom of the selenolate should result in a shorter bond. The average C=Se
distance (1.867(6) Å) in 2 and 6b is only slightly elongated compared to the unbound
ligand (1.843 Å75). The observed average C-S (1.715(6) Å) and C-Se (1.867(6) Å) bond
distances in all of the structures are indicative of C=S and C=Se in thiones and selones
compared to single bonds (typically 1.808(1) Å and 1.970(1) Å for C-S and C-Se,
respectively76). The bis-thione and -selone complexes 1 and 2 exhibit longer Fe-S/Se
bond distances than their tetrakis (5b and 6b) counterparts, perhaps due to the better πdonor abilities of the chloride ligands in 1 and 2.
The average C2-C3, N1-C1, and N2-C1 bond lengths for dmit complexes 1 and
5b (1.32(1) and 1.318(5) Å for C2-C3; 1.350(9) and 1.346(4) Å for the averages of N1C1 and N2-C1, respectively) are not significantly different from unbound dmit (1.3255(3)
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and 1.3489(3) Å77). Likewise, the average N1-C2 and N2-C3 bond lengths in 1 and 5b
are similar (1.385(8) and 1.379(5) Å, respectively) to dmit (1.394(6) Å77) and close to the
analogous bond lengths for the aromatic imidazolium cation (1.363(3) Å78), indicating
that the bound dmit ligands in these complexes may favor the zwitterionic form (Figure
2.3A).
For complex 2, The average C2-C3 bond length for iron-coordinated dmise
(1.348(4) Å) does not differ from that of unbound dmise (1.345(7) Å75), but the C2-C3
bond length for the tetrakis-dmise complex 6b is slightly shorter (1.32(1) Å). Although
the average N1-C1 and N2-C1 bond lengths for 2 and 6b are not significantly different
from uncoordinated dmise (1.343(7) Å75), the average N1-C2 and N-C3 bond lengths in
these complexes are slightly longer than those of unbound dmise (1.371(7) Å75). This is
opposite the trend observed in dmit complexes 1 and 5b, and indicates slightly different
coordination properties for dmit and dmise. X-ray diffraction analysis also showed that
the [Fe(dmit)4]2+ (5a) and

[Fe(dmise)4]2+ (6a) cations crystallized with triflate

counterions are effectively identical to their tetrafluoroborate analogs (5b and 6b). The
E
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triflate counterions in these structures are not well-behaved, however, resulting in poor
statistical residuals despite consistency of all supporting characterization with the
molecular structure. Complexes 7 and 8 proved difficult to crystallize as X-ray-quality
single crystals due to low solubility of the complexes. A discussion of the crystal growth
attempts and structure of 7 are provided at the end of the experimental section (Figures
2.12 and 2.13 and Tables 2.7 and 2.8).
Density functional theory calculations. Density functional theory (DFT) geometry
optimizations were performed for 1-6 assuming tetrahedral coordination of a high spin
state Fe(II) center. Bond lengths and angles for the DFT structures are generally
consistent with X-ray structures of 1, 2, 5 and 6 (Table 2.2). For 1 and 2, the dmit/dmise
ligands do not have the same conformation as the X-ray structure and prefer to rearrange
to a C2v orientation with CH···Cl interactions to the dmit/dmise methyl groups (Figure
2.4). We note that the conformation in the X-ray structures (~4 kcal/mol above the C2v
Table 2.2. Selected DFT(mPW1PW91) bond lengths (Å) and angles (˚) for FeCl2(dmit)2 (1), FeCl2(dmise)2
(2), [Fe(dmit)2(MeCN)2]2+ (3), [Fe(dmise)2(MeCN)2]2+ (4), [Fe(dmit)4]2+ (5) and [Fe(dmise)4]2+ (6).
1
3A
3B
5a
Fe-S
2.437
Fe-S
2.345
2.344
Fe-S
2.381
Fe-Cl
2.290
Fe-N
2.066
2.065
S-C
1.735
S-C
1.721
S-C
1.737
1.738
C-N
1.149
1.150
Cl-Fe-S
110.1
N-Fe-S
103.1, 113.2 112.2, 116.4 S-Fe-S
105.3, 118.3
S-Fe-S
97.0
S-Fe-S
120.1
96.4
Fe-S-C
108.2
Cl-Fe-Cl
117.6
N-Fe-N
102.2
103.7
Fe-S-C
97.0
Fe-S-C
113.4
113.0
2
4A
4B
6a
Fe-Se
2.555
Fe-Se
2.469
2.467
Fe-Se
2.501
Fe-Cl
2.293
Fe-N
2.070
2.067
S-C
1.889
S-C
1.875
S-C
1.891
1.894
C-N
1.149
1.150
Cl-Fe-Se
110.0
N-Fe-Se
103.2, 113.6 113.2, 117.1 Se-Fe-Se 103.8, 120.9
Se-Fe-Se
98.6
Se-Fe-Se
121.2
93.7
Fe-Se-C
105.9
Cl-Fe-Cl
116.6
N-Fe-N
101.1
103.3
Fe-Se-C
92.8
Fe-Se-C
109.9
110.2
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structures) is stabilized by intermolecular interactions that are not represented in the gasphase calculations. Two possible conformations of the dmit/dmise ligands for 3 and 4
were found in which the imidazole groups are either tilted toward (3A, 4A) or away from
(3B, 4B) the iron (Figure 2.4). The latter structure is 1-3 kcal/mol more stable and has a
larger E-Fe-E angle in its distorted tetrahedral coordination (Table 2). Fe-E bond
distances in these complexes are shorter than the dichloro and tetrakis complexes due to
reduced steric effects around the metal and lesser electrostatic competition with the
acetonitrile ligands.
Trends in the DFT bond distances for the dmit and dmise ligands in the
complexes versus free thione and selone are consistent with increased contribution of the
zwitterionic resonance structure upon Fe(II) coordination. The structures of free dmit and
dmise themselves show significant contribution of the zwitterionic resonance structure
(Fig. 3A). The dmit/dmise C-E bonds (1.684 and 1.838 Å, respectively) are significantly
longer than the “true” chalcogenones thioacetone (1.638 Å) or selenoacetone (1.779 Å)

Figure 2.4. Conformations of 1, 2, 3 and 4 obtained by DFT geometry optimizations. Bond distances given
in Å.
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calculated at the same level of theory, but similar to the N,N’-dimethyl thio- and
selenoureas (1.686 and 1.843 Å, respectively). The shift to the zwitterionic resonance
structure is also evident in the partial charge of E in dmit/dmise (qS = -0.633e, qSe =
-0.544e) relative to the ketones (qS = -0.396e, qSe = -0.322e). The zwitterionic character
of dmit/dmise is consistent with the HOMO, which is of C-E * character weighted
toward the E, much like a p-type lone pair localized on E. Therefore, the dmit/dmise
ligands should be assumed to coordinate as the zwitterion with -donation through one ptype E lone pair orbital and -donation from a second p-type orbital perpendicular to the
bond axis similar to thiolate/selenolate ligands (Fig. 3B). As a result, changes in bond
length upon complex formation are not as significant as would be expected from a “true”
chalcogenone, and coordination only further shifts the ligand toward the zwitterionic
form as indicated by the slight increase in the C-E bond (0.04-0.05 Å). The longest bond
distances are found in the cationic complexes 3B and 4B that are better able to stabilize
the partial thiolate/selenolate character of the zwitterionic ligand.
Infrared spectroscopy. Infrared spectroscopy was used to characterize all the
synthesized Fe(II)-thione and -selone complexes (Table 2.3). Upon Fe(II) binding, the
dmit ligands in complexes 1, 3, 5a, and 5b show a C=S stretch ranging from 1174-1178
cm-1, slightly shifted to lower energy compared to unbound dmit (1181 cm-1 79). The CN
stretches at 2372 and 2343cm-1 for 3 and 4, respectively, confirm iron(II)-acetonitrile
binding due to the shift to higher energies compared to unbound acetonitrile (2282 cm-1),
in accord with reported values for Fe(NCCH3)2Cl2.80 In contrast, selone complexes 2, 4,
6a, and 6b have C=Se stretching vibrations ranging from 1149-1155 cm-1, slightly shifted
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Table 2.3. Comparison of C=E stretching modes (cm-1) in Fe(II) dmit/dmise complexes.
experimental
1181
1148
1176
1149
1177
1153
1178
1155

dmit
dmise
1
2
3
4
5
6

DFT
1215
1177
1206
1180
1201 (3B)
1178 (4B)
1203, 1204
1178, 1181

to higher energies compared to unbound dmise (1147 cm-1

81,82

) indicating primarily

donor bond character interactions for dmise-Fe(II) binding. Similar differences in
bonding modes of thione and selone ligands have been observed for complexes with
Cu(I),58,59,61 Ni(II),82 and Co(II).83 DFT calculations of 1 - 5 agree well with the
experimental spectra and trends in the C=E bands (Table 2.3) which are shown to couple
with the modes of the imidazole ring.
In the polymeric complexes {Fe(ebit)Cl2}n (7) and {Fe(ebis)Cl2}n (8), the C=S/Se
stretch shifts to significantly higher energy (1152 and 1139 cm-1, respectively) compared
to unbound ebit or ebis (1136 and 1126 cm-1, respectively84), an effect opposite that
observed for the mononuclear thione complexes but similar to other Fe-dmise complexes.
Similar shifts to higher energy for the C=E stretches of bound ebit and ebis ligands are
also observed for polymeric {Co(ebit/ebis)Cl2}n.82
NMR spectroscopy. Although these Fe(II) complexes are paramagnetic, 1H NMR
spectra are observed after only a few scans, and
than 24 h. Both 1H and

13

C{1H} NMR can be acquired in less

13

C{1H} NMR resonances show shifting and broadening

commonly observed in paramagnetic NMR spectra. For example, the 1H NMR spectrum
of Fe(dmit)2Cl2 (1) shows a large downfield shift for the methyl proton resonance (δ
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15.3) and a large upfield shift of the olefinic proton resonance (δ 2.12) compared to
unbound dmit (δ 3.53 and δ 6.64, respectively85), as confirmed by peak integrations and
the increased broadening of the methyl resonances due to closer proximity of the methyl
groups to paramagnetic Fe(II).86 Thione complexes 3, 5a, and 5b also show similar, but
less pronounced, downfield shifts for the methyl proton resonances and upfield shifts for
the olefinic proton resonances in their 1H NMR spectra. 1H and

13

C{1H} NMR data for

complexes 1-8 are given in Table 2.4, and 1H NMR spectra are provided in Figures. 2.14
- 3.22.
In contrast to the Fe(II)-thione complexes, 1H NMR spectra of Fe(II)-selone
complexes 2 (Figure 2.5A), 4, 6a, and 6b show much less downfield shifting of the
methyl and olefinic resonances compared to unbound dmise.85 Although similar
downfield shifts
Table 2.4. 1H and
ligands.

13

C{1H} NMR chemical shifts of Fe(II)-thione and -selone complexes and unbound
1

13

C{1H} shift (δ)

H shift (δ)

Ligand or Fe(II) complex
dmit
Fe(dmit)2Cl2 (1)
[Fe(dmit)2(CH3CN)2][BF4]2 (3)

CH3
3.61
15.3
8.94

H-4/5
6.72
2.12
5.65

[Fe(dmit)4][OTf]2 (5a)

7.40

[Fe(dmit)4][BF4]2 (5b)
dmise
Fe(dmise)2Cl2 (2)
[Fe(dmise)2(CH3CN)2][BF4]2 (4)
[Fe(dmise)4][OTf]2 (6a)
[Fe(dmise)4][BF4]2 (6b)
ebit
{FeCl2(ebit)}n (7)
ebis
{FeCl2(ebis)}n (8)
n.o. = not observed

8.51
3.71
3.62
4.69
6.08
6.41
3.77
3.42
3.85
3.81

CH3
35.7
30.9
23.6

CH-4/5
117.9
100.1
108.2

C=S/Se
162.6
91.0
147.7

5.94

27.5

111.1

141.8

5.81
6.88
7.19
6.69
7.26
5.77
7.09, 6.84
6.71, 6.10
7.30, 7.03
7.13, 6.94

23.8
37.2
37.6
36.9
28.2
37.0
35.2
n.o.
37.2
n.o.

108.9
119.7
121.9
114.8
111.4
116.3
118.8
n.o.
119.9
n.o.

139.0
155.7
151.5
168.6
146.5
132.9
162.4
n.o.
155.8
n.o.
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CH2

4.31
4.71
4.07
4.61

CH2

45.6
54.4
47.3
n.o.

Figure 2.5. A) 1H NMR spectrum and B) 13C{1H} NMR spectrum of Fe(dmise)2Cl2 (2) in CD3CN.

for the olefinic resonances upon metal binding have been reported for copper- and
platinum-thione complexes and attributed to increased aromaticity of the thione ligand
upon metal binding,58,59,87 Fe(II) paramagnetic effects make similar ligand binding trends
in complexes 1-8 difficult to determine by NMR spectroscopy. Differences in 1H NMR
chemical shifts for 5a/5b and 6a/6b may result from varying cation-anion interactions.
Unlike the monodentate dmit complexes, the 1H NMR spectrum of {Fe(ebit)Cl2}n
(7) shows upfield shifts for both the imidazole and methyl resonances, whereas the
bridging ethylene protons shift downfield compared to unbound ebit.84 {Fe(ebis)Cl2}n (8)
shows similar upfield shifts for the imidazole and methyl resonances and downfield shifts
for the bridging ethyl resonances compared to unbound ebis.84
Paramagnetic broadening and shifting, particularly for the C=S/Se carbon
resonance, is also observed in the

13

C{1H} NMR for complexes 1 - 6. Unlike in the 1H

NMR spectra, methyl resonances ( 27.6 - 37.6) always appear upfield of the olefinic
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resonances ( 100.1 – 121.9) in the

13

C{1H} NMR spectra of these complexes, as

confirmed by DEPT-90 spectra. Upon Fe(II) binding, the S/Se=C carbon resonances in
the iron-thione complexes 1, 3, and 5 show upfield shifts of δ 15 to 72 compared
unbound dmit. The

13

C{1H} NMR spectrum of Fe(dmise)2Cl2 (2) is shown in Figure

2.5B, and the C=Se resonance for this complex is shifted upfield by δ 4 compared to
unbound dmise.85 Similar upfield shifts in the C=S/Se 13C{1H} NMR resonances are also
observed for Hg(II)- and Cu(I/II)-thione complexes as well as Cu(I/II)-selone
complexes.40,58,59,61 However, Fe(II)-selone complexes 4, 6a, and 6b show significant
broadening and both upfield and downfield shifts of this resonance relative to that of
unbound dmise, due to paramagnetic effects from proximity to Fe(II). Most

13

C{1H}

NMR resonances for complexes 7 and 8 were not observed due to the low solubility of
these complexes in any solvent.
Cyclic voltammetry. Electrochemical studies of Cu(I) [TpmRCu(dmit/dmise)]+
complexes showed that dmit or dmise coordination decreased the Cu(II/I) redox potential
by 347–847 mV relative to acetonitrile binding.59 If similar thione and selone complexes
form in vivo, these Cu(II/I) potentials may sufficiently low to prevent Cu(II) reduction by
NAD(P)H, inhibiting catalytic metal-mediated hydroxyl radical generation.10,62 In
addition, hydrogen-peroxide oxidation studies of [TpmMeCu(dmit/dmise)]+ demonstrated
that the dmit and dmise ligands oxidize prior to Cu(I).59 Thus, electrochemical studies of
Fe(II)-thione and -selone complexes 1 - 8 were of particular interest to determine whether
thione and selone

coordination significantly alters iron and/or

electrochemical potentials.
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ligand-based

The electrochemical behavior of thiones and selones is complex, reflecting the
redox accessibility typical of sulfur and selenium compounds. Although these studies are
conducted in acetonitrile, it is expected that the electrochemical trends would not be
significantly altered in aqueous solution because these thiones and selones cannot be
protonated. The cyclic voltammogram of dmit (Figure 2.6A) shows irreversible reduction
(Epa) and oxidation (Epc) waves at -0.14 and 0.59 V, respectively (Table 2.5). The
voltammogram of dmise (Figure 2.6A) shows similar irreversible redox behavior (Epa = 0.15 V and Epc = 0.37 V). However, preventing reduction by starting the negative scan at
0.30 for dmit or 0.16 V for dmise results in only an oxidation wave (Figure 2.6B),
indicating that reduction occurs only after oxidation of dmit or dmise to the
corresponding disulfide or diselenide. This dependence of reduction on prior oxidation
has been previously reported for methimazole.88,89 The two-electron process is confirmed
in the negative differential pulse voltammogram (DPV) for dmit (Figure 2.27A), where
two, one-electron waves are observed upon reduction of oxidized dmit. The cyclic
voltammograms of ebit and ebis (Figure 2.23A) also show irreversible reduction and
oxidation waves, with a similar dependence of the reduction wave on prior ebit or ebis
oxidation (Table 2.5 and Figure 2.23B). The DPV of ebis shows two reduction waves in
the DPV (Figure 2.29), corresponding to two, one-electron reductions of the oxidized
product. Due to the dependence of the reduction waves on prior thione and selone
oxidation, E1/2 values are not reported for the ligand-based redox potentials in Table 5.
Dmise and ebis undergo oxidation more readily than dmit and ebit, with an average
oxidation potential 0.21 V lower than their thione analogs.
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Figure 2.6. Cyclic voltammograms of 10 mM dmit (dashed) and dmise (solid) with initial potentials of A)
1.0 V and B) 0.30 V and 0.16 V, respectively, showing dependence of the dmit and dmise reduction wave
upon prior oxidation.

The cyclic voltammograms of Fe(II)-thione complexes 1, 3, 5a, and 7 (Figures 2.7
and 2.24) show both ligand-based reduction (Epc) and oxidation (Epa) waves, similar to
electrochemistry observed for unbound dmit and ebit (Figure 2.23). As is the case for the
unbound thiones, the thione-based ligand reduction waves are dependent upon prior
ligand-based oxidation (Figure 2.25). Two, ligand-based, one-electron reductions of the
oxidized disulfides observed in the negative DPV for 1, 3, 5a, and 7 (Figures 2.31, 2.33,
2.35, and 2.37). Fe(II) binding in 1, 3, and 5a increases the dmit-based oxidation and
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Table 2.5. Redox potentials of selone and thione ligands and their iron complexes versus NHE.

Ligand or Complex
FeCl2 · 4H2O

Ligandbased
Potentials
(V)
Epca
Epa

FeII/0-based Potentials (V)

FeIII/II-based Potentials (V)

Epc

Epa

∆E

E1/2

Epc

Epa

∆E

E1/2

-

-1.31

-0.24

1.07

-0.78

0.11

0.26

0.15

0.18

0.59

-

-

-

-

-

-

-

-

Fe(dmit)2Cl2 (1)

0.14
0.15

0.69

-1.54

-0.50

1.05

-1.02

-0.55

0.23

0.78

0.16

[Fe(dmit)2(CH3CN)2][OTf]2 (3)

0.05

0.59

-1.23

-0.09

1.14

-0.66

-

-

-

-

[Fe(dmit)4][OTf]2 (5a)

0.69

-1.04

-0.01

0.94

-0.53

-0.52

-

-

-

0.37

-

-

-

-

-

-

-

-

Fe(dmise)2Cl2 (2)

0.12
0.15
0.14

0.41

-1.53

-0.50

1.04

-1.01

-0.57

0.13

0.70

0.22

[Fe(dmise)2(CH3CN)2][OTf]2 (4)

0.05

0.36

-1.10

-0.10

0.94

-0.63

-

-

-

-

dmit

dmise

[Fe(dmise)4][OTf]2 (6a)

0.11 0.36
-1.01
-0.08
0.93 -0.54 -0.40
ebit
0.51
0.01
{Fe(ebit)Cl2}n (7)
0.08 0.64
-1.48
-0.55
0.94 -1.02 -0.56
0.19
0.75
ebis
0.32
0.27
{Fe(ebis)Cl2}n (8)
0.38
-1.44
-0.46
0.98 -0.95 -0.60
-0.17 0.43
0.06
a
Ligand and ligand-based reduction potentials are dependent on oxidation to the disulfide and diselenide.

-0.18
-0.38

Figure 2.7. Cyclic voltammograms of Fe(dmit)2Cl2 (1; dashed) and Fe(dmise)2Cl2 (2; solid) in acetonitrile.
Initial scan starting at +1.53 V running negative to -1.67 V.

reduction potentials by an average of 0.14 and 0.27 V, respectively, compared to
unbound dmit, indicating that iron-bound dmit is more easily oxidized and reduced. For
{Fe(ebit)Cl2}n (7) the ligand-based oxidation wave also increases by 0.13 V, whereas the
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ligand-based reduction wave decreases by 0.05 V compared to that of unbound ebit.
Cyclic voltammograms of Fe(II)-selone complexes 2, 4, 6a, and 8 (Figure 2.7 and
2.24) also exhibit selone-ligand-based oxidation and reduction waves where the ligandbased reductive wave is dependent upon prior ligand-based oxidation (Figure 2.25).
Similar to the Fe-thione complexes, two, selone-based, one-electron reduction waves are
also observed in the negative DPV for complexes 2, 4, 6a, and 8, and one selone-based
oxidation wave is observed in their positive DPV spectra (Figures 2.32, 2.34, 2.36, and
2.38). Changing the counterion from triflate to tetrafluoroborate in the tetrakis Fe(II)dmit and -dmise complexes 5a, 5b, 6a, and 6b does not significantly alter their
electrochemistry.
The cyclic voltammograms of Fe(II)-dmise complexes 2, 4, and 6a have ligandbased oxidation potentials more negative by an average of 0.15 V relative to Fe(II)-dmit
complexes 1, 3, and 5a (Table 2.5), indicating that iron-coordinated dmit is more readily
oxidized than iron-coordinated dmise. When the chlorides in complexes 1 and 2 are
replaced with solvato ligands in complexes 3 and 4, all ligand-based potentials are
reduced by 0.05-0.10 V. Replacing the chlorides in 1 and 2 with additional dmit and
dmise ligands to form the Fe-tetrakis complexes 5a and 6a results in a slight decrease in
the dmit-based reduction potential for 5a (-0.03 V) and both dmise-based reduction and
oxidation potentials for 6a (-0.03 and -0.05 V, respectively). The cyclic voltammograms
for polymeric complexes 7 and 8 have ligand-based oxidation potentials for Fe(II)-bound
ebit and ebis lower than those of Fe(II)-bound dmit and dmise in complexes 1 and 2 by
an average of 0.40 V, indicating that Fe(II)-bound ebit and ebis are more susceptible to
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oxidation than Fe(II)-bound dmit and dmise.
Two-electron, irreversible redox behavior is observed for the Fe(II/0)-derived
redox potentials (E1/2) in the CV of complexes 1 - 7, whereas the CV of complex 8 only
exhibits a Fe(II/0)- derived reduction potential. When thione and selone ligands bind
Fe(II) in 1, 2, 7, and 8, the Fe(II/0)-derived reduction potentials become more negative by
an average of 0.22 V compared to FeCl2·4H2O (Table 1.5 and Figure 2.26). In contrast,
the Fe(II)-dmit/dmise acetonitrile complexes 3 and 4 and the tetrakis dmit/dmise
complexes 5a and 6a show a 0.12-0.25 V increase in Fe(II/0) reduction potentials
compared to FeCl2·4H2O. The significantly lower Fe(II/0)-derived E1/2 values for the
dichloride complexes 1, 2, 7, and 8 relative to 3, 4, 5a, and 6a indicate that the chloride
ligands stabilize Fe(II) relative to additional dmit, dmise, or acetonitrile ligands.
The cyclic voltammograms of complexes 1, 2, 7, and 8 also show one-electron,
quasi-reversible redox waves attributable to Fe(III/II)-derived E1/2 reduction potentials,
whereas only Fe(III/II)-derived reduction waves are observed for the tetrakis complexes
5a and 6a (Table 2.5). Fe(III/II)-derived reduction waves in 5a and 6a and all Fe(III/II)derived waves for complexes 3 and 4 are not observed in their voltammograms due to
overlap with ligand-based waves. When dmit or ebit binds Fe(II) in complexes 1 and 7,
the Fe(III/II)-derived reduction potentials become substantially more negative by 0.34
and 0.36 V, respectively, compared to FeCl2·4H2O. When dmise or ebis binds Fe(II) in
complexes 2 and 8, the Fe(III/II)-derived reduction potentials become even more negative
by 0.40 and 0.56 V, respectively. The more negative shift for iron-selone Fe(III/II)derived reduction potentials compared to those of their thione analogs indicates that
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selone binding stabilizes Fe(III) more than thione binding. Similar Cu(II) stabilization
trends upon selone and thione coordination are also observed for Cu(I)-dmit and -dmise
complexes.58,59
These electrochemical data provide insight into whether similar Fe-thione and
selone complexes formed in vivo could cycle between Fe(III/II). Complexes with
reduction potentials lower than -0.32 V (versus NHE) cannot be reduced by cellular
reductants such as NADH, preventing catalytic hydroxyl radical formation.62,90 The
iron-selone complexes 2 and 8 have Fe(III/II)-derived reduction potentials of -0.22 and
-0.38 V, respectively, significantly lower potentials than for their iron-thione
counterparts. This same trend has been previously observed for [TpmRCu(dmit/dmise)]+
complexes with Cu(II/I) redox potentials ranging from -0.28 to -0.39 V for the copperdmise complexes and -0.07 to -0.23 V for copper-dmit complexes.59 Selone-copper
binding shifts Cu(II/I) reduction potentials near or outside the range of cellular
reductants, but the same cannot be said for dmit- or dmise-iron binding. Although
Fe(III/II)-derived E1/2 potentials for FeCl2·4H2O are significantly higher than dmit- and
dmise-bound Fe(II), the Fe(III/II)-derived potentials for 1, 2, and 7 still fall above -0.32
V, suggesting that similar biological complexes would not inhibit catalytic hydroxyl
radical formation by Fe(II). Only the Fe(III/II)-derived E1/2 potential for ebis complex 8
falls outside the reducing range of NAD(P)H, but biological bidentate selones are not
known. However, the significant electrochemical potential differences between ligandbased thione/selone and Fe(II/III)-derived oxidation potentials for complexes 1, 2, 7, and
8 (0.46, 0.28, 0.45, and 0.55 V, respectively) suggests that the bound thione or selone
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would undergo oxidation prior to Fe(II). Thus, thione and selone binding may protect
Fe(II) from oxidation to Fe(III) by sacrificial ligand oxidation. Overall, our results
suggest that further investigation of the biological antioxidant behavior of selone and
thione-containing compounds should explore the role of iron binding.

2.3 Conclusions
Biologically relevant Fe(II)-thione and -selone complexes have been synthesized
and characterized, the first such report of Fe(II)-selone complexes. DFT calculations and
1

H and

13

C{1H} NMR studies are consistent with dmit and dmise ligands favoring the

zwitterionic resonance structures when bound to Fe(II). Cyclic voltammetry studies
indicate that Fe(II/III)-derived reduction potentials of Fe-thione and most Fe-selone
complexes fall well within the window of biological reductants such as NADH (-0.32 V
versus NHE62). However, the thione and selone ligands in these Fe(II) complexes have
significantly higher ligand-based oxidation potentials then their corresponding Fe(II/III)derived potentials, suggesting that bound thiones and selones would more readily
undergo oxidation and potentially protect Fe(II) from oxidation. Oxidation studies of
these complexes and of iron bound to other thione and selone ligands, including
methimazole and 2-mercaptoimidazole, are ongoing.

2.4 Experimental Methods
General procedures. The handling and synthesis of all iron complexes were
carried out under an inert atmosphere of nitrogen or argon with dry solvents using
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standard glove-box and Schlenk techniques. Iron(II) triflate,91 dmit,92 dmise,92 ebit,68 and
ebis68 ligands were synthesized following reported procedures. Hydrated iron(II) chloride
(Acros) and hydrated iron(II) tetrafluoroborate (Acros) were used as received, as were all
other reagents.
Instrumentation. 1H and 13C NMR spectra were obtained on a Bruker-AVANCE
300 MHz NMR spectrometer. 1H NMR chemical shifts are reported in δ relative to
tetramethylsilane (δ 0) and referenced to solvent. 1H NMR and

13

C{1H} chemical shifts

of complexes 1-8 are listed in Table 2.4, and all 1H NMR spectra for complexes 1-8 are
provided in Figures 2.2 and 2.14 – 2.22. Infrared spectra were obtained using Nujol mulls
on KBr salt plates with a Magna 550 IR spectrometer. Abbreviations used in the
description of vibrational data are as follows: vs, very strong; s, strong; m, medium; w,
weak; b, broad. MALDI mass spectrometry experiments were performed using a Bruker
Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-tert-butylphenyl)-2methyl-2-propenyldiene (250.34 m/z) as the matrix. Electrospray ionization mass
spectrometry (ESI-MS) was conducted using a SYNAPT G2 LC/MS/MS System from
Waters via direct injection of sample (0.10 mL/min flow rate) into a Turbo Ionspray
ionization source. Samples were run under positive mode in acetonitrile, with an ionspray
voltage of 2500 V and in QTOF scan mode.

All observed peak envelopes match

theoretical calculations for their ions. UV-vis spectra were collected using a Shimadzu
UV-3101 PC spectrophotometer in quartz cuvettes with a path length of 1 cm.
Cyclic voltammetry. A three-compartment cell was used with an Ag/AgCl
reference electrode, a Pt counter-electrode, and a glassy carbon working electrode.

88

Acetonitrile (distilled and stored over 4Å molecular sieves) was used as solvent with
tetra-n-butyl ammonium phosphate as the supporting electrolyte. Solutions containing 0.1
M electrolyte were deaerated for 10 minutes by vigorous nitrogen purge. All E1/2 values
were calculated from (Epa + Epc)/2 at a scan rate of 100 mV/s. The ferrocenium/ferrocene
couple was measured under the same conditions to correct for junction potentials. The
measured potentials were adjusted from Ag/AgCl to NHE (-0.197 V93) and then corrected
with the measured ferrocenium/ferrocene couple vs. NHE (0.400 V94).

Cyclic

voltammograms for unbound ebis and ebit and complexes 1, 2, 5a, 6a, 7, 8, and
FeCl2∙4H2O are provided in Figures 2.23 - 2.26 and DPV data for all compounds are
given in Figures 2.27 -2.38).
Synthesis of Fe(dmit)2Cl2 (1). FeCl2∙4H2O (256 mg, 1.31 mmol) was dissolved in
triethylorthoformate (5 mL) and to this was added dmit (334 mg, 2.61 mmol) in a mixed
solvent system of triethylorthoformate/dichloromethane 2:1 (6 mL) via cannula. Upon
addition of dmise to the FeCl2∙4H2O solution, a brown precipitate immediately formed.
The reaction mixture was stirred for 6 h, filtered, and dried under vacuum to afford a
brownish solid. The solid was washed with diethyl ether (10 mL) to afford a pale beige
solid. Crystals for X-ray analysis were grown via slow vapor diffusion of ether into
acetonitrile. Yield: 430 mg, 86%. IR (cm-1): 3400 (b), 3121 (s), 2925 (s,b), 2728 (w),
1704 (w), 1559 (w,b), 1563 (s), 1482 (s,b), 1397 (s), 1231 (s), 1176 (s), 1127 (s), 1090
(s), 1017 (w), 858 (w), 756 (s), 678 (s), 632 (w), 612 (w), 499 (s). UV-vis λmax (nm): 215
(sh), 255, 303, 352. MALDI-MS (m/z) = 130 [FeCl2H]+, 256 [Fe(dmit)Cl2H]+, and 349
[Fe(dmit)2Cl]+. Anal. Calcd. for C10H16Cl2FeN4S2: C, 31.35; N, 14.65; H, 4.21. Found: C,
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31.11; N, 14.36; H, 4.22. Melting point: 189 oC (dec.).
Synthesis of Fe(dmise)2Cl2 (2). Complex 2 was prepared following the procedure
for 1 except that FeCl2∙4H2O (208 mg, 1.04 mmol) dmise (368 mg, 2.08 mmol) was used
in place of dmit. Crystals suitable for X-ray analysis were grown via slow vapor diffusion
of ether into acetonitrile. Yield: 420 mg, 84%. IR (cm-1): 3400 (b), 3112 (s), 2919 (b),
2856 (w), 2723 (w), 1701 (w), 1606 (w), 1564 (vs), 1467 (vs), 1386 (vs), 1226 (m), 1149
(m), 1090 (m), 864 (w), 752 (w) 664 (w), 468 (w). UV-vis λmax (nm): 232 (sh), 269, 318,
354. MALDI-MS (m/z) = 130 [FeCl2H]+, 304 [Fe(dmise)Cl2H]+. Anal. Calcd. for
C10H16Cl2FeN4Se2: C, 25.18; N, 11.75; H, 3.38. Found: C, 25.08; N, 11.50; H, 3.35.
Melting point: 147 oC (dec.).
Synthesis of [Fe(dmit)2(CH3CN)2][BF4] 2 (3). Complex 3 was prepared following
the procedure for 1 except that Fe(BF4)2.6H20 (297 mg, 0.176 mmol) instead of
FeCl2∙4H2O and dmit (226 mg, 0.176 mmol) was used. The acetonitrile reaction mixture
was stirred for 4 h, and the solvent was reduced to 5 mL. The product was precipitated
with diethyl ether to afford a peach colored solid that was air-dried under argon. Yield:
321.3 mg, 70%. 1H and 13C{1H} NMR resonances for the bound acetonitrile ligands were
not observed, likely due to a combination of paramagnetic line broadening and exchange
with CD3CN. IR (cm-1): 3165 (w), 2925 (s,b), 2726 (w), 2372 (w), 2343 (w), 1568 (m),
1488 (w), 1460(s), 1397 (w), 1376 (m), 1303 (w), 1239 (m), 1177 (m), 1054 (s), 743 (m),
675 (w). UV-vis λmax (nm): 217 (sh), 256, 324. ESI-MS (m/z) = 197.24
[Fe(dmit)2(CH3CN)2]2+. Anal. Calcd. for C14H22B2F8FeN6S2C14H22B2F8FeN6S2: C, 29.61;
N, 14.80; H, 3.90. Found: C, 29.96; N, 14.90; H, 4.01. Melting point: 188oC (dec.).
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Synthesis of [Fe(dmise)2(CH3CN)2][BF4] 2 (4). Compound 4 was prepared
following the procedure for 3 except for dmise (308.7 mg, 1.41 mmol) was used in place
of dmit yielding a yellow solid. Yield: 327.9 mg, 70%. 1H and 13C{1H} NMR resonances
for the bound acetonitrile ligands were not observed, likely due to a combination of
paramagnetic line broadening and exchange with CD3CN. IR (cm-1): 3463 (s,b), 3138
(w), 2926 (s,b), 2727 (w), 2673 (w), 2370 (w), 2344 (w), 2315 (w), 2267 (w), 1654 (m),
1568 (m), 1448(w), 1457 (s), 1377 (s), 1288 (w), 1240 (m), 1153 (m), 1066 (s,b), 754
(w), 742 (w), 723 (w), 662 (m). ESI-MS (m/z) = 268.72 [Fe(dmise)2(CH3CN)2]2+. Anal.
Calcd. for C14H22B2F8FeN6Se2FeN6Se2: C, 25.41; N, 12.70; H, 3.35. Found: C, 25.32; N,
12.65; H, 3.29. Melting point: 188oC (dec.).
Synthesis of [Fe(dmit)4][OTf] 2

(5a). Fe(OTf)2 (102.4 mg, 0.288 mmol) was

dissolved in acetonitrile (5 mL), and to this was added dmit (147.7 mg, 1.153 mmol) in
acetonitrile (10 mL) via cannula. The solution was stirred for 12 h, and the solvent was
reduced to 5 mL. The product was precipitated with diethyl ether then dried under
vacuum, affording a yellow solid. Yield: 175 mg, 70%. IR (cm-1): 3400 (b), 3121 (s)
2925 (s,b), 2727 (w), 1706 (w), 1557 (w,b), 1565 (s), 1483 (s,b), 1395 (s), 1232 (s), 1177
(s), 1127 (s), 1090 (s), 1016 (w), 859 (w), 755 (s), 676 (s), 633 (w), 613 (w), 498 (s).
UV-vis λmax (nm): 217 (sh), 256, 324. MALDI-MS (m/z) = 284.4 [Fe(dmise)4]2+. Anal.
Calcd. for C22H32F6FeN8O6S4C22H32F6 FeN8O6S4: C, 30.49; N, 12.93; H, 3.72. Found: C,
30.26; N, 12.80; H, 3.73. Melting point: 188 oC (dec.).
Synthesis of [Fe(dmit)4][BF4] 2 (5b). Complex 5b was prepared following the
procedure for 5a, except Fe(BF4)2.6H2O (226 mg, 0.670 mmol) was used in place of
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Fe(OTf)2 and more dmit (345 mg, 2.69 mmol) was used. Crystals suitable for X-ray
crystallography were grown via slow diffusion of ether into acetonitrile. Yield: 370 mg,
74%. IR (cm-1): 3433 (s,b), 3168 (m), 3141 (m), 3115 (w), 2920 (s,b), 2729 (w), 1569 (s),
1490 (w), 1463 (w), 1399 (s), 1377 (s), 1241 (m), 1178 (m), 1056 (b), 1015 (w), 850 (w),
801 (w), 746 (s), 677 (m), 521 (m), 499 (m). UV-vis λmax (nm): 217 (sh), 256, 324.
MALDI-MS (m/z) = 284.4 [Fe(dmise)4]2+. Anal. Calcd. for C20H32B2F8FeN8S4: C, 32.26;
N, 15.15; H, 4.35. Found: C, 25.82; N, 12.02; H, 3.53. Melting point: 188 oC (dec.).
Synthesis of [Fe(dmise)4][OTf] 2 (6a). Complex 6a was prepared following the
procedure for 5a except that dmise (168 mg, 1.30 mmol) was used in place of dmit.
Yield: 213 mg, 85%. IR (cm-1): 3400 (b), 3122 (s) 2926 (s,b), 2727 (w), 1705 (w), 1556
(w,b), 1563 (s), 1483 (s,b), 1398 (s), 1233 (s), 1151 (s), 1128 (s), 1092 (s), 1015 (w), 858
(w), 756 (s), 678 (s), 633 (w), 612 (w), 497 (s). UV-vis λmax (nm): 233 (sh), 267, 240.
MALDI-MS

(m/z)

=

[Fe(dmise)4]2+.

378.1

Anal.

Calcd.

for

C22H32F6FeN8O6S2Se422FeN8O6S2Se4: C, 25.06; N, 10.63; H, 3.06. Found: C, 24.55; N,
10.45; H, 3.00. Melting point: 188 oC (dec.).
Synthesis of [Fe(dmise)4][BF4] 2 (6b). Complex 6b was prepared following the
procedure for 5b except Fe(BF4)2.6H2O (180.9 mg, 0.536 mmol) and dmise (0.377 mg,
214 mmol) was used in place of dmit. Crystals suitable for X-ray analysis were grown via
slow vapor diffusion of ether into acetonitrile. Yield: 400 mg, 80%. IR (cm-1): 3166 (w),
3139 (w), 3112 (w), 2913 (s,b), 2727 (w), 1708 (w), 1569 (m), 1488 (w), 1463 (s,b), 1378
(m), 1344 (w), 1287 (w), 1240 (m), 1155 (w), 1052 (b), 861 (w), 754 (m), 663 (m), 614
(w), 521 (w), 470 (w). UV-vis λmax (nm): 233 (sh), 267, 240. MALDI-MS (m/z) = 378.1
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[Fe(dmise)4]2+. Anal. Calcd. for C20H32B2F8FeN8Se4: C, 25.83; N, 12.05; H, 3.47. Found:
C, 25.82; N, 12.02; H, 3.53. Melting point: 188 oC (dec.).
Synthesis of {Fe(ebit)Cl2}n (7). FeCl2.4H2O (130.5 mg, 0.65 mmol) was dissolved
in triethyl orthoformate (5 mL) and to this was added ebit (160.9 mg, 0.65 mmol) in a
mixed solvent system of triethyl orthoformate/dichloromethane (6 mL; 2:1) via cannula.
Upon addition of dmise to FeCl2.4H2O a precipitate was immediately formed. The
reaction was stirred for 6 h, filtered and dried under vacuum to afford a tan solid. Crystals
suitable for X-ray analysis were grown via slow vapor diffusion of ether into acetonitrile.
Yield: 237.5 mg, 95%. %. IR (cm-1): 3400 (b), 3147 (m), 3100 (m), 3027 (s), 2925 (b),
2855 (w), 2724 (s), 1720 (s), 1610 (s), 156s (m), 1464 (s), 1385 (s), 1318 (m), 1263 (vs),
1231 (s), 1211 (s), 1152 (m), 1089 (s), 1072 (s), 953 (s), 869 (s), 789 (vs), 764 (m), 750
(m), 679 (s), 662 (s), 649 (s), 605 (vs), 501 (m). UV-vis λmax (nm): 231 (sh), 262, 326.
MALDI-MS

(m/z)

=

345.35

[Fe(ebit)Cl]+,

380.96

[Fe(ebit)Cl2]H+,

504.35

[Fe2(ebit)Cl4]H+, 599.11 [Fe(ebit)2Cl]+, 724.92 [Fe2(ebit)2Cl3]+. Anal. Calcd. for
C10H14Cl2FeN4S2: C, 31.51; N, 14.70; H, 3.70. Found: C, 31.41; N, 14.61; H, 3.75
Melting point: 220 oC (dec.).
Synthesis of {Fe(ebis)Cl2}n (8). Compound 8 was prepared following the same
procedure as 7 except that ebis (183.8 mg, 0.52 mmol) was used in place of ebit. Crystals
suitable for X-ray analysis were grown via slow vapor diffusion of ether into acetonitrile.
Yield: 195 mg, 78% of a yellow powder. IR (cm-1): 3368 (b), 3146.8 (s), 3091 (s), 2894
(b), 2728 (s), 1717 (s), 1564 (s), 1462 (m), 1405 (vs), 1377 (vs), 1244 (m), 1211 (vs),
1174 (vs), 1139 (s), 1091 (vs), 1075 (vs), 1020 (vs), 802 (s), 758 (s), 742 (vs), 714 (vs),
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673 (m), 622 (vs), 487 (vs). UV-vis λmax (nm): 232 (sh), 271, 360. MALDI-MS (m/z) =
476.83 [Fe(ebis)Cl2H]+, 600.163 [Fe2(ebis)Cl4]H+. Anal. Calcd. for C10H14Cl2FeN4Se2: C,
25.29; N, 11.80; H, 2.97. Found: C, 25.30; N, 11.76; H, 3.05. Melting point: 210oC
(dec.).
Single crystal X-ray data collection. Single crystals of Fe(dmit)2Cl2 (1),
crystallized as colorless rods, Fe(dmise)2Cl2 (2), crystallized as brown rods,
[Fe(dmit)4][BF4]2 (5b), crystallized as colorless prisms, and [Fe(dmise)4][BF4]2 (6b),
crystallized as light green prisms, were grown from vapor diffusion of diethyl ether into
an acetonitrile solution, were mounted on a glass filament with epoxy glue, and
immediately placed on the diffractometer in a room-temperature nitrogen gas stream.
Intensity data were collected using a Rigaku Mercury CCD detector and an AFC8S
diffractometer. The space groups P21/n, P21/n, Pbcn, and Pbcn were determined from the
systematic absences for complexes 1, 2, 5b, and 6b respectively (Table 6). Fluorine
atoms around the boron centers in 5b were disordered based on residual electron density
identified in this region during refinements. Data reduction, including application of
Lorentz and polarization effects and absorption corrections, was performed using the
CrystalClear95 program. The structures were solved by direct methods and subsequent
Fourier difference techniques, and refined anisotropically, by full-matrix least squares, on
F2 using SHELXTL 6.10.96,97 The quantity minimized by the least squares program was
Σw = (Fo2 - Fc2)2 where w = {[σ2(Fo2)]+(0.0307P)2 + 1.57P} where P = (Fo2)+2Fc2)/3. In
the final cycle of least squares, independent anisotropic displacement factors were refined
for the non-hydrogen atoms, and hydrogen atoms were fixed in idealized positions with
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Table 2.6. Summary of crystallographic data for complexes 1, 2, 5b, and 6b.
1
2
5b
Chemical formula
C10H16Cl2FeN4S2
C10H16Cl2FeN4Se2
C20H32B2N8F8FeS4
F.W. (g/mol-1)
383.14
476.94
742.25
Space group
P21/n
P21/n
Pbcn
Crystal system
monoclinic
monoclinic
orthorhombic
a, Å
9.416 (2)
9.1566 (19)
12.022 (2)
b, Å
13.653 (2)
13.693 (3)
21.648 (4)
c, Å
13.120 (3)
13.279 (3)
12.825 (3)
α, deg
90
90
90
β, deg
109.477 (8)
108.25 (3)
90
γ, deg
90
90
90
V, Å-3
1590.6 (6)
1643.4 (6)
3337.7 (12)
Z
4
4
4
3
Dcal, mg/m
1.6
1.928
1.477
indices (min)
[-11, -16, -10]
[-11, -16, -16]
[-14, -25, -14]
indices (max)
[11, 15, 15]
[11, 17, 16]
[14, 25, 15]
parameters
176
176
233
F(000)
784
928
1520
μ, mm-1
1.54
5.66
0.77
2θ range, deg
2.7-26.4
2.7-26.4
3.0-25.3
collected reflections
9758
15290
26627
unique reflections
2844
3351
3026
Final R (obs. data)a R1 0.0734
0.0276
0.0481
wR2
0.1576
0.0641
0.1305
final R(all data), R1
0.0945
0.0276
0.0550
2
wR
0.1798
0.0659
0.1417
goodness of fit (S)
1.1
1.14
1.10
largest diff. peak
0.755
0.611
0.453
largest diff. hole
-0.689
-0.68
-0.334
a
2
2
2 2 1/2.
R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR = {Σw(F0 - Fc ) }

6b
C20H32B2N8F8FeSe4
941.83
Pbcn
orthorhombic
12.0512 (2)
21.7092 (4)
13.1986 (3)
90
90
90
3453.04 (12)
4
1.798
[-14, -23, -15]
[14, 25, 15]
231
1808
4.72
2.4-30.3
33185
3060
0.0475
0.1210
0.0578
0.1333
1.093
0.597
-0.557

C—H = 0.96 Å. Isotropic hydrogen atom displacement parameters were set equal to 1.5
times Ueq of the attached carbon atom.
For 1, the largest peak in the final Fourier difference map (0.76 e A -3) was located
1.240 Å from Cl2 and the lowest peak (-0.69 e∙A-3) was located at a distance of 0.89 Å
from Fe1. For 2 the largest peak in the final Fourier difference map (0.61 e A-3) was
located 1.128 Å from H3A and the lowest peak (-0.68 e A-3) was located at a distance of
0.80 Å from Se2. For 5b the largest peak in the final Fourier difference map (0.45 e A-3)
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was located 1.128 Å from Fe1 and the lowest peak (-0.33 e A-3) was located at a distance
of 0.83 Å from Fe1. For 6b the largest peak in the final Fourier difference map (0.60 e A 3

) was located 0.89 Å from Se1 and the lowest peak (-0.56 e A-3) was located at a

distance of 0.84 Å from Se1.
DFT calculations. Geometries were optimized using the mPW1PW9198 exchange
correlation functional in Gaussian 09.99 Iron was represented by the Wachters-Hay allelectron basis set.100,101 Sulfur and selenium basis sets were represented by the Wadt-Hay
relativistic effective core potential basis set102 modified to include a set of diffuse and
polarization functions. Carbon, oxygen, nitrogen and hydrogen basis sets were of triple-
quality augmented with diffuse and polarization functions.103 All structures were
confirmed as minima on the potential energy surface through analysis of the vibrational
frequencies.
Crystallization attempts with {Fe(ebit)Cl2}n (7) and {Fe(ebis)Cl2}n (8) and X-ray
structure of 7. Crystal growth for the polymeric complexes 7 and 8 was attempted by
vapor diffusion of ether into acetonitrile, dichloromethane, and mixtures of these solvents
at both room and low temperatures as well as evaporation of acetonitrile and
dichloromethane solutions. Small crystals were obtained only in low yields for
{Fe(ebit)Cl2}n (7), and its structure was determined using the best available crystal of the
limited selection. Complex 7 crystallizes in space group P21/c with a = 7.717(3), b =
16.526 (5), c = 15.059(5) Å, and β = 104.36(1)°, and the structure and crystal data are
provided in Fig. S5 and Tables S1 and S2. Fe(II) ions are in a distorted tetrahedral
coordination environment with angles ranging from 93.0(1)° to 114.4(1)°, an average Fe-
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Cl distance of 2.275(3) Å, and an average Fe-S distance of 2.366(3) Å, similar to values
observed in complex 1 and slightly shorter than {Fe(L1/L2)Cl2}n complexes (L1 = 1,1’methylenebis(3-methyl-imidazole-2-thione and L2 = 1,1’-methylenebis(3-tertbutylimidazole-2-thione) with average Fe-S bond lengths of 2.3725(5) Å and 2.3819(5) Å,
respectively.1 The ebit ligands bridge symmetry-related Fe atoms through the Fe-S bonds,
propagating the structure in a chain-like fashion, similar to the polymeric {Fe(L1/L2)Cl2}n
complexes.1 The chains are connected by C-H---Cl intermolecular hydrogen bonding
(Figure 2.13) as well as hydrogen bonding with a crystallized acetonitrile molecule. The
average bond lengths for ebit in complex 7 do not differ from those of the unbound ebit
ligand.2

Figure 2.8. Crystal packing diagram for Fe(dmit)2Cl2 (1) showing short Cl-Cl and Cl-H interactions as
viewed along the a-axis with 50% probability density ellipsoids.
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Figure 2.9. Crystal packing diagram for Fe(dmise)2Cl2 (2) showing short Cl-H interactions as viewed along
the a-axis with 50% probability density ellipsoids.

Figure 2.10. Crystal packing diagram for [Fe(dmit)4][BF4]2 (5b) showing short F-H interactions as viewed
along the a-axis with 50% probability density ellipsoids
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Figure 2.11. Crystal packing diagram for [Fe(dmise)4][BF4]2 (6b) showing short F-H interactions as
viewed along the a-axis with 50% probability density ellipsoids.

Figure 2.12. Crystal structure diagram with 50% probability density ellipsoids for {Fe(ebit)Cl2}n (7).
Hydrogen atoms are omitted for clarity.
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Figure 2.13. Crystal packing diagram for {Fe(ebit)Cl2}n (7) showing short Cl-H interactions as viewed
along the a-axis with 50% probability density ellipsoids.
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Table 2.7. Summary of crystallographic data for {Fe(ebit)Cl2}n (7).
Parameter

Value

Chemical formula

C12H17Cl2FeN5S2

F.W. (g/mol-1)

422.18

Space group

P21/c

Crystal system

monoclinic

a,Å

7.717 (3)

b,Å

16.526 (5)

c,Å

15.059 (5)

α, deg

90

β, deg

104.363 (12)

γ, deg

90

V,Å-3

1860.5 (12)

Z

4
3

Dcal, mg/m

1.507

indices (min)

[-9, -19, -17]

indices (max)

[6, 19, 17]

parameters

202

F(000)

864

μ, mm-1

1.32

2θ range, deg

2.5-25.1

collected reflections

11826

unique reflections

3275

a

final R(obs. data) , R1

0.097

wR2

0.343

final R (all data), R1

0.126

wR2

0.393

goodness of fit (S)

1.49

largest diff. peak

3.00

largest diff. hole

-0.92

a

R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR2 = {Σw(F02 - Fc2)2}1/2.
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Table 2.8. Selected bond lengths and angles for {Fe(ebit)Cl2}n (7).
Bond lengths (Å)

Bond angles (o)

Fe1—S1

2.362 (3)

Cl1—Fe1—S1

111.23 (12)

Fe1—S2

2.371 (3)

Cl2—Fe1—S1

111.06 (13)

Fe1—Cl1

2.271 (3)

Cl1—Fe1—S2

111.48 (11)

Fe1—Cl2

2.281 (3)

Cl2—Fe1—S2

114.42 (12)

S1—C1

1.723 (10)

S1—Fe1—S2

92.95 (10)

S2—C6

1.737 (11)

C1—S1—Fe1

103.1 (3)

C6—S2—Fe1

102.4 (3)

Cl1—Fe1—Cl2

113.90 (12)

*

Figure 2.14. 1H NMR spectrum of Fe(dmit)2Cl2 (1) in CD3CN. Spectra were acquired from δ -10 to 20 and
no additional signals were observed. The asterisk indicates the resonance from residual CH 3CN solvent.
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*

Figure 2.15. 1H NMR spectrum of [Fe(dmit)2(CH3CN)2][BF4]2 (3) in CD3CN. Spectra were acquired from
δ -10 to 20 and no additional signals were observed. The asterisk indicates the residual CH3CN solvent
resonance.

*

Figure 2.16. 1H NMR spectrum of [Fe(dmise)2(CH3CN)2][BF4]2 (4) in CD3CN. Spectra were acquired from
δ -10 to 20 and no additional resonances were observed. The asterisk indicates the resonance from residual
CH3CN solvent.
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*

Figure 2.17. 1H NMR spectrum of [Fe(dmit)4][OTf]2 (5a) in CD3CN. Spectra were acquired from δ -10 to
20 and no additional signals were observed. The asterisk indicates the residual CH3CN solvent resonance.

*

Figure 2.18.. 1H NMR spectrum of [Fe(dmise)4][OTf]2 (6a) in CD3CN. Spectra were acquired from δ -10
to 20 and no additional signals were observed. The asterisk indicates the residual CH3CN solvent
resonance.
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*

Figure 2.19. 1H NMR spectrum of [Fe(dmit)4][BF4]2 (5b) in CD3CN. Spectra were acquired from δ-10 to
20 and no additional signals were observed. The asterisk indicates the residual CH3CN solvent resonance.

*

Figure 2.20. 1H NMR spectrum of [Fe(dmise)4][BF4]2 (6b) in CD3CN. Spectra were acquired from δ -10 to
20 and no additional signals were observed. The asterisk indicates the residual CH3CN solvent resonance.
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Figure 2.21. 1H NMR spectrum of {Fe(ebit)Cl2}n (7) in CD3CN. Spectra were acquired from δ -10 to 20
and no additional signals were observed except a residual CH3CN resonance at δ 1.94.

*

Figure 2.22. 1H NMR spectrum of {Fe(ebis)Cl2}n (8) in CD3CN. Spectra were acquired from δ -10 to 20
and no additional signals were observed. The asterisk indicates the residual CH3CN solvent resonance..
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Figure 2.23. Cyclic voltammetry with initial starting potential at A) 0.94 V for ebis (solid) and 0.80 V for
ebit (dashed) and B) 0.09 V for ebis (solid) and 0.26 V for ebit (dashed).

Figure 2.24. Cyclic voltammograms of A) [Fe(dmit)2(CH3CN)2][OTf]2 (3; dashed line) and
[Fe(dmise)2(CH3CN)2][OTf]2 (4; solid line) starting at 1.53 V; B) [Fe(dmit)4][OTf]2 (5a; dashed) and
[Fe(dmise)4][OTf]2 (6a; solid) starting at 1.49 V; and C) {Fe(ebit)Cl2}n (7; dashed) and {Fe(ebis)Cl2}n (8;
solid) starting at 1.48 V. All data were collected with 10 mM complex in acetonitrile.
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Figure 2.25. Cyclic voltammograms of A) Fe(dmit)2Cl2 (1; dashed) and Fe(dmise)2Cl2 (2; solid) starting at
0.5 V for 1 and 0.15 V for 2, respectively; B) [Fe(dmit)2(CH3CN)2][OTf]2 (3; dashed) and
[Fe(dmise)2(CH3CN)2[OTf]2 (4; solid) starting at 0.4 V for 3 and 0.15 V for 4, respectively; C)
[Fe(dmit)4][OTf]2 (5a; dashed) and [Fe(dmise)4][OTf]2 (6a; solid) starting at 0.45 V for 5a and 0.15 V for
6a, respectively; and D) {Fe(ebit)Cl2}n (7; dashed) and {Fe(ebis)Cl2}n (8; solid) starting at 0.25 V for 7 and
0.10 V for 8. All data were collected with 10 mM complex in acetonitrile.

Figure 2.26. Cyclic voltammogram for FeCl2∙4H2O (10 mM) in acetonitrile starting at 1.48 V.
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Figure 2.27. Differential pulse voltammograms of dmit (10 mM) in acetonitrile: A) negative mode and B)
positive mode; potentials are reported vs. NHE.
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Figure 2.28. Differential pulse voltammograms of dmise (10 mM) in acetonitrile: A) negative mode and B)
positive mode; potentials are reported vs. NHE.
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Figure 2.29. Differential pulse voltammograms of ebit (10 mM) in acetonitrile: A) negative mode and B)
positive mode; potentials are reported vs. NHE.
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Figure 2.30. Differential pulse voltammograms of ebis (10 mM) in acetonitrile: A) negative mode and B)
positive mode; potentials are reported vs. NHE.

Figure 2.31. Differential pulse voltammograms of Fe(dmit)2Cl2 (1; 10 mM) in acetonitrile: A) negative
mode and B) positive mode; potentials are reported vs. NHE.

Figure 2.32. Differential pulse voltammograms of Fe(dmise)2Cl2 (2; 10 mM) in acetonitrile: A) negative
mode and B) positive mode; potentials are reported vs. NHE.
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Figure 2.33. Differential pulse voltammograms of [Fe(dmit)2(CH3CN)2][OTf]2 (3; 10 mM) in acetonitrile:
A) negative mode and B) positive mode; potentials are reported vs. NHE.

Figure 2.34. Differential pulse voltammograms of [Fe(dmise)2(CH3CN)2][OTf]2 (4; 10 mM) in acetonitrile:
A) negative mode and B) positive mode; potentials are reported vs. NHE.

Figure 2.35. Differential pulse voltammograms of [Fe(dmit)4][OTf]2 (5a; 10 mM) in acetonitrile: A)
negative mode and B) positive mode; potentials are reported vs. NHE.

111

Figure 2.36. Differential pulse voltammograms of [Fe(dmise)4][OTf]2 (6a; 10 mM) in acetonitrile: A)
negative mode and B) positive mode; potentials are reported vs. NHE.

Figure 2.37. Differential pulse voltammograms of {Fe(ebit)Cl2}n (7; 10 mM) in acetonitrile: A) negative
mode and B) positive mode; potentials are reported vs. NHE.

Figure 2.38. Differential pulse voltammograms of {Fe(ebis)Cl2}n (8; 10 mM) in acetonitrile: A) negative
mode and B) positive mode; potentials are reported vs. NHE.
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CHAPTER THREE
OXIDATION OF FE(II)-THIONE AND –SELONE COMPLEXES WITH
HYDROGEN PEROXIDE: A MECHANISTIC STUDY
3.1. Introduction
In human cells under oxidative stress conditions, the cellular pathways used to
maintain iron homeostasis and non-protein-bound iron concentrations in the 1-30 µM1-6
range become overwhelmed, leading to an increase in non-protein-bound iron (100 1000 µM7). More Fe2+ can result in overproduction of the hydroxyl radial (Reaction 1)
and an increase in iron-mediated DNA damage, the primary cause of cell death under
oxidative stress conditions.5,8-10 The resulting oxidative stress, DNA damage, and cell
death is an underlying cause of cardiovascular diseases, neurodegenerative diseases, and
cancer.11-17
Fe2+ + H2O2 → Fe3+ + •OH + OH-

(1)

Antioxidants are of significant interest for prevention of damage caused by
reactive oxygen species (ROS) and diseases caused by oxidative stress.14,17-19 Discovery
of the antioxidant properties of thione (C=S) and selone (C=Se) compounds arose from
studies of the amino acid ergothioneine and, more recently, its selone analog, selenoneine
(Figure 3.1). Ergothioneine prevents copper-mediated oxidative deoxyribose damage20
and scavenges ROS.21-23 Selenoneine also is a potent radical scavenger in 2,2-diphenyl-1picrylhydrazyl (DPPH) studies24 and also binds Fe2+ in hemoglobin and myoglobin,
preventing iron oxidation.24-28
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Figure 3.1. Thione and selone antioxidants.

N,N’-dimethylimidazole thione (dmit) and selone (dmise; Figure 3.1), compounds
with structures similar to ergothioneine and selenoneine, are also antioxidants, preventing
iron- and copper-mediated DNA damage in in vitro gel electrophoresis assays.29 Copper
generates ROS and causes DNA damage in a manner similar to iron.30-32 Previous
copper-coordination studies with [TpmRCu(dmit/dmise)] (R = H, CH3, iPr) complexes
demonstrate that when bound to Cu+, dmit and dmise binding decreases the Cu2+/+ redox
potentials by 374 - 874 mV relative to acetonitrile binding.33 Although dmit binding
lowers the Cu2+/+ redox potentials in these complexes to 70 to -232 mV,33 they still fall
within the range that the cellular reductant NADH can reduce Cu2+ to ROS-producing
Cu+ (-324 mV vs NHE34). In contrast, dmise binding lowers the Cu2+/+ redox potentials
in these complexes to -283 to -390 mV33), sufficiently low enough that dmise binding
might prevent Cu2+ reduction by NADH, inhibiting catalytic copper-mediated hydroxyl
radical generation.32,35
Oxidation studies of [TpmMeCu(dmit/dmise)]+ complexes with H2O2 in
acetonitrile solution have shown that dmit and dmise undergo sacrificial oxidation to
form imidazolium cation, and [S/SeO2H]- species in addition to [TpmMeCu(CNCH3)]+
(Reaction 2).36 This sacrificial thione or selone oxidation protects Cu+ from oxidation.36
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Electrochemical studies of Fe(dmit/dmise)2Cl2 complexes (Chapter 2) have
established that ligand-based, Fe2+-bound dmit and dmise potentials (0.41 and 0.59 V;
respectively) are significantly higher than the metal-based Fe2+/3+oxidation potentials of
these complexes (0.16 and 0.22 V, respectively).37 This large electrochemical difference
suggests that Fe2+-bound dmit or dmise would undergo oxidation prior to Fe2+ oxidation
to Fe3+. Thus, thione and selone binding may protect Fe2+ from oxidation to Fe3+ by
sacrificial ligand oxidation.37
To provide proof of this ROS-scavenging antioxidant mechanism for Fe2+-bound
thione and selone complexes, Fe(dmit)2Cl2 and Fe(dmise)2Cl2 were treated with up to six
equivalents of hydrogen peroxide (H2O2) and characterized by 1H and

13

C{1H} NMR

spectroscopy, MALDI-MS, and ESI-MS to identify their products of oxidation. These
studies will provide insight into metal-coordination antioxidant mechanisms to aid in the
development of more effective thione and selone antioxidants and may shed light on the
antioxidant activity of biologically relevant thiones and selones.
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3.2. Results and Discussion
Reactivity of Fe(dmit)2Cl2 and Fe(dmise)2Cl2 with H2O2. Fe(dmit)2Cl2 and
Fe(dmise)2Cl2 were dissolved in acetonitrile and treated with 1, 2, 4, and 6 equivalents of
H2O2. Upon addition of one equivalent of H2O2, both the Fe(dmit)2Cl2 and Fe(dmise)2Cl2
reactions changed color from light yellow to nearly colorless, and the Fe(dmit)2Cl2
reaction forms a dark reddish-brown precipitate, while the Fe(dmise)2Cl2 solution forms a
orange/light red precipitate. Due to this precipitate formation, the acetonitrile in these
reaction mixtures was removed under vacuum and the resulting solid was completely
dissolved in deuterated dimethylsulfoxide for NMR studies.
Prior to H2O2 treatment, the 1H NMR spectrum of Fe(dmit)2Cl2 (Figure 3.2A)
shows single methyl and olefinic proton resonances at δ 3.33 and 6.94, respectively.
Upon treating Fe(dmit)2Cl2 with 1 equivalent of H2O2, these 1H NMR resonances (Figure
3.2A) show significant broadening with unobservable resonances for oxidized products,

C

Figure 3.2. 1H NMR spectra in (CD3)2SO for A) Fe(dmit)2Cl2, B) Fe(dmise)2Cl2 upon H2O2 treatment, and
C) the resonance labeling scheme, with the primary symbol indicating resonances arising from oxidation.
Residual H2O resonances are labeled with an asterisk.
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due to Fe3+ paramagnetic effects as Fe2+ is oxidized. Upon treatment with 2 equivalents
of H2O2, a new set of resonances emerge the 1H NMR spectrum at δ 3.75, 7.57, and 8.40,
corresponding to N,N’-dimethylimidazolium cation formation as the S=C bond is
cleaved. Similar imidazolium cation formation was observed upon H2O2 oxidation of
[Tpm*Cu(dmit)]+.36 Upon addition of 4 equivalents of H2O2 to Fe(dmit)2Cl2, 63% of
bound dmit becomes oxidized, based on olefinic proton resonance integrations. After
adding 6 equivalents of H2O2, no distinguishable 1H NMR resonances are observed due
to broadening of all resonances into the baseline from the extreme paramagnetism of Fe3+
in the sample. Thus, dmit binding does not fully protect Fe2+ from oxidation under these
conditions.
The 1H NMR spectrum of Fe(dmise)2Cl2 prior to H2O2 treatment (Figure 3.2B)
shows methyl and olefinic proton resonances at δ 3.55 and 7.51, respectively. The 1H
NMR spectrum of Fe(dmise)2Cl2, upon treatment with 1 equivalent of H2O2, shows the
emergence of three new resonances at δ 3.83, 7.68, and 9.10, similar to those observed
upon oxidation of the iron-dmit complex and indicating imidazolium formation. The
difference in imidazolium resonance shifts in H2O2-oxidized Fe(dmit)2Cl2 (δ 8.40)
compared to oxidized Fe(dmise)2Cl2 (δ 9.10) may be due to the greater Fe3+ paramagnetic
effects observed during Fe(dmit)2Cl2 oxidation. Upon addition of 4 equivalents of H2O2
to Fe(dmise)2Cl2, the 1H NMR spectrum shows 85% oxidation of the iron- bound dmise
ligands based on olefinic integrations. When treated with 6 equivalents of H2O2, the 1H
NMR spectrum of Fe(dmise)2Cl2 shows 100% oxidation and a significant increase in
resonance breadth, indicating significant oxidation of Fe2+ to Fe3+.
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The 1H NMR resonances of Fe(dmise)2Cl2 do not significantly broaden upon
treatment with up to 4 equivalents of H2O2, unlike those of Fe(dmit)2Cl2 that broadened
upon treatment with only one equivalent of H2O2, indicating that dmise binding protects
Fe2+ from oxidizing more than dmit coordination. Because fewer equivalents of H2O2 are
required for more complete iron-bound dmise oxidation than iron-bound dmit oxidation,
dmise is more prone to H2O2 oxidation than its thione analog under these conditions. A
similar trend was observed upon [Tpm*Cu(dmit/dmise)]+ oxidation: the dmise complex
required addition 2 equivalents of H2O2 for complete oxidation, whereas the dmit analog
required addition of 3 equivalents of H2O2 for the same degree of oxidation.36
Mass spectrometry was used to further identify the products of H2O2 oxidation.
Upon treatment of Fe(dmit)2Cl2 with 1 equivalent of H2O2, MALDI-MS confirmed
formation of a major product N,N′-dimethylimidazolium cation (m/z 97.1) and a minor
product [dmit-OH]- (m/z 145.1). In addition, the Fe2+-containing product [FeCl3]- (m/z
160.8) and the Fe3+-containing product [FeCl4]- (m/z 197.9) were observed in a 1:8 ratio
based on isotopic peak intensities; this [FeCl3]- to [FeCl4]- ratio increases with increasing
equivalents of H2O2. When 1 is treated with 6 equivalents of H2O2, only [FeCl4]- is
observed, indicating complete oxidation of Fe2+ to Fe3+.
Since MALDI-MS could not aid in identification of oxidized sulfur products, ESIMS experiment were also performed. ESI-MS indicated formation of sulfite [SO3H]- (m/z
79.9) and sulfate [SO4H]- (m/z 96.8) from 3 to 6 equivalents of H2O2, indicating that dmit
oxidized with concomitant C=S bond cleavage and oxidation of the S atom when treated
with at least three equivalents of H2O2. Control samples of Na2SO3 and Na2SO4 were

125

analyzed using ESI-MS and showed small peaks of sulfite and sulfate, similar to those
observed when Fe(dmit)2Cl2 was treated with with 3 – 6 equivalents of H2O2.
N,N′-dimethylimidazolium was also observed by MALDI-MS upon treating of
Fe(dmise)2Cl2 with 1 equivalent of H2O2, along with [FeCl3]- and [FeCl4]- products in a
1:2 ratio. This Fe2+:Fe3+ ratio remains fairly constant at a ratio of 1:2 - 1:3 upon adding
up to 4 equivalents of H2O2, but treatment with 6 equivalents increases the Fe2+:Fe3+ ratio
substantially to 1:7. ESI-MS results indicate oxidized [SeO2H]- (m/z 113.0) is formed
upon treatment of Fe(dmise)2Cl2 with 2 - 6 equivalents of H2O2. Control samples of SeO2
and Na2SeO4 were also analyzed under similar conditions and showed small peakes for
[SeO2H]- as observed upon treatment Fe(dmise)2Cl2 with 2 – 6 equivalents of H2O2.
To determine how much Fe2+ was oxidized to Fe3+ during sample preparation,
MALDI mass spectrometry in the negative mode was also conducted on a FeCl2 ∙ 4H2O
standard, and peaks for [FeCl3]- and [FeCl4]- were observed in a 1:4 ratio based on peak
intensities. Thus, a significant fraction of the Fe2+ in the standard was oxidized to Fe3+
during preparation and/or analysis of the mass spectrometry samples. Nonetheless, the
Fe2+:Fe3+ ratio of 1:8 observed upon oxidation of Fe(dmit)2Cl2 with 1 equivalent of
hydrogen peroxide, indicates a significant increase in Fe3+ products observed compared
to the untreated FeCl2 ∙ 4H2O standard. This increase in Fe3+ ratio indicates that dmit
binding does not prevent Fe2+ from oxidizing to Fe3+ upon H2O2 addition. In contrast, the
Fe2+:Fe3+ ratio of 1:2 observed after treatment of Fe(dmise)2Cl2 with 1 equivalent of H2O2
is lower than that observed for untreated FeCl2 ∙ 4H2O (1:4) and much lower than that
observed for Fe(dmit)2Cl2 oxidation with H2O2 (1:8), indicating that dmise coordination
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prevents Fe2+ oxidation, not only upon treatment with H2O2, but also during sample
preparation and analysis.
Taken together, the results of 1H NMR and mass spectroscopy experiments
indicate that iron-bound dmit and dmise scavenge H2O2 by undergoing sacrificial
oxidation (Reactions 3 and 4, respectively). Whereas dmise preferentially protects Fe2+
from significant oxidation to Fe3+, its thione analog dmit does not, as demonstrated by an
increase in 1H NMR paramagnetic effects and an increase in [FeCl4]- species observed in
MALDI-MS.

Previous H2O2 oxidation studies with unbound dmit and dmise showed that the
selone dmise requires 2 equivalents of H2O2 to fully oxidize, forming N,N′dimethylimidazolium cation and [SeO2H]- as determined by 1H NMR and ESI-MS,
whereas dmit requires 3 equivalents of H2O2 to form N,N′-dimethylimidazolium,
[SO3H]-, and [SO4H]- species.36 Similar reactivity of the copper-bound dmit and dmise
ligands was observed upon H2O2 oxidation of [Tpm*Cu(dmit/dmise)] complexes.35
Similar to unbound dmit, unbound dmise, and [Tpm*Cu(dmit/dmise)]+
complexes, the iron-bound dmise ligand in Fe(dmise)2Cl2 is more sensitive to H2O2
oxidation, requiring 4 equivalents of H2O2 to oxidize Fe(dmise)2Cl2 to nearly 85%
oxidized dmise, whereas the analogous Fe(dmit)2Cl2 complex, when treated with 4
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equivalents of H2O2, shows only 63% ligand oxidation. Iron-bound dmise sacrificially
oxidizes and protects Fe2+ from oxidation as determined by the lack of line broadening
observed in the 1H NMR spectra (Figure 3.2) and by mass spectroscopy results that show
a much smaller [FeCl3]- to [FeCl4]- ratio compared to the oxidized iron-dmit complex or
the FeCl2 ∙ 4H2O control. Importantly, the results in these studies corroborate the reported
electrochemical results (Chapter 2) for Fe(dmit/dmise)2Cl2 and definitively establish that
these thione and selone compounds, when bound to iron, act as sacrificial antioxidants.
In addition, these results indicate that biological ergothioneine and selenoneine also may
prevent iron-mediated DNA damage via iron binding and sacrificial oxidation.

3.3. Conclusions
Treatment of Fe(dmit)2Cl2 and Fe(dmise)2Cl2 with H2O2 results in oxidation of
the S and Se atoms, cleavage of the C=S or C=Se bonds, and formation of the
dimethylimidazolium cation and sulfur and selenium oxide species. When bound to Fe2+,
dmise protects Fe2+ from oxidation to Fe3+ significantly more than dmit, as observed by
1

H NMR and MALDI-MS. Similar sacrificial oxidation of iron-bound dmit is observed

upon treatment by H2O2; however, because of the increase in paramagnetic effects
observed in the 1H NMR titration studies and a significant increase in [FeCl4]- formation,
it is clear that the Fe2+ is not fully protected from oxidation. Therefore, iron-mediated
oxidative damage may be prevented by coordination of selones more so than thiones via
sacrificial oxidation in vivo.

128

3.4. Experimental Methods
Materials. Acetonitrile was dried over calcium hydride and freshly distilled prior
to use. Fe(dmit)2Cl2, and Fe(dmise)2Cl2 were synthesized according to published
procedures.36 Hydrogen peroxide (30% by volume in water; VWR) was used as received.
Instrumentation. 1H NMR spectra were obtained on Bruker 500 or 300 MHz
NMR spectrometers. 1H NMR chemical shifts are reported in δ vs. trimethylsilane (TMS;
δ 0) and referenced to solvent. MALDI mass spectrometry experiments were performed
using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-3-(4-tertbutylphenyl)-2-methyl-2-propenyldiene (m/z 250.3) as the matrix. Electrospray ionization
mass spectrometry (ESI-MS) was conducted by Lynn Zang using a QSTAR XL Hybrid
MS/MS System from Applied Biosystems via direct injection of sample (0.05 mL/min
flow rate) into a Turbo Ionspray ionization source. Samples were run under both positive
and negative ion mode, with an ionspray voltage of 5500 V, and TOF scan mode. All the
peak envelopes obtained match calculated values.
Reactivity of Fe(dmit)2Cl2 with H2O2. Fe(dmit)2Cl2 (50 mg, 0.131 mmol) was
dissolved in acetonitrile (10 mL) and was treated with 1.0, 2.0, 4.0, or 6.0 equiv of H2O2
(15, 30, 60, or 90 μL of 30% solution (9.44 M) in water, respectively). The reaction
mixtures changed from yellow to reddish-brown immediately upon addition of H2O2, and
a reddish-brown precipitate formed. The reaction mixtures were stirred for 10 min and
dried in vacuo, yielding reddish-brown solids. Yield of N,N’-dimethylimidazolium upon
addition of 4 equiv H2O2: 63% by 1H NMR spectroscopy. 1H NMR data for N,N’dimethylimidazolium based on imidazole proton resonances (d6-DMSO): δ 3.75 (s, 6H,
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CH3), 7.57 (s, 2H, CH), 8.40 (S, 1H, CH). ESI-MS: m/z positive ionization: 97.1
[C5H9N2]+; negative ionization: 79.9 [SO3H]-, 96.8 [SO4H]-. MALDI-MS: m/z positive
ionization: 97.1 [C5H9N2]+; negative ionization 160.8 [FeCl3]-, 197.9 [FeCl4]-.
Reactivity of Fe(dmise)2Cl2 with H2O2. Fe(dmise)2Cl2 (50 mg, 0.105 mmol) was
dissolved in acetonitrile (10 mL) and to this solution was added 1.0, 2.0, 4.0, or 6.0 equiv
of H2O2 (11, 22, 44, or 66 μL of 30% solution (9.44 M) in water, respectively). Upon
H2O2 addition, of the solution immediately changed from yellow to orange-red with
formation of an orange precipitate. The reaction mixtures were stirred for 10 min and
dried in vacuo, yielding light red/orange solids. Yield of N,N’-dimethylimidazolium upon
addition of 4 equiv H2O2: 85% by 1H NMR spectroscopy. 1H NMR data for N,N’dimethylimidazolium based on imidazole proton resonances (d6-DMSO): δ 3.83 (s, 6H,
CH3), 7.68 (s, 2H, CH), 9.10 (s, 1H, CH). ESI-MS: m/z positive ionization: 97.1
[C5H9N2]+; negative ionization: 113.0 [SeO2H]-. MALDI-MS: m/z positive ionization:
97.1 [C5H9N2]+; negative ionization 160.8 [FeCl3]-, 197.9 [FeCl4]-.
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CHAPTER FOUR
ZINC(II)–THIONE AND –SELONE COMPLEXES: A MECHANISTIC
STUDY OF THIONE AND SELONE ANTIOXIDANT ACTIVITY

4.1 Introduction
The biological thione- (C=S) and selone- (C=Se) containing compounds
ergothioneine and selenoneine (Figure 4.1) have not been highly investigated, and their
biological functions are not well established.1-6 Several studies have determined that both
are potent radical-scavenging antioxidants,7-13 whereas only ergothioneine was tested for
copper-binding antioxidant activity and found to prevent copper-mediated DNA
damage.14 Selenoneine prevents iron auto-oxidation by binding to Fe(II) in hemoglobin
and myoglobin.6
The Brumaghim group has examined the metal binding properties of dmit and
dmise (Figure 4.1) with Cu(I) and Fe(II), since they are thione and selone analogs of
ergothioneine and selenoneine.15-18 When dmit and dmise bind Cu(I) and Fe(II), these
ligands favor their zwitterionic over non-zwitterionic resonance structures (Figure 4.1) as
confirmed by NMR spectroscopy, X-ray diffraction structures, and DFT calculations.15-18
Upon H2O2 oxidation of [TpmMeCu(dmit/dmise)]+ (TpmMe = tris(3,5-

Figure 4.1. Thione and selone antioxidants (left) and the resonance forms of dmit and dmise (right).
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dimethylpyrazolyl)methane) and Fe(dmit/dmise)2Cl2, dmit and dmise undergo sacrificial
oxidation, yielding the N,N’-dimethimidazolium cation and [SOnH]- (n = 2, 3, or 4) or
[SeO2H]- (Chapter 3).19 This sacrificial ligand oxidation protects Cu(I) and Fe(II) from
oxidation to Cu(II) and Fe(III).
Dmise-copper and -iron binding was found to significantly lower the Cu(II/I) and
Fe(III/II)

redox

potentials

in

[TpmRCu(dmise)]+

(TpmR

=

tris(3,5-di-R-

pyrazolyl)methane; R = H, CH3, and iPr)16 and Fe(dmise)2Cl218 complexes. These
Cu(II/I) and Fe(III/II) redox potentials occur near or below -0.32 V, the potential at which
NADH cannot reduce Cu(II) to Cu(I) or Fe(III) to Fe(II).20 Analogous dmit-copper and
-iron complexes have Cu(II/I) and Fe(III/II) redox potentials higher than their selone
counterparts, suggesting that thione coordination may not be as effective at preventing
metal oxidation as their selone counterparts.16,18 However, ligand-based potentials are
significantly higher than Fe(III/II) redox potentials in Fe(dmit/dmise)2Cl2, indicating that
bound dmit and dmise should undergo oxidation prior to Fe(II) and protect it from
oxidation.18
When Fe(dmit)2Cl2 was treated with H2O2 (Chapter 3), 1H NMR and mass
spectrometry studies indicated formation of the imidazolium cation, [SO3H]-, and [FeCl4]species, in which Fe(II) is oxidized to Fe(III). When Fe(dmise)2Cl2 was treated with H2O2
the dmise ligand undergoes sacrificial oxidation to the imidazolium cation, and [SeO2H]species similar to its sulfur analog, however Fe(II) does not become oxidized to Fe(III),
indicating dmise may prevent iron-mediated hydroxyl production through sacrificial
oxidation. These results indicate that dmise and dmit have different antioxidant
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mechanisms for the prevention of metal-mediated oxidative DNA damage.
Iron(II) and Cu(I) generate hydroxyl radical upon hydrogen peroxide oxidation
(Reaction 1),21-23 and hydroxyl radical production becomes catalytic in vivo when cellular
reductants such as NADH reduce Fe(III) to Fe(II) or Cu(II) to Cu(I). In cells, hydroxyl
radical damages lipids, proteins, and DNA,24-29 leading to development of cardiovascular
diseases, neurodegenerative diseases, and cancer.25,27-29 Unlike iron(II) and copper(I),
zinc(II) lacks redox activity due to its d10 electron configuration, but it is a strong Lewis
acid.30 This lack of redox activity makes Zn(II) a stable ion in biological systems, and it
is incapable of generating hydroxyl radical by one-electron reduction of hydrogen
peroxide.31,32
Fe(II)/Cu(I) + H2O2  Fe(III)/Cu(II) + •OH + OH-

(1)

After iron, zinc is the second most abundant trace d-block metal in humans, with
an average 2 - 4 g of zinc in an adult human.33 Similar to iron(II), zinc(II) is classified as
a “borderline” Lewis acid that will readily coordinate O, N, or S atoms,34 and many zinccontaining proteins contain Zn-S bonds to the amino acids histidine and cysteine.34 Since
zinc is known to bind sulfur-containing amino acids ergothioneine and its selenium
analog, selenoneine, should also bind in a similar fashion through the sulfur and selenium
atoms. Since dmit and dmise are analogs of ergothioneine and selenoneine, we have
examined them as mimics of these biological thione and selone compounds.
In this chapter, we describe the synthesis and characterization of the novel thione
and selone complexes Zn(dmit)2Cl2 (1) and [Zn(dmise)4][BF4]2 (4) as well as introduce a
novel synthetic method for the synthesis of previously reported [Zn(dmit)4][BF4]2 (3).35
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Crystal structures of Zn(dmise)2Cl236 (2) and [Zn(dmit)4][BF4]235 (3) have been reported;
however, that is it extent of their characterization. In addition, we have examined the
reactivity of Zn(dmit/dmise)2Cl2 (1 and 2) with H2O2 to determine how binding to a
non-redox active metals effects the oxidation mechanisms of dmit and dmise.
Syntheses of complexes 1 and 4 were carried out by undergraduates Amanda
Owen, Hayden Smith, Mathew Wasilewski, and Caleb Cohen. Hayden Smith and
Amanda Owen characterized complexes 1 - 4 by 1H and

13

C{1H} NMR, and IR

spectroscopy, and electrochemical and oxidation studies of 1 and 2 were carried out by
Amanda Owen. These contributions to understanding how thiones and selones bind to
zinc would not have been made possible without their dedication and hard work.

4.2 Results and Discussion
Synthesis of Zn(II)-thione and –selone complexes. Zn(dmit)2Cl2 (1) was
synthesized following reported procedures for synthesis of the dmise analog,
Zn(dmise)2Cl2 (2)36 (Scheme 4.1A). Synthesis of 1 and 2 were performed under
atmospheric conditions, with yields of 84-86% as colorless crystals of 1 and pale yellow
crystals of 2. Both complexes are stable in air and are soluble only in dimethylsulfoxide
and dimethylformamide at room temperature. Single crystals of Zn(dmit)2Cl2 (1), as
colorless rods, were grown from cooling a reaction mixture in acetonitrile.
To

compare

homoleptic

complexes

of

dmise

and

dmit,

the

novel

[Zn(dmise)4][BF4]2 (4) complex was synthesized according to the reaction shown in
Scheme 4.1B. This new synthetic method was also used to synthesize the reported
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[Zn(dmit)4][BF4]2 (3).35

Treating Zn(BF4)2 with four equivalents of dmit or dmise

affords white or yellow powders of [Zn(dmit)2][BF4]2 (3) and [Zn(dmise)4][BF4] (4),
respectively. The syntheses of 3 and 4 were originally carried out under atmospheric
conditions utilizing ethanol as a solvent,35 but this procedure afforded less-than-desirable
yields (50-55%), perhaps due to oxidation of dmit and dmise. Using air-free synthetic
techniques increased yields of 3 and 4 to 74% and 80%, respectively. As observed for 1
and 2, complexes 3 and 4 are air-stable in solution and in the solid state, but they are
much more soluble than 1 and 2 in a variety of organic solvents. [Zn(dmise)4][BF4]2 (4),
crystallized as light yellow prisms, were grown from vapor diffusion of diethyl ether into
an acetonitrile solution.
Scheme 4.1

Structural analysis of zinc-thione and –selone complexes. Structures of
Zn(dmit)2Cl2 (1) and [Zn(dmise)4][BF4]2 (4) were determined by X-ray diffraction
(Figure 4.2); structures of Zn(dmise)2Cl236 and [Zn(dmit)4][BF4]235 have been reported.
Selected interatomic distances and angles for 1 and 4 are summarized in Table 4.1.
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Complexes 1 and 2 are an isomorphous pair, containing Zn(II) bound to two Cl atoms
and two S/Se atoms from a heterocyclic chalcogenone (Figure 4.2A; the crystal packing
diagram for 1 is shown in Figure 4.4 at the end of the experimental section). In 3 and 4,
Zn is coordinated to four S (3) or Se (4) atoms to form the tetrakis [Zn(dmit/dmise)4]2+
complexes (Figure 4.2B; the crystal packing diagram for 4 is shown in Figure 4.5 at the
end of the experimental section), likewise forming an isomorphous pair. The Zn(II)

Figure 4.2. Crystal structure diagrams with 50% probability density ellipsoids for A) Zn(dmit) 2Cl2 (1) and
B) [Zn(dmise)4][BF4]2 (4). Hydrogen atoms and counterions are omitted for clarity.
Table 4.1. Selected bond lengths (Å) and angles (°) for Zn(dmit) 2Cl2 (1) and [Zn(dmise)4][BF4]2 (4).
1
Zn1—S1

4
2.3540 (9)

Zn1—Se1

2.4635 (9)

i

2.4635 (9)

Zn1—S2

2.3766 (10)

Zn1—Se1

Zn1—Cl1

2.2616 (10)

Zn1—Se2

2.4526 (10)

i

2.4526 (10)

Zn1—Cl2

2.2865 (9)

Zn1—Se2

S1—C1

1.713 (3)

Se1—C1

1.860 (7)

S2—C6

1.719 (4)

Se2—C6

1.850 (7)

i

Cl1—Zn1—S1

119.04 (4)

Se2 —Zn1—Se2

122.42 (6)

Cl2—Zn1—S1

107.26 (3)

Se2i—Zn1—Se1i

103.85 (2)

Cl1—Zn1—S2

108.01 (4)

Se2—Zn1—Se1i

104.93 (3)

i

Cl2—Zn1—S2

110.40 (4)

Se2 —Zn1—Se1

104.93 (3)

S1—Zn1—S2

103.65 (3)

Se2—Zn1—Se1

103.85 (2)

i

Cl1—Zn1—Cl2

108.30 (4)

Se1 —Zn1—Se1

117.88 (6)

C1—S1—Zn1

102.02 (11)

C1—Se1—Zn1

96.43 (19)

C6—S2—Zn1

100.55 (12)

C6—Se2—Zn1

96.88 (19)

i symmetry operator for symmetrically equivalent atoms: -x, y, -z+3/2.
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valence was confirmed by the two coordinated Cl- ions in 1 and 2,36 and the presence of
uncoordinated [BF4]- counterions in a 2:1 ratio with Zn in 335 and 4.

The Zn(II)

complexes 1 - 4 are isostructural with their Fe(II) analogs.18 The novel zinc-thione and
-selone complexes 1 and 4 favor tetrahedral coordination about the metal center similar to
reported zinc36 and iron18 analogs.
All the Zn(II) centers adopt a distorted tetrahedral coordination geometry with
bond angles ranging from 103.65(3) to 119.04(4) degrees for 1, and 103.85(2) to
122.42(6) degrees for 4. These correspond to τ4 distortion index values of 0.926 and
0.881, respectively (Table 4.2). Thus, the tetrakis-dmit complex appears to be more
distorted about the Zn(II) center compared to the bis-dmit complex, perhaps due to the
larger size of the dmise ligand in 4 compared to chloride ligand in 1. In particular, the τ4
index of 4 indicates a trigonal pyramidal distortion of the four- coordinate geometry.
The tau value for the Fe(dmit)2Cl2 complex is very similar to 1, with only a 0.003
difference. Comparable dichloride bis-selone complexes, M(dmise)2Cl2, (M = Fe(II),
Zn(II), Co(II)) also have similar geometries (τ4 = 0.919 to 0.981).18,36,37
The M-S/Se bond distances for the complexes listed in Table 4.2 are all
significantly shorter than the sum of their respective M-S/Se van der Waals radii (VDW)
by an average of 1.86 Å, indicating significant orbital overlap and covalent bonding. The
average Zn-S bond length of Zn(dmit)2Cl2 (1: 2.365(1) Å) is shorter than the Fe-S bond
length of Fe(dmit)2Cl2 (2.382(1) Å) by 0.017(1) Å. This difference is significantly shorter
than the difference in the sums of their M-S van der Waals (VDW) radii (ΔVDW = 0.050
Å). The average Zn-Se bond length of 2.478(1) Å is shorter than its iron analog,
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Table 4.2. Selected structural parameters for M(dmit/dmise)2Cl2 and [M(dmit/dmise)4]2+ complexes.
Average
Sum of VDW radii
Complex
τ4
M-S/Se (Å)
of M-S/Se (Å)
Reference
Zn(dmit)2Cl2 (1)

0.926

2.365(1)

4.28

This work

Fe(dmit)2Cl2

0.929

2.382(1)

4.33

18

[Zn(dmit)4]2+ (3)

0.872

2.346 (1)

4.28

35

0.881

2.345(1)

4.33

18

Zn(dmise)2Cl2 (2)

0.930

2.478(1)

4.21

36

Fe(dmise)2Cl2

0.919

2.501(1)

4.26

18

Co(dmise)2Cl2

0.981

2.346(1)

4.22

37

[Zn(dmise)4]2+ (4)

0.881

2.457(1)

4.21

This work

0.846

2.455(1)

4.26

18

[Fe(dmit)4]

2+

[Fe(dmise)4]

2+

Fe(dmise)2Cl2 (2.501(1) Å), by 0.023(1) Å and significantly shorter than the difference of
the sums of the M-Se van der Waals radii (ΔVDW 0.050 Å). The decrease in M-S bond
length for the zinc complexes 1 and 2 is expected due the smaller VDW radii of zinc
compared to iron; however, the difference in M-S/Se bond length does not match the
difference in their VDW radii, indicating strengthening of the C=S bond in dmit
compared to the C=S bond in dmise when bound to zinc compared to iron.
The Zn-S bond length in [Zn(dmit)4]2+ (3; 2.346(1) Å) is not significantly
different than the Fe-S bond in its iron analog [Fe(dmit)4]2+ (2.345(1) Å18). The same true
for the Zn-Se and Fe-Se bond lengths in their selenium analogs [Zn(dmise)4]2+ (4;
2.457(1) Å) and [Fe(dmise)4]2+ (2.455(1) Å18). The difference in the M-S/Se ΔVDW sum
of 0.05 Å seen for 1 and 2 is not observed for the Zn-S/Se bond lengths in 3 and 4,
indicating a strengthening of the C=S/Se bond in these homoleptic complexes when dmit
and dmise are bound to zinc compared to their iron analogs.
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The Zn-S bond lengths of the dichloride complexes 1 and 2 increase by an
average of 0.020 Å as compared to their tetrakis-thione and -selone analogs 3 and 4. This
increase in bond length indicates a decrease in orbital overlap and a weakening of the
M-S/Se bond when chlorides are bound to the zinc metal center, a trend similarly
observed for their iron analogs.18 The increase in M-S/Se bond length for 1 and 2 also
indicates a stronger C=S/Se bond as compared to 3 and 4.
The average C-S bond distances in 1 (1.716(4) Å) also do not vary significantly
from those of other M(L)2Cl2 (M = thione) complexes, ranging from 1.705(2) to 1.722(1)
Å.18,38-46 For 4, the observed Zn-Se bond distances average 2.46(1) Å, comparable to FeSe distances in [Fe(dmise)4]2+ (2.454(1) Å18). The average C-Se bond distance of
1.855(7) Å in 4 falls within the expected range of other first row transition metal-selone
complexes (1.862(3) – 1.873(6) Å).18,36,37
Infrared spectroscopy. Upon complexation with Zn(II), the bis-thione complex
Zn(dmit)2Cl2 (1) shows a C=S stretching vibration at 1173 cm-1, slightly shifted to lower
energy compared to unbound dmit (1181 cm-1 23). In contrast to 1, Zn(dmise)2Cl2 (2) has a
C=Se stretching vibration at 1150 cm-1, not significantly different than unbound dmise
(1148 cm-1 32). The tetrakis-thione complex 3 also shows no significant shift of the C=S
stretching vibration (1180 cm-1) compared to free dmit, and the tetrakis-selone complex 4
has a C=Se stretching vibration (1149 cm-1) similar to that of unbound dmise. Similar
S/Se=C energies have also been observed for [TpmRCu(dmit)]+,16 Fe(dmit)2Cl2, and
[Fe(dmit)4]2+ 18 complexes. The C=S/Se stretches of zinc-bound dmit and dmise indicate
that these ligands bind through primarily σ and π donation to the zinc, as previously
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observed for their Fe2+ analogs.18
NMR spectroscopy. 1H NMR spectra of Zn(dmit)2Cl2 (1), Zn(dmise)2Cl2 (2),
Zn(dmit)4[BF4]2 (3), and [Zn(dmise)4][BF4]2 (4) were acquired in deuterated
dimethylsulfoxide due to the limited solubility of 1 and 2. For Zn(dmit)2Cl2 (1), the
methyl and imidazole proton resonances shift slightly downfield (δ 3.54 and 7.32,
respectively) compared to unbound dmit (δ 3.43 and 7.10, respectively). However, in
[Zn(dmit)4][BF4]2 (3), dmit resonances show no significant shifts for either the methyl or
imidazole protons (δ 3.43 and 7.09, respectively) compared to unbound dmit.
Similar trends are observed in the 1H NMR spectra of the Zn-dmise complexes. A
slight downfield shift is observed for both the methyl and imidazole proton resonances of
Zn(dmise)2Cl2 (2) (δ 3.56 and 7.38, respectively) compared to unbound dmise (δ 3.52 and
7.30, respectively). However, the

1

H NMR spectrum of [Zn(dmise)4][BF4]2 (4)

demonstrates no significant resonance shifts for the dmise methyl and imidazole protons
(δ 3.52 and 7.30, respectively). The slight downfield shifts observed for the 1H NMR
resonances of bis-thione and -selone complexes 1 and 2 demonstrate that when two dmit
ligands are bound to Zn(II), the bound thione ligands shift more toward the zwitterionic
resonance structure compared to unbound dmit and dmise (Figure 4.1). In contrast, the 1H
NMR spectra for the tetrakis-thione and –selone complexes 3 and 4, show no significant
resonance structure shifting compared to unbound dmit and dmise, as similarly observed
via bond length differences of the thione and selones when bound to zinc in their X-ray
crystallographic data.
Oxidation studies with hydrogen peroxide. Previous studies involving the
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treatment of free dmit with H2O2 demonstrated that dmit requires 3 equivalents of H2O2
to fully oxidize to the N,N’-dimethylimidazolium cation, [SO3H]-, and [SO4H]- species.19
Similarly, treatment of free dmise with H2O2 yielded similar products, forming N,N’dimethylimidazolium and [SeO2H]-; however, dmise requires only 2 equivalents of H2O2
for complete oxidation.19 Thus, unbound dmise more readily undergoes oxidation
compared to its thione analog dmit.19
Treatment of Zn(dmit)2Cl2 (1) and Zn(dmise)2Cl2 (2) with H2O2 were performed
to determine how binding to a redox-inactive metal ion affects thione and selone
antioxidant mechanisms. To oxidize these complexes, deuterated dimethylsulfoxide
solutions of Zn(dmit/dmise)2Cl2 (1 and 2) were treated with up to six equivalents of
H2O2. Upon oxidation of Zn(dmit)2Cl2 (1) with multiple equivalents of H2O2, new
resonances emerge at δ 3.83, 7.67, and 9.01, corresponding to formation of the
imidazolium cation (Figure 4.3A). Interestingly, a fourth new resonance appears at δ
10.22, corresponding to a dmit-bound hydroxyl group, typically found in the range of δ
10 - 11.47 This assignment was confirmed via IR spectroscopy with an observed strong,
broad O-H vibration (3410 cm-1) and a S-O vibration (645 cm-1).47 The 1H NMR spectra
of 1 treated with 6 or 8 equivalents of H2O2 show no change compared to the spectrum
observed for treatment of 1 with only four equivalents of H2O2, indicating that the
maximum complex oxidation has occurred with only 4 equiv of H2O2.
1

H NMR spectra of the oxidized Zn(dmise)2Cl2 (2) show similar emergences of
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A

B

Figure 4.3. 1H NMR spectra in DMSO-d6 for A) Zn(dmit)2Cl2, B) Zn(dmise)2Cl2 upon H2O2 treatment, and
C) the resonance labeling scheme, with the prime symbol indicating resonances arising from oxidation
products.

new resonances at δ 3.84, 7.67, and 9.07, corresponding to formation of the imidazolium
cation (Figure 4.3B). Upon treatment of 2 with four equivalents of H2O2, 85% of zincbound dmise becomes oxidized to the imidazolium cation as observed via the ratios of
imidazole ring proton integrations.
Mass spectrometry of the H2O2 oxidation reaction products of Zn(dmit)2Cl2
indicate formation of N,N’-dimethylimidazolium (m/z 97.1), corroborating 1H NMR
results. Since Zn(II) is not redox active under these conditions, only the Zn(II) species
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[ZnCl3]- (m/z 169.7) is observed. After treatment of Zn(dmit)2Cl2 (1) with one equivalent
of H2O2, small intensity peaks for [dmit(OH)]H+ (m/z 146.6) and [dmit(OH)3]- (m/z
179.9) are observed, as well as multiple sulfur-oxide species, including [SO2]- (m/z 64.2),
[SO3]- (m/z 79.5), and [SO4H]- (m/z 97.1). Treatment of unbound dmit with two or three
equivalents of H2O2 results in the cleavage of the C=S bond of the imidazole with the
emergence of the oxidized sulfur products [SO3]- and [SO4H]- observed by ESI-MS.19
Observation of dmit-OH species after treatment of 1 with up to 8 equivalents of H2O2
also corroborates our 1H NMR observations of the new resonance at δ 10.22, attributed to
the this species. Thus, oxidation of zinc-bound dmit does not always result in cleavage of
the C=S bond.
Upon treatment of Zn(dmise)2Cl2 with H2O2, mass spectrometry data indicates
formation of N,N’-dimethylimidazolium (m/z 97.1), similar to its dmit analog 1, as well
as the selenium containing species [SeO2H]- (m/z 113.0). Again, the sole zinc-containing
species observed is [ZnCl3]- (m/z 169.7).

In contrast to oxidation studies of 1, no

evidence for dmise-OH species formed upon hydrogen peroxide treatment of 2 is
observed by NMR spectroscopy or mass spectrometry.
Oxidation of [TpmMeCu(dmit)]+19 and Fe(dmit)2Cl2 (Chapter 3) with H2O2
demonstrated that dmit requires 3 equivalents of H2O2 to fully oxidize to the imidazolium
cation when bound to copper and iron, similar to free dmit. Although Cu(I) was protected
from oxidation to Cu(II),19 the Fe(II) was not protected from oxidation to Fe(III) as
observed by formation of the Fe(III) species [FeCl4]- (Chapter 3). In contrast, when dmit
is bound to non-redox active Zn(II) in 1 and treated with H2O2, dmit C=S bond cleavage
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is

reduced

by

the

formation

of

a

dmit-OH

species

as

well

as

slight

N,N’-dimethylimidazolium cation formation indicating thione coordination to non-redox
active metals may hinder C=S bond cleavage by H2O2.
Treatment of [TpmMeCu(dmise)]+

19

and Fe(dmise)2Cl2 (Chapter 3) complexes

with H2O2 show that dmise undergoes sacrificial oxidation, protecting both Cu(I) and
Fe(II) from oxidation and requiring 2 equivalents of H2O2 for formation of the maximally
oxidized products: imidazolium cation and [SeO2H]- species. These results indicate that
dmise undergoes sacrificial oxidation to the same products when coordinated to both
redox active and non-redox active metal ions. This redox-active metal-dependency of
thione oxidation should to be further explored with other biological metals such as Co(II),
Ni(II) since these are also redox-active, and Mg(II) since it is non-redox active biological
metal.
Electrochemistry. Cyclic voltammetry was used to determine how dmit and dmise
ligand and zinc metal redox potentials are altered when bound in complexes 1-4 (Table
4.3). The cyclic voltammogram of dmit shows irreversible reduction (Epa) and oxidation
(Epc) waves at 0.69 V and 0.12 V, respectively. The voltammogram of dmise shows
similar irreversible redox behavior (Epa = 0.58 V and Epc = 0.08 V). However, when
preventing reduction by starting the negative scan at 0.30 V for dmit and 0.20 for dmise
results in only an oxidation wave as previously observed for methimazole,48 dmit,18 and
dmise,18 indicating reduction is dependent on prior ligand oxidation. Due to the
dependence of reduction waves on prior thione and selone oxidation, E1/2 values are not
reported for ligand-based redox potentials (Table 4.3).
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The cyclic voltammograms for the zinc-dichloro complexes 1 and 2 show no
observed zinc redox waves, since they are outside the observed electrochemical window.
However, for the tetrakis complexes 3 and 4, Zn(II/0) reduction and oxidation waves
observed in their respective cyclic voltammograms. For 3, the observed Zn(II/0)
reduction wave is observed at -1.70 V, and the Zn(0/II) oxidation wave is observed at 0.74 V. For its selenium analog 4, the Zn(II/0) reduction wave is observed at a more

Figure 4.4. Cyclic voltammograms of A) Zn(dmit)2Cl2 (1; dashed line) and Zn(dmise)2Cl2 (2; sold line)
and B) [Zn(dmit)4][BF4]2 (3; dashed line) and [Zn(dmise)4][BF4]2 (4; solid line). All data were collected
with 10 mM complex in dimethylformamide.
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Table 4.3. Redox potentials of selone and thione ligands and their Zn(II) and Fe(II) complexes vs NHE.
Ligand-based
Potentials (V)
Ligand or Complex
Dmise

Epc* (V)
0.08

Epa (V)
0.58

Reference
This work

Zn(dmise)2Cl2 (1)

0.03

0.53

This work

[Zn(dmise)4][BF4]2 (3)

0.01

0.36

This work

Fe(dmise)2Cl2

0.14

0.41

[Fe(dmise)4][BF4]2

0.11

0.36

18
18

Dmit

0.12

0.69

This work

Zn(dmit)2Cl2 (2)

0.09

0.68

This work

[Zn(dmit)4][BF4]2 (4)

0.02

0.66

This work

Fe(dmit)2Cl2

0.15

0.69

[Fe(dmit)4][BF4]2

0.12

0.69

18
18

*Ligand-based reduction potentials are dependent on prior oxidation to the disulfide and diselenide.

positive potential, -1.51 V, as is the Zn(0/II) oxidation wave at -0.47 V.
The cyclic voltammograms of Zn-dmit and dmise complexes 1 – 4 (Figure 4.4)
show both ligand-based reduction and oxidation waves, similar to that observed for
unbound dmit and dmise18 and their Fe(II) complex analogs (Chapter 2), with ligand
reduction dependent on prior ligand oxidation. Zn(II)-dmit binding in complexes 1 and 3
decreases the dmit-based oxidation and reduction potentials by an average of 0.07 V and
0.02 V, respectively, compared to unbound dmit (0.69 V), indicating zinc-bound dmit
becomes less readily oxidizable. The cyclic voltammograms of Zn(II)-dmise complexes 2
and 4 also exhibit dmise-based oxidation and reduction waves. Similar to the zinc-thione
complexes 1 and 3, the ligand-based oxidation potentials become more negative by an
average of 0.12 V compared to unbound dmise (0.58 V), indicating that zinc-bound
dmise also becomes less readily oxidizable than the unbound ligand.
When the chloride ligands in 1 and 2 are replaced with additional dmit and dmise
ligands to form the zinc-tetrakis dmit and dmise complexes 3 and 4, a decrease in
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reduction (0.02 and 0.07 V, respectively) and oxidation (0.02 and 0.17 V, respectively)
potentials is observed. These lower oxidation potentials suggest that dmit and dmise
ligands in 1 - 4 become less readily oxidizable when bound to zinc, in contrast to that
observed for Fe(dmit/dmise)2Cl2 and [Fe(dmit/dmise)4]2+ complexes in which the ligandbased oxidation potentials increase compared to unbound dmit and dmise.18
Previous work by Goldberg et al.49 utilized functional models of the iron enzyme
cycteine dioxygenase (CDO) of the formulae [Fe(II)(LN3S)][OTf] and its zinc analog
[Zn(II)(LN3S)][OTf]

(L

=

bis(imino)pyridine).

Both

[Fe(II)(LN3S)][OTf]

and

[Zn(II)(LN3S)][OTf] complexes were treated with excess O2. X-ray crystallography and
laser desorption ionization mass spectrometry (LDIMS) identified the newly formed
[Fe(II)(LN3SO3)][OTf],

oxidized

via

sulfur

oxygenation.49

However,

when

[Zn(II)(LN3S)][OTf] was treated with O2 over 7 days, no reactivity of the zinc-thiolate
complex was observed, due to non-redox-active zinc coordination.49 Thus, the Fe(II)
redox active metal center was found to be critical for sulfur oxygenation in this CDO
analog, despite the fact that only the ligand was oxidized.49 However, these results
indicate that thione oxidation occurs with both iron and zinc coordination for both thiones
and selones; however, thione coordination to zinc does hinder C=S bond cleavage while
thione coordination to iron as well as selone coordination to both iron and zinc allows
S/Se=C bond cleavage when treated with H2O2.
Previous electrochemical studies of Cu(I) [TpmRCu(dmit/dmise)]+ complexes
showed that dmit or dmise coordination decreased the Cu(II/I) redox potential by 347 847 mV relative to acetonitrile binding, possibly inhibiting catalytic metal-mediated
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hydroxyl radical generation.16 In contrast, electrochemical studies of Fe(dmit/dmise)2Cl2
and {Fe(ebit/ebis)Cl2}n complexes showed that thione or selone coordination decreases
the Fe(III/II) redox potential by 340 – 560 mV, relative to FeCl2·4H2O, however, the
Fe(III/II) redox potentials still fall within the window of catalytic metal-mediated radical
generation (Chapter 2). In addition, the ligand–based redox potentials increase when
bound to iron and are significantly higher than the Fe(III/II) potentials, indicating an
increase in ease of ligand oxidation and suggesting that sacrificial oxidation of the
ligands should occur prior to iron oxidation to prevention of catalytic metal-mediated
radical generation (Chapter 2). However, zinc bound dmit and dmise redox potentials
decrease, suggesting a reduction in the ease of thione and selone oxidation. When zincbound dmit was treated with H2O2 S=C bond cleavage is hindered cooraborating
electrochemical results. While the zinc-bound dmise redox potentials are also reduced,
zinc-dmise oxidation mechanism is not hindered and readily undergoes Se=C bond
cleavage as previously observed with copper19 and iron complexes (Chapter 3). These
results indicate that thione C=S bond cleavage is metal-dependent while selones readily
undergo oxidation cleaving the C=Se bond even when bound to non-redox active metals.

4.3 Conclusions
Zn(II)-thione and –selone complexes have been synthesized and characterized,
and their reactivity with H2O2 and their electrochemical behavior have been investigated.
Zn(dmit)2Cl2 (1) and [Zn(dmise)4][BF4]2 (4) are structurally similar to their previously
synthesized dmise and dmit analogs, with a tetrahedral coordination environment around
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the zinc center. When dmit and dmise bind to zinc, both show a slight increase in
zwitterionic character typical of thione and selone coordination to first-row d-block metal
ions with  and π donation as their primary metal-coordination mode. Treatment of
Zn(dmit)2Cl2 and Zn(dmise)2Cl2 with H2O2 shows that the dmit ligands are less readily
oxidizable than dmise ligands and form dmit-OH species. Both dmit and dmise undergo
sacrificial oxidation to cleave the C=S/Se bond, however dmise undergoes C=Se bond
cleavage alone, whereasthe C=S bond is cleaved to form a mixture of imidazolium cation
as well as oxidized dmit (dmit-OH) species. Electrochemical studies indicate that when
bound to zinc, dmit and dmise ligands become less readily oxidizable compared to free
dmit and dmise, opposite the trend observed for similar Cu(I) and Fe(II) complexes. 16,19
Although dmit oxidation is metal-dependent, dmise oxidation is unaltered whether bound
to redox-active metals such as copper and iron or the non-redox active zinc.

4.5 Experimental Methods
General procedures. The synthesis of complexes 3 and 4 were carried out under
an inert atmosphere of argon using standard Schlenk techniques. The following reagents
were used as received: acetonitrile (Acros), diethyl ether (Acros), zinc(II) chloride
(Acros) and zinc(II) tetraflouroborate (Acros). Dmit and dmise were synthesized
following reported procedures.50 All other reagents and solvents were used without
further purification unless noted.
Instrumentation. 1H and 13C NMR spectra were obtained on a Bruker-AVANCE
300 MHz NMR spectrometer. 1H NMR chemical shifts are reported in δ relative to
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tetramethylsilane (δ 0) and referenced to solvent. Infrared spectra were obtained using
Nujol mulls on KBr salt plates with a Magna 550 IR spectrometer. Abbreviations used in
the description of vibrational data are as follows: vs, very strong; s, strong; m, medium;
w, weak; b, broad. MALDI mass spectrometry experiments were performed using a
Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-tert-butylphenyl)2-methyl-2-propenyldiene (m/z 250.3) as the matrix. Electrospray ionization mass
spectrometry (ESI-MS) was conducted by Lynn Zang using a SYNAPT G2 LC/MS/MS
System from Waters via direct injection of sample (0.10 mL/min flow rate) into a Turbo
Ionspray ionization source. Samples were run under positive mode in acetonitrile, with an
ionspray voltage of 2500 V and in QTOF scan mode. All observed peak envelopes match
theoretical calculations for their ions.
Electrochemistry. A three-compartment cell was used with an Ag/AgCl reference
electrode,

a

Pt

counter-electrode,

and

a

glassy

carbon

working

electrode.

Dimethylformamide (freshly distilled) was used as solvent with tetra-n-butyl ammonium
phosphate as the supporting electrolyte. Solutions containing 0.1 M electrolyte were
deaerated for 10 minutes by vigorous nitrogen purge. All E1/2 values were calculated from
(Epa + Epc)/2 at a scan rate of 100 mV/s. The ferrocenium/ferrocene couple was
measured under the same conditions to correct for junction potentials. The measured
potentials were adjusted from Ag/AgCl to NHE (-0.197 V51) and then corrected with the
measured ferrocenium/ferrocene couple vs. NHE (0.400 V52). Cyclic voltammograms
complexes 1 - 4 are provided in Figure 4.6.
Synthesis of Zn(dmit)2Cl2 (1). Into a 25 mL Erlenmeyer flask, dmit (327 mg, 2.55
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mmol) was dissolved in boiling acetonitrile (25 mL). ZnCl2 (174 mg, 1.28 mmol) was
added with stirring, and the mixture was heated at a slow boil for approximately 20 min
until the reaction volume was reduced to approximately 5 mL. Colorless crystals formed
upon cooling to room temperature, and the flask was covered and refrigerated for 12 h.
The solution was then filtered, and the crystals were washed with cold acetonitrile. Yield:
430 mg, 86%. 1H NMR (DMSO-d6): δ 3.45 (s, 6H, CH3), 7.11 (s, 2H, CH).

13

C{1H}

NMR (DMSO-d6): δ 34.5 (CH3), 118.1 (CH), 161.6 (S=C). IR (cm-1): 3149 (m), 3099
(m), 2920 (b), 2727 (w), 2671 (w), 1707 (w), 1606 (w), 1563 (s), 1463 (vs), 1378 (vs),
1241 (w), 1227 (m), 1172 (m), 1085 (m), 865 (w), 751 (s), 740 (s), 678 (s), 630 (w), 501
(m), 480 (w).MALDI-MS (m/z) = 228.0 [Zn(dmit)Cl]+, 357.0 [Zn(dmit)2Cl]+, 392.9
[Zn(dmit)2Cl2]H+. Anal. Calcd. for C10H16Cl2N4S2Zn: C, 30.59; N, 14.27; H, 4.11.
Found: C, 30.85; N, 14.30; H, 4.08. Melting point: 198-200 °C.
Synthesis of Zn(dmise)2Cl2 (2). Complex 2 was prepared following the procedure
for 1 except that ZnCl2 (140 mg, 1.03 mmol) was used and dmise (380 mg, 2.06 mmol)
was used in place of dmit. After filtration, pale yellow crystals were obtained. Yield: 420
mg, 84%. 1H NMR (DMSO-d6): δ 3.54 (s, 6H, CH3), 7.31 (s, 2H, CH).

13

C{1H} NMR

(DMSO-d6): δ 36.4 (CH3), 120.3 (CH), 154.8 (S=C). IR (cm-1): 3148 (w), 3095 (m), 2926
(b), 2727 (w), 1711 (w), 1609 (w), 1562 (m), 1456 (vs), 1378 (vs), 1242 (w), 1225 (m),
1149 (m), 1087 (m), 865 (w), 754 (s), 737 (s), 663 (m), 613 (w), 468 (m). MALDI-MS
(m/z) = 276.0 [Zn(dmise)Cl]+, 450.8 [Zn(dmise)2Cl]+, 486.8 [Zn(dmise)2Cl2]H+. Anal.
Calcd. for C10H16Cl2N4Se2Zn: C, 24.69; N, 11.52; H, 3.32. Found: C, 24.92; N, 11.56; H,
3.21. Melting point: 208-210 °C (dec.).
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Synthesis of [Zn(dmit)4][BF4] 2 (3). Zn(BF4)2 (226 mg, 0.67 mmol) was dissolved
in acetonitrile (5 mL) and added to a solution of dmit (170 mg, 1.3 mmol) in acetonitrile
(10 mL). The solution stirred for 12 h, and the solvent volume was then reduced to 5 mL.
The product was precipitated with diethyl ether and dried under vacuum, yielding a light
yellow powder. Crystals were grown by slow vapor diffusion of ether into acetonitrile.
Yield: 370 mg, 74%. 1H NMR (DMSO-d6): δ 3.45 (s, 12H, CH3), 7.10 (s, 4H, CH).
13

C{1H} NMR (DMSO-d6): δ 34.4 (CH3), 118.0 (CH), 161.9 (S=C). IR (cm-1): 3168 (w),

3140 (w), 3115 (w), 2925 (vs, b), 2727 (w), 1570 (m), 1490 (w), 1459 (s), 1398 (w), 1377
(m), 1288 (w), 1180 (m), 1054 (s), 861 (w), 745 (m), 679 (m), 521 (w), 502 (w). MALDIMS (m/z) = 288.1 [Zn(dmit)4]2+, 663.2 [Zn(dmit)4][BF4]+. Anal. Calcd. for
C20H32B2F8N8S4Zn: C, 31.95; N, 14.91; H, 4.29. Found: C, 31.98; N, 14.91; H, 4.29.
Melting point: <260 °C.
Synthesis of [Zn(dmise)4][BF4] 2

(4). Complex 4 was prepared using the same

procedure as complex 3 except Zn(BF4)2 (180 mg, 0.53 mmol) was used and dmise (187
mg, 1.06 mmol) was used instead of dmit. Yellow crystals were grown by slow vapor
diffusion of ether into acetonitrile. Yield: 400 mg, 80%. 1H NMR (DMSO-d6): δ 3.54 (s,
12H, CH3), 7.32 (s, 4H, CH).

13

C{1H} NMR (DMSO-d6): δ 36.3 (CH3), 120.1 (CH),

155.1 (S=C). IR (cm-1): 3165 (w), 3139 (w), 3106 (w), 2972 (s), 2853 (s), 1569 (w), 1459
(s), 1378 (m), 1260 (w), 1237 (m), 1146 (w), 1055 (s), 800 (w), 740 (m), 652 (w), 521
(w). MALDI-MS (m/z) = 383.0 [Zn(dmise)4]2+, 854.9 [Zn(dmise)4][BF4]+ Anal. Calcd.
for C20H32B2F8N8Se4Zn: C, 25.57; N, 11.93; H, 3.43. Found: C, 25.46; N, 11.71; H, 3.40.
Melting point: <260 °C.
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Reactivity of Zn(dmit)2Cl2 with H2O2. Zn(dmit)2Cl2 (20 mg, 0.041 mmol) was
dissolved in dimethylsulfoxide-d6 (0.5 mL) and to this was added 1.0, 2.0, 3.0 or 4.0
equiv of H2O2 (0.041 , 0.082, 0.123, or 0.164 mmol; 1.45, 2.90, 4.35, or 5.80 μL). The
reaction mixtures were stirred for 10 min. Yield of oxidized product using 4 equiv H2O2:
53% by 1H NMR spectroscopy. 1H NMR (DMSO-d6): δ 3.83 (s, 6H, 2CH3), 7.67 (s, 2H,
2CH), 9.01 (s, 1H, CH). MALDI-MS: m/z positive ionization: 97.1 [C5H9N2]+, 100.0
[ZnCl]+; negative ionization: 81.0 [SO3H]-.
Reactivity of Zn(dmise)2Cl2 with H2O2. Zn(dmise)2Cl2 (20 mg, 0.051 mmol) was
dissolved in dimethylsulfoxide-d6 (0.5 mL) and to this was added 1.0, 2.0, 3.0, or 4.0
equivalents of H2O2 (0.051, 0.102, 0.153, or 0.204 mmol; 1.20, 2.40, 3.60, or 4.80 μL).
The reaction mixtures were stirred for 10 min. Yield of oxidized product using 4
equivalents of H2O2: 85% by 1H NMR spectroscopy. 1H NMR (DMSO-d6): δ 3.84 (s, 6H,
2CH3), 7.67 (s, 2H, 2CH), 9.07 (s, 1H, CH). MALDI-MS: m/z positive ionization: 97.1
[C5H9N2]+, 100.0 [ZnCl]+; negative ionization: 113.0 [SeO2H]-.
Single crystal X-ray data collection. Single crystals of Zn(dmit)2Cl2 (1),
crystallized as colorless rods, were grown from cooling the reaction mixture of
acetonitrile solution. [Zn(dmise)4][BF4]2 (4), crystallized as light yellow prisms, were
grown from vapor diffusion of diethyl ether into an acetonitrile solution. Both crystals
were mounted on a glass filament with epoxy glue, and immediately placed on the
diffractometer in a room-temperature nitrogen gas stream. Intensity data were collected
using a Rigaku Mercury CCD detector and an AFC8S diffractometer. The space groups
P21/n and Pbcn were determined from the systematic absences for complexes 1 and 4
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respectively (Table 4.4). The structures were solved by direct methods and subsequent
Fourier difference techniques, and refined anisotropically, by full-matrix least squares, on
F2 using SHELXTL 6.10.53 The quantity minimized by the least squares program was
Σw = (Fo2 - Fc2)2 where w ={[σ2(Fo2)]+(0.0307P)2 + 1.57P} where P = (Fo2)+2Fc2)/3. In
the final cycle of least squares, independent anisotropic displacement factors were refined
for the non-hydrogen atoms, and hydrogen atoms were fixed in idealized positions with
C—H = 0.96 A. Isotropic hydrogen atom displacement parameters were set equal to 1.5
times Ueq of the attached carbon atom. For 1, the largest peak in the final Fourier
difference map (0.45 e·A-3) was located 0.81 Å from H8 and the lowest peak (-0.40 e·A3) was located at a distance of 0.82 A from Zn1. For 4 the largest peak in the final
Fourier difference map (0.84 e·A-3) was located 0.92 Å from F1 and the lowest peak (0.84 e·A-3) was located at a distance of 0.45 Å from F5.

Figure 4.5. Crystal packing diagram for Zn(dmit)2Cl2 (1) showing short Cl-H interactions as viewed along
the a-axis.
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Figure 4.6. Crystal packing diagram for [Zn(dmise)4][BF4]2 (4) showing short F-H interactions as viewed
along the c-axis.

157

Table 4.4. Summary of crystallographic data for complexes 1 and 4.
1

4

C10H16Cl2N4S2Zn

C20H32B2F8N8Se4Zn

F.W. (g/mol-1)

392.66

939.37

Space group

P21/n

Pbcn

Monoclinic

Orthorhombic

a, Å

9.364(1)

11.960(2)

b, Å

13.590(1)

21.373(4)

c, Å

13.202(2)

13.163(3)

α, deg

90

90

β, deg

108.736

90

γ, deg

90

90

V, Å-3

1591.4(4)

3364(1)

4

4

1.639

1.854

indices (min)

[-11, -16, -15]

[-14, -25, -15]

indices (max)

[10, 15, 15]

[14, 25, 15]

parameters

176

223

F(000)

Chemical formula

Crystal system

Z
Dcal, mg/m3

800

1824

-1

2.13

5.13

2θ range, deg

2.7-26.4

2.5-26.7

collected reflections

11422

25454

unique reflections

2859

2445

Final R (obs. data) , R1

0.0371

0.0563

wR2

0.0829

0.1452

final R (all data), R1

0.0445

0.0682

wR2

0.0895

0.1593

goodness of fit (S)

1.147

1.11

largest diff. peak

0.45

0.84

-0.40

-0.82

μ, mm

a

largest diff. hole
a

R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR2 =

{Σw(F02

2 2 1/2

- Fc ) } .
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CHAPTER FIVE
SYNTHESIS AND CHARACTERIZATION OF IMIDAZOLE THIONES
AND SELONES AND THEIR DERIVATIVES
5.1 Introduction
Thione and selone compounds feature a sulfur- or selenium-carbon double bond
(S/Se=C), respectively, and they have been studied in a variety of applications, including
zinc selenide synthons for electronics,1-3 biological antioxidants,4-8 and as antithyroid
drugs.9-16 Initial interest in antioxidant thiones, selones, and their derivatives arose from
the discovery of ergothioneine (Figure 5.1).17-23 More recently, ergothioneine’s selenium
analog, selenoneine (Figure 5.1), was discovered in the blood of bluefin tuna and has
been reported in human blood in concentrations up to 9 nM.23 Both ergothioneine and
selenoneine have been studied for their ability to act as antioxidants through radical
scavenging and metal coordination.24,25 Ergothioneine prevents Cu(I)-mediated

Figure 5.1. Ergothioneine, selenoneine, methimazole, dmit, dmise and their novel sulfur and selenium
containing compounds.
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deoxyribose damage in concentrations up to 1 mM.25 Although little is known about
selenoneine, it scavenges 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical and protects Fe2+
from oxidation in hemoglobin and myoglobin in vitro.23
Methimazole, a derivative of ergothioneine and a widely-prescribed anti-thyroid
drug, is a potent ROS-scavenging antioxidant and prevents oxidative DNA damage.14,26
Recently, the selenium analog of methimazole (MSeI; Figure 5.1) has attracted
considerable attention, since MSeI is expected to be more nucleophilic than
methimazole.27,28 Interestingly, methimazole, MSeI, and their derivatives do not exist in
true selone or thione form (Figure 5.2A), but rather they exist primarily in the
zwitterionic resonance structure (Figure 5.2B).8,11-14,28
N,N’-Dimethylimidazole thione (dmit) and selone (dmise; Figure 5.1), thione and

selone analogs of ergothioneine and selenoneine, prevent copper- and iron-mediated
DNA damage at micromolar concentrations.29 Interestingly, dmit and dmise are
multifunctional antioxidants, preventing oxidative DNA damage through both radicalscavenging and metal-binding mechanisms.29 Altering the N-substituted functional groups,

(R = H, CH3, and Py) and potential denticity for metal chelation significantly alters the
antioxidant activity of these thiones and selones.29
To expand upon studies of the well-investigated dmit and dmise compounds as

Figure 5.2. Thione and selone A) non-zwitterionic and B) zwitterionic resonance structures.

164

well as commercially available methimazole, we have synthesized novel sulfur- and
selenium-containing compounds 1 - 4. Adding electron-withdrawing or -donating
substituents to these imidazole thiones and selones may alter the resonance in these
molecules to favor either the zwitterionic or non-zwitterionic structures, affecting their
metal binding and antioxidant abilities.

5.2 Results and Discussion
Synthesis. The sulfur and selenium compounds 1, 2, 5, and 6 were synthesized
either by nucleophilic sulfur and selenium addition, utilizing a carbene reaction of the
imidazolium salt, or through electrophilic sulfur or selenium addition, utilizing lowtemperature metalation. Compounds 1 and 2 were synthesized by methyl iodide
methylation of 4,5-dichloroimidazole to yield 4,5-dichloro-1,3-dimethylimidazolium
iodide, followed by nucleophilic addition of elemental sulfur or selenium resulting in the
corresponding dichloro-substituted thione (1) and selone (2) compounds (Scheme 5.1A).
The trityl-substituted compound (3) was synthesized by deprotonation of the
secondary amine, followed by trityl protection of the sulfur (Scheme 5.1B). This tritylprotected thiol (3) blocks metal coordination to the sulfur atom, allowing for sole
coordination through the nitrogen atom of the imidazole ring, a binding mode that is not
observed for methimazole-metal coordination.30 Although trityl protection of sulfur
atoms is not novel, trityl-protection of the sulfur is a novel synthetic route for addition of
substituents to the nitrogen atom of thiones. Similar trityl-protection of the selone analog
was also attempted; however under these conditions, the selone compound
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Scheme 5.1

decomposes, as observed by NMR spectroscopy.
Treatment of 3 with chloroacetone, followed by acidic deprotection of the trityl
group and purification yields the keto-substituted thione (4; Scheme 5.1B). Adding a keto
group onto the imidazole nitrogen not only alters the electronics within the imidazole
ring, but also may increase denticity by adding the keto oxygen as a possible metalbinding site.
The novel compound 5 and the reported compound 610 were synthesized using a
new synthetic route by methylation of 1-methylimidazole, resulting in an imidazolium
salt, followed by lithiation by n-butyllithium and subsequent electrophilic addition of
elemental sulfur or selenium. Utilizing an acid workup yields the oxidized disulfide (5) or
diselenide (6) salts (Scheme 5.1C). Rather than adding dmise to a solution of
lactoperoxidase (LPO), H2O2, and KI in aqueous phosphate buffer,10 this method allows
for a cheaper and more reliable synthetic route for good yields of 5 and 6.
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Structural

analysis

of

thione

and

selone

compounds.

Crystals

of

4,5-dichloro-1.3-dimethylimidazole thione (1) and 4,5-dichloro-1.3-dimethylimidazole
selone (2) were grown by recrystallization from methanol solutions, and tritylmethimazole (3) as a 1:1 adduct with trityl-alcohol were grown by recrystallization from
acetonitrile solutions at -20 ˚C. Single crystal X-ray diffraction data were collected by Dr.
Collin McMillen (Department of Chemistry, Clemson University) for 1 and 2, which
crystallized as colorless columns, and 3, which crystallized as colorless blocks. The
resulting molecular structures are shown in Figure 5.3, and selected bond distances are
summarized in Table 5.1.
The C=S bond length of 1.664(3) Å for the dichloro-thione (1) is significantly
shorter than those in methimazole (1.699(5) Å31) and dmit (1.692(1) Å32), suggesting that
1 favors a resonance structure with more double bond character than methimazole and
dmit. The C=Se bond length in 2 (1.829(6) Å) is also slightly shorter than those in MSeI
(1.849(3) Å28) and dmise (1.843(9) Å33), again suggesting less zwitterionic character in
the structure of the cloro-substituted selone. This decrease in C=S/Se bond lengths and

Figure 5.3. Crystal structure diagrams with 50% probability density ellipsoids for A) 1,3-dimethyl-4,5dichloroimidazole thione (1), B) 1,3-dimethyl-4,5-dichloroimidazole selone (2), and C) trityl-methimazole
(3). Hydrogen atoms are omitted for clarity.
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Table 5.1. Selected average interatomic distances (Å) for methimazole, dmit, dmise, 1, 2, and 3.
Compound
C-N
S/Se=C
References
dmit

1.349(1)

1.692(1)

32

methimazole

1.356(2)

1.696(5)

31

1

1.365(4)

1.664(3)

this work

3
dmise

1.35(1)

1.74(1)

this work

1.343(9)

1.843(9)

33

MSeI

1.347(3)

1.849(3)

28

2

1.361(9)

1.829(6)

this work

zwitterionic character compared to methimazole, MSeI, dmit, and dmise, likely results in
decreased metal-binding affinity for 1 and 2 if the negative charge on the sulfur or
selenium atom is reduced.
Interestingly, the dichloro-thione (1) and dichloro-selone (2) crystallize in
different space groups (P6522 and P21/n, respectively; Table 3). Since this is not the case
for isostructural dmise and dmit,32,33 we speculate that the interactions involving the
chlorine atoms are integral in directing different packing arrangements for 1 and 2. In
particular, differences in crystal packing may be due to additional stabilization from
interaction of the chlorine atoms with π electron density from the imidazole ring enabled
by the screw axis in the hexagonal packing (Figures 5.4 and 5.5) of 1. Furthermore, for 1,
Cl-S interactions of 3.383(2) Å with C-Cl---S of 170.5(2)° are observed to occur in the ab
plane. This shorter, highly directional contact (~5% shorter than the sum of the van der
Waals radii) is suggestive of Cl---S halogen bonding as a contributor to the unique
packing of 1. In the case of 2, similar C-Cl---Se interactions are observed (Cl---Se =
3.52(4) Å, C-Cl---Se = 171.9(1)°), but the interaction of Cl with the imidazole π electron
density appears absent.
The aromaticity of methimazole, MSeI, dmit, dmise, and compounds 1 - 4 were
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also considered based on the average imidazole C-N bond length (Table 5.1). As
previously reported, methimazole has an average C-N bond length of 1.356(2) Å.31 For
dmit, addition of a methyl group onto the imidazole nitrogen decreases the average C-N
bond length within the ring (1.349(1) Å32) by 0.007 Å, indicating slightly more
aromaticity of the imidazole ring in dmit. The dichloro-thione 1 has an average imidazole
C-N bond length of 1.365(4) Å, 0.016 Å longer than that in dmit.32 The increase in
average C-N bond length for 1 as compared to methimazole and dmit indicates an
increase in C-N single bond character, and slightly less aromatic character than
methimazole and dmit. Similar trends in aromaticity are also observed for the selones 2,
MSeI,28 and dmise.33 MSeI has an average C-N bond length of 1.347(3) Å, whereas
dmise has an average C-N bond length of 1.343(9) Å.33 The dichloro selone 2 has an
average C-N bond length of 1.361(9) Å, 0.018 Å longer than that of dmise33 and 0.014 Å
longer than MSeI. Both the lengthening of the C-N bonds and the shortening of the
C=S/Se bonds relative to unsubstituted methimazole and MSeI are consistent with a
decrease in the aromatic imidazole resonance structure the dichloro-thione (1) and
-selone (2; Figure 5.2).
Trityl-methimazole (3) has a C-S bond length of 1.74(1) Å, confirming single
bond character fairly typical for thiol compounds (1.806(6) Å34). The average C-N bond
length of 1.350(5) Å is very similar to the C-N bond length of methimazole and dmit
(1.356(2) Å31 and 1.349(1) Å32; respectively). Compound 3 presents an interesting case
for future study, since as a ligand it will only bind metal ions through the non-methylated
nitrogen site on the imidazole ring. This may permit a comparison study of the
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requirement for metal-sulfur binding in metal-mediated DNA damage prevention.
NMR and IR spectroscopies. The 1H NMR resonances of the methyl and olefinic
protons for complexes 1 – 4 are listed in Table 5.2. For the dichloro-thione 1, the methyl
proton resonances (δ 3.59) are slightly shifted upfield compared to the methyl resonances
of dmit (δ 3.6111) due to the induction effect of the Cl atoms into the imidazole ring. This
effect is also observed for the selone analog 2 when comparing its methyl resonance (δ
3.65) to the methyl resonance of dmise (δ 3.7111). These 1H NMR shifts corroborate the
X-ray data, indicating a shift to the non-zwitterionic resonance form for 1 and 2
compared to dmit and dmise (Figure 5.2). The opposite trend is observed for the methylketo-thione (4), since the electron withdrawing methyl-keto substituent increases the
induction effect of the opposite nitrogen-bound methyl, as supported by the slight
downfield resonance shift of the methyl protons 4 (δ 3.68) compared to 1 and dmit.11 The
increase in zwitterionic character of 4 is further confirmed by the downfield shift of the
imidazole protons (δ 6.95 and 7.04) compared to dmit (δ 6.72). This increase in
zwitterionic character of 4 as well as a possible chelate effect of the methyl-keto
substituent may increase its metal binding affinity.
The methyl proton resonance of the trityl-protected thiol 3 (δ 2.92) is significantly
shifted upfield compared to the thiones 1, 3, and dmit (δ 3.59 - 3.68), whereas the
imidazole proton resonances of 1 and 3 (δ 6.79 and 7.05) are shifted downfield compared
to those of dmit (δ 6.72). This resonance shifting indicates a greater aromatic character
compared to dmit. Because the trityl-protected thiol 3 is not a thione and should solely
bind metals through the available nitrogen within the imidazole ring, the increase in
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Table 5.2. Selected 1H NMR resonances (in CDCl3) and IR stretches for compounds 2 - 4, dmit, dmise, and
methimazole.
1

IR (cm-1)

H NMR shifts (δ)

Compound
1

CH3
3.59

Imidazole C-H
n/a

Reference
This work

S/Se=C
1164

Reference
This work

2

3.65

n/a

This work

1144

This work

3

2.92

6.79, 7.05

This work

-

-

4

3.68

6.95, 7.04

This work

1152

This work

dmit

3.61

6.72

11

1181

34

dmise

3.71

6.88

11

1147

28

methimazole

3.60

6.68, 6.72

35

1150

36

imidazole aromatic character compared to 1, 3, and dmit may afford an increase in metal
binding affinity due to an increase in zwitterionic character. The increase in zwitterionic
character increases the partial negative charge on the S atom, potentially increasing metal
binding affinity.
The S/Se=C bond IR stretching frequencies of the thione and selone complexes 1,
2, 4, dmit, dmise, and methimazole are listed in Tables 5.2. For the dichloro-thione 1, the
observed S=C stretching vibration (1164 cm-1) is significantly shifted to lower energy
compared dmit (1181 cm-1 34). The same shift to lower energy is observed for the methylketo thione 4 (1152 cm-1) compared to dmit, however the S=C bond energy is similar to
methimazole (1150 cm-136). The decrease in S=C bond energy of the dichloro-thione 1
indicates an increase in single bond character compared to dmit similar to the observed
effect in 1H NMR spectroscopy, however it is an opposite effect observed in X-ray
possibly due to π-stacking with the imidazole ring and chloride atoms as observed in
Figure 5.3 as well as possible solid vs. solution state interactions.
Although large changes are observed in the S=C stretching vibration for the
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thiones 1, 4, dmit, and methimazole, the same is not true for their selone counterparts.
The observed Se=C stretching vibration for the dichloro-selone 2 (1144 cm-1) is similar to
that observed for dmise (1147 cm-1 28), indicating little change in Se=C bond strength
upon chloro substitution. This is not surprising, since unbound dmise has increased
zwitterionic character compared to dmit as reported using DFT calculations.8
Syntheses of these imidazole thione and selone compounds and their derivatives
have required development of novel synthetic strategies. In particular, trityl protection of
the sulfur atom allows for direct addition of aliphatic substituents onto the imidazolium
nitrogen. The ability to synthesize novel thione and selone compounds under atmospheric
conditions enables facile synthesis of new thiones and selones not achievable through
reported methods.

5.3 Conclusions
We have synthesized novel sulfur and selenium compounds 1 - 4 and synthesized
compounds 5 and 6 using new experimental methods. In addition, we have introduced a
novel synthetic route for addition of aliphatic substituents to the nitrogen of the imidazole
thione ring of by trityl protection of the sulfur, as observed in 3; however, the same
synthetic procedures do not work for their selenium analogs. Synthesis of these novel
thione and selone compounds 1 - 4 can be easily carried out under non-oxygen sensitive
conditions. X-ray diffraction studies indicate that the addition of chloride atoms onto the
imidazole ring decreases the zwitterionic character of thiones, however the selone analog
shows no significant difference in zwitterionic character. 1H NMR and IR spectroscopies
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indicate an increase in zwitterionic character for the dichloro-thione (1) and -selone (2)
compounds, possibly increasing their metal binding affinities. The 1H NMR and IR data
for the methyl-keto thione (4) indicates an increase in the increase in zwitterionic
character compared to dmit and methimazole, possibly increasing its metal binding
affinity. The keto-substituent also may afford an increase in metal binding affinity via
increase in denticity though the available O and S atoms. Introduction of the trityl
protection of the sulfur atom may be worth exploring as a method to easily synthesize
novel thione derivatives.

5.4 Experimental Methods
All reagents were used as received with no purification; 1,3-dimethylimidazolium
iodide was synthesized following published procedures.11
Instrumentation. 1H and

13

C{1H} NMR spectra were obtained on a Bruker-

AVANCE 300 MHz NMR spectrometer. 1H NMR chemical shifts are reported in δ
relative to tetramethylsilane (δ 0) and referenced to solvent. Infrared spectra were
obtained using on KBr salt plates with a Magna 550 IR spectrometer. Abbreviations used
in the description of vibrational data are as follows: vs, very strong; s, strong; m,
medium; w, weak; b, broad. MALDI mass spectrometry experiments were performed
using a Bruker Microflex MALDI-TOF mass spectrometer with trans-2-[3-(4-tertbutylphenyl)-2-methyl-2-propenyldiene (m/z 250.3) as the matrix. In all cases, observed
isotopic patterns matched their calculated values.
Synthesis of 4,5-dichloro-1,3-dimethy-imidazole thione (1). A mixture of
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4,5-dichloroimidazole (0.25 g, 1.83 mmol), iodomethane (0.115 g, 1.83 mmol), and
potassium carbonate (0.375 g, 2.75 mmol) in acetonitrile (10 mL) was stirred at room
temperature for 48 h. The mixture was filtered, and the filtrate was dried under vacuum to
give a yellowish-white solid. The solid was dissolved in CH2Cl2 (25 mL) and washed
with water (8 mL × 2) to remove potassium carbonate. The organic layer was separated
and dried over MgSO4, and the resulting solution was evaporated to dryness under
vacuum to afford a white solid. This white solid was dissolved in acetonitrile (0.5 mL),
and iodomethane (0.5 mL, 8 mmol) was then added. The resulting solution was heated at
55 °C for 18 h in a pressure tube, yielding white crystals that were then filtered, washed
with diethyl ether (30 mL × 2), and dried under vacuum. Analysis of the white crystals of
4,5-dichloro-1,3-dimethylimidazolium iodide (246 mg; 0.702 mmol) matches reported 1H
NMR values.11 To a solution of 4,5-dichloro-1,3-dimethylimidazolium iodide (246 mg;
0.702 mmol) dissolved in methanol (10 mL), sulfur powder (28 mg; 0.772 mmol) and
potassium carbonate (97.0 mg; 0.900 mmol) were added and the solution was heated to
reflux for 36 h. The hot yellow-brown mixture was filtered through a pad of celite to
remove potassium carbonate and excess sulfur. The filtrate was dried under vacuum, and
the resulting solid was dissolved in methanol (2 mL). The methanolic solution was cooled
to -20 °C, yielding 4,5-dichloro-1,3-dimethy-imidazole thione (1) as colorless needles.
Yield: 116 mg, 46%. 1H NMR (300 MHz, CDCl3): δ 3.59 (s, 6H).

13

C{1H}NMR

(CDCl3): δ 36.2 (s, CH3), 117.3 (s, C-Cl), 162.1 (s, C=S). IR (cm-1): 2914 (s, br), 2866 (s,
b) 1592 (m), 1462 (s), 1378 (s), 1338 (m), 1222 (w), 1164 (m), 1132 9 (w), 1066 (m), 970
(w), 951 (w), 854 (m), 665 (w), 616 (w), 565 (m), 416 (m). MALDI-MS (m/z): 197.2
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[C4H6Cl2N2S]H+. Anal. Calcd. for C4H6Cl2N2S: C, 30.47; H, 3.07; N, 14.21. Found: C,
30.23; H, 3.02; N, 14.16. m.p.: 180 – 182 ˚C.
Synthesis of 4,5-dichloro-1,3-dimethylimidazole selone (2). To a solution of
4,5-dichloro-1,3-dimethylimidazolium iodide (426 mg; 1.45 mmol) dissolved in
methanol (10 mL), Se powder (126 mg; 1.60 mmol), and K2CO3 (169 mg; 1.22 mmol)
were added, and the mixture was heated to reflux for 36 h. The resulting black solution
was filtered through a pad of celite to remove potassium carbonate and excess selenium.
The filtrate was dried under vacuum, and the resulting solid was dissolved in methanol (2
mL). The methanolic solution was cooled to -20 °C, yielding 4,5-dichloro-1,3-dimethyimidazole selone (2) as colorless needles. Yield: 187 mg, 44%. 1H NMR (300 MHz,
CDCl3): δ 3.65 (s, 6H). 13C{1H}NMR (CDCl3): δ 35.2 (s, CH3), 114.4 (s, C-Cl), 156.8 (s,
C=Se). IR (cm-1): 3434 (s, b), 2082 (m, b), 1636 (s), 1438 (w), 1372 (m), 1337 (w), 1144
(m), 1134 (m), 851 (w), 602 (w), 540 (w), 432 (w), 420 (w). MALDI-MS (m/z): 244.8
[C4H6Cl2N2S]H+. Anal. Calcd. for C4H6Cl2N2Se: C, 24.61; H, 2.48; N, 11.48. Found: C,
24.59; H, 2.51; N, 11.50. m.p.: 185 – 187 ˚C.
Synthesis of trityl-methimazole (3). To a solution of methimazole (250 mg, 2.19
mmol) dissolved in dry acetonitrile (50 mL), Cs2CO3 (856 mg, 2.62 mmol) and trityl
chloride (610 mg, 2.19 mmol) were added, and the reaction mixture was stirred for 12 h.
The solvent was removed under vacuum, and the resulting solid was washed with
distilled H2O (30 mL × 2) and filtered leaving a peach colored solid of tritylmethimazole. Yield: 333 mg, 43%. 1H NMR (CDCl3): δ 2.92 (s, CH3), 6.79 (JHH = 0.6,
d, CH), 7.05 (JHH = 0.6, d, CH), δ 7.23 - 7.38 (m, trityl CH). 13C{1H} NMR (CDCl3): δ
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33.0 (s, CH3), 72.9 (s, S-C trityl), 122.9 (s, CH), 127.2 (s, CH), 127.3 (m, CH), 130.0 (s,
CH), 130.5 (s, CH), 144.0 (s, C), 146.9 (s, C-Ph). IR (cm-1): 3407 (s, br), 3082 (m), 3055
(m), 3029 (m), 2367 (w), 2334 (w), 1956 (w), 1594 (w), 1490 (s), 1445 (s), 1407, (w),
1340 (w), 1280 (m), 1183 (w), 1158 (w), 1118 (w), 1061 (w), 1033 (m), 914 (w), 892
(w), 846 (w), 735 (s), 699 (s), 669 (w), 620 (w), 502 (w). MALDI-MS (m/z): 157.1
[C23H20N2S]H+. Anal. Calcd. for C23H20N2S: C, 77.49; H, 5.66; N, 7.86. Found: C, 77.47;
H, 5.68; N, 7.88. m.p.: 164 – 167 ˚C.
Synthesis of 1-keto-3-methylimidazole thione (4). Trityl-methimazole (4) (367.5
mg, 1.03 mmol) was dissolved in acetonitrile (80 mL) and cooled to 0 °C. Once cooled,
chloroacetone (0.1 mL, 1.14 mmol) was added and the reaction mixture was solution was
stirred for 6 h at 0 ˚C. The solution was treated with 10 mL of 1% TFA in water and the
reaction mixture was stirred for 30 min producing a white precipitate. The white
precipitate was removed via vacuum filtration and the filtrate was dried under vacuum to
yielding 1-keto-3-methylimidazole thione (4) as a dark brown oil. Yield: 180 mg; 50%.
1

H NMR (CDCl3): δ 2.29 (s, CH3), 3.68 (s, CH3), 4.07 (s, CH2), 6.95 (s, CH), 7.04 (s,

CH). 13C{1H} NMR (CDCl3): δ 30.2 (s, CH3), 42.6 (CH3), 67.4 (s, CH2), 117.9 (s, CH),
118.3 (s, CH), 162.3 (s, C=S), 201.9 (C=O). IR (cm-1):3431 (s, br), 2370 (w), 2343 (w),
1734 (w), 1654 (m, br), 1637 (m, br), 1577 (w), 1458 (w), 1281 (w), 1034 (w), 1152 (w),
1064 (w), 1035 (w), 688 (m, br).

MALDI-MS (m/z): 114.0 [C4H5N2S]H+ and 171.1

[C7H10N2OS]H+. Anal. Calcd. for C7H10N2OS: C, 49.39; H, 5.92; N, 16.46. Found: C,
49.28; H, 5.90; N, 16.40.
Synthesis of 2,2'-disulfanediylbis(1,3-dimethyl-2,5-dihydro-1H-imidazol-3-ium)
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(5). 1,3-dimethylimidazolium iodide (1.36 g, 6.09 mmol) was dissolved in dry
tetrahydrofuran (50 mL), and the solution was cooled to -78 °C. Once cooled,
n-butyllithium (2.2 mL, 2.5 M in hexanes) was added and the reaction mixture was
allowed to stir for 35 min. The reaction mixture was warmed to room temperature, and
then sulfur powder (292 mg, 9.12 mmol) was added, the reaction mixture was stirred for
12 h, quenched with water (10 mL), and neutralized with 1 N HCl (10 mL). From the
resulting solution, the desired product was extracted with dichloromethane (25 mL × 3),
and the organic layer was washed with brine (20 mL) and then dried over sodium sulfate.
The dichloromethane was removed under vacuum, affording 2,2'-disulfanediylbis(1,3dimethyl-2,5-dihydro-1H-imidazol-3-ium) (5) as a brown solid. Yield: 1.30 g, 73%. 1H
NMR (CDCl3): δ 3.62 (s, 6H), 6.68 (s, 2H). 13C{1H} (CDCl3): δ 35.2 (s, CH3), 117.5 (s,
CH), 162.8 (C=S). IR (cm-1): 3434 (s, b), 3157 (w), 3116 (w), 1637 (m), 1574 (w), 1493
(m), 1466 (m), 1438 (m), 1394 (w), 1240 (m), 1182 (w), 1085 (w), 731 (m), 663 (m), 515
(w). MALDI-MS (m/z): 389.0 [C10H22N4S2I]+. Anal. Calcd. for C10H22N4S2I2; C, 30.85;
H, 5.70; N, 14.39. Found: C, 30.83; H, 5.69; N, 14.35. m.p.: 148 – 150 ˚C.
Synthesis of 2,2'-diselanediylbis(1,3-dimethyl-2,5-dihydro-1H-imidazol-3-ium)
(6). Compound 6 was synthesized similarly to 5, except selenium powder (4.10 g, 51.9
mmol) was used instead of sulfur powder. The resulting orange solid was dried under
vacuum, affording 2,2'-diselanediylbis(1,3-dimethyl-2,5-dihydro-1H-imidazol-3-ium).
Yield 8.02 g, 76%. 1H NMR (CDCl3): δ 3.71 (s, 6H), 6.86 (s, 2H).

13

C{1H} NMR

(CDCl3): δ 35.6 (s, CH3), 117.7 (s, CH), 171.6 (C=Se). IR (cm-1): 3434 (s, b), 2088 (w,
b), 1635 (s), 1486 (w), 1433 (w), 1384 (m), 1238 (w), 1148 (m), 737 (w), 652 (w).
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MALDI-MS (m/z): 485.9 [C10H22N4Se2I]+. Anal. Calcd. for C10H22N4Se2I2; C, 19.69; H,
3.64; N, 9.18. Found: C, 19.60; H, 3.60; N, 9.12. m.p.: 153 – 156 ˚C.
X-ray data collection and structural determination. Single crystals grown from
vapor diffusion were mounted on a glass filament with epoxy. The crystals were grown
by recrystallization from methanol for 4,5-dichloro-1,3-dimethy-imidazole thione (1) and
4,5-dichloro-1,3-dimethy-imidazole selone (2) and acetonitrile for trityl-methimazole (3).
Intensity data were collected using a Rigaku Mercury CCD detector and an AFC8S
diffractometer. The space groups P6522 for 1 and P21/n for 2 and 3 were determined from
the observed systematic absences. Data reduction including the application of Lorentz
and polarization (Lp) effects and absorption corrections used the CrystalClear program. 37
The structures were solved by direct methods and subsequent Fourier difference
techniques, and refined anisotropically, by full-matrix least-squares, on F2 using
SHELXTL 6.10.38 The quantity minimized by the lest squares program was Σw(Fo2 Fc2)2 where w = 1/[σ2(Fo2) + (0.0646P)2 + 1.0966P] for 1, w = 1/[σ2(Fo2) + (0.0537P)2 +
3.3289P] for 2, w = 1/[σ2(Fo2) + (0.0768P)2 + 3.2106P] for 3, and P = (Fo2 + 2Fc2)/3. In
the final cycle of least squares, independent anisotropic displacement factors were refined
for the non-hydrogen atoms, and the methyl hydrogen atoms were fixed in idealized
positions with C-H = 0.96 Å. Their isotropic displacement parameters were set equal to
1.5 times Ueq of the attached carbon atom.
For complex 1, the largest peak in the final Fourier difference map (0.26 eÅ-3)
was located 1.20 A ° from Cl1, and the lowest peak (-0.28 eÅ-3) was located at a distance
of 0.86 Å from Cl1. For complex 2, the largest peak in the final Fourier difference map
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(0.66 eÅ-3) was located 0.77 A from Se1, and the lowest peak (-0.61 eÅ-3) was located at
a distance of 0.81 A from Se2. For 3, the largest peak in the final Fourier difference map
(0.22 eÅ-3) was located 1.41 Å from O1, and the lowest peak (-0.26 eÅ-3) was located at a
distance of 0.87 Å from S1. Final refinement parameters for the structures of 1, 2, and 3
are given in Table 5.3, and selected bond distances are summarized in Table 5.1.

Figure 5.4. Crystal packing diagram for 4,5-dichloro-1,3-dimethylimidazole thione (1) showing π-overlap
of the imidazole rings and Cl atoms.

Figure 5.5. Crystal packing diagram for 4,5-dichloro-1,3-dimethylimidazole selone (2).
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Table 5.3. Summary of crystallographic data for compounds 1, 2, and 3.
1
2
Chemical formula
C5H6Cl2N2S
C5H6Cl2N2Se
F.W. (g/mol-1)

197.08

243.98

616.79

Space group

P6522

P21/n

P21/n

Crystal system

hexagonal

monoclinic

Monoclinic

a,Å

8.5087(12)

11.872 (2)

16.574(3)

b,Å

8.5087(12)

14.261 (3)

8.6031(17)

c,Å

20.583(4)

15.506 (3)

23.214(5)

α, deg

90

90

90

β, deg

90

103.76(3)

92.89

γ, deg

90

90

90

V,Å

1290.5(4)

2549.8(9)

3305.8(11)

Z

6

12

4

Dcal, Mg/m3

1.522

1.907

1.239

indices (min)

[-10, -10, -19]

[-14, -17, -18]

[-19, -9, -27]

indices (max)

[10, 10, 24]

[11, 17, 18]

[19, 10, 27]

parameters

49

278

416

F(000)

600

1416

1304

μ, mm

0.924

4.973

0.134

2θ range, deg

2.76-25.14

1.97-25.25

2.46-25.25

collected reflections

8247

21802

27561

unique reflections

758

4607

5990

Final R (obs. Data)a, R1

0.0499

0.0447

0.0691

0.1329

0.113

0.1624

0.0525

0.054

0.0978

0.1351

0.121

0.1912

goodness of fit (S)

1.087

1.087

1.039

Absolute structure param. (Flack)

0.08 (31)

-

-

largest diff. Peak

0.259

0.656

0.216

-0.609

-0.259

-3

-1

wR

2

final R (all Data), R1
wR

2

largest diff. Hole
a

3
[C29H20N2S][C19H16O]

-0.283
R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR2 = {Σw(F02 - Fc2)2}1/2.
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CHAPTER SIX
SYNTHESIS AND CHARACTERIZATION OF IRON(II) AND ZINC(II)
COMPLEXES OF METHIMAZOLE AND ITS DERIVATIVES

6.1 Introduction
Methimazole, 2-mercaptoimidazole, and their substituted derivatives are of
interest due to their various biological and metal coordination properties.1-17
Ergothioneine (Figure 6.1) is a potent antioxidant, preventing oxidative damage to lipids,
proteins, and DNA.18-20 DFT and gel electrophoresis studies have shown that
ergothioneine-copper coordination prevents copper-mediated oxidative DNA damage by
inhibition of copper redox cycling.21,22 Methimazole (Figure 6.1) is a widely-prescribed
antithyroid drug that inhibits thyroid hormone synthesis.23 Imidazole-2-thione derivatives
have additional biological properties, including as a potentially new class of potent CCR2
antagonists for the treatment of thyroid disorders,24 inhibition of peroxidase-catalyzed
iodination reactions,1 and potent antioxidants for oxidative DNA damage prevention.17,25
Although imidazole-2-thione derivatization chemistry is well-explored, only recently

Figure 6.1. Representative thione and selone compounds and their oxidized dimers.
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have selenium analogs of these molecules been investigated.26-28 The selenium analog of
ergothioneine, selenoneine (Figure 6.1), was recently discovered in the blood of bluefin
tuna and humans with heavy tuna consumption in 5-10 nM concentrations.29 Selenoneine
binds iron(II) in hemoglobin and myoglobin, preventing iron(II) auto-oxidation.29 The
selenium analog of methimazole (MSeI; Figure 6.1) and its derivatives have also
attracted attention because of the greater nucleophilicity of selone-containing compounds
compared to their sulfur analogs,30-32 and these selones may inhibit thyroid peroxidase
(TPO) and lactoperoxidase (LPO) enzymes by a different mechanism than their sulfur
counterparts.7 Other investigations utilizing DNA gel electrophoresis have shown that
imidazole-2-thione and –selone derivatives are potent antioxidants, preventing metalmediated DNA by radical scavenging as well as iron and copper coordination.17
We have investigated the Fe(II) and Zn(II) coordination of methimazole and 2mercpatoimidazole because iron and zinc are the two most abundant d-block metal ions
in biological systems,33 and metal binding may contribute to their biological effects. In
addition, comparing the properties of these iron and zinc complexes will allow us to
determine the effect of redox activity of the metal ion on the ability of these metal-bound
thione complexes to generate and/or scavenge radical species. Methimazole and its
selenium analog (MSeI) oxidize to their respective disulfide and diselenide
compounds,4,7-9,34 but unlike their parent thiones and selones, the biological and
antioxidant effects of these disulfide (mimMe)2 and diselenide (seimMe)2 (Figure 6.1)
compounds have not been examined. We have investigated the coordination modes of
(mimH)2, (mimMe)2, and (seimMe)2 with Fe(II) and Zn(II) to investigate their potential
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antioxidant mechanisms and their metal binding properties.

6.2 Results and Discussion
Synthesis of Fe(II)- and Zn(II)-thione and -selone complexes. The syntheses of
iron and zinc thione and selone complexes 1, 2, and 3 are shown in Scheme 1. Treating
FeCl2·4H2O with two equivalents of methimazole (Scheme 6.1A) in a mixture of
dichloromethane and triethylorthoformate (to remove water from the Fe(II) starting
material) forms four-coordinate Fe(methimazole)2Cl2 (1) complexes in good yield (70%).
Complex 1 decomposes in air within 20 min in the solid state and within 2-5 min in
solution.
Scheme 6.1
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To compare the properties of analogous Fe2+ and Zn2+ complexes, Zn2+methimazole and 2-mercaptoimidazole complexes were also synthesized. Treating ZnCl2
with two equivalents of methimazole or 2-mercaptoimidazole in acetonitrile for 4 h forms
four-coordinate ZnL2Cl2 (L = methimazole (2) or 2-mercaptoimidazole (3) complexes in
83% yields (Scheme 6.1A). Unlike the iron methimazole complex 1, the zinc thione
complexes 2 and 3 are air-stable in the solid state and in solution.
Since methimazole and MSeI oxidize to form (mimR)2 and (seimR)2 (Figure 6.1),
Fe(II) and Zn(II) complexes of these oxidized disulfide and diselenide ligands were
synthesized. Treating FeCl2·4H2O with 1 equivalent of (mimH)2 in a mixture of methanol
and triethylorthoformate forms four-coordinate [(κ2-mimH)2]FeCl2 (4) in reasonable yield
(60%, Scheme 6.1B). Similar to the Fe(II) complex 1, complex 4 decomposes in air
within 20 min in the solid state and 2-5 min in solution. Complex 5 was similarly
synthesized in 53% yield (Scheme 6.1B) and is also air sensitive, decomposing within 30
min in the solid state and within 10 min in solution.
The analogous Fe(II) diselenide complex 6 was also synthesized by treating
FeCl2·4H2O with 1 equivalent of (κ2-seimMe)2 in a mixture of methanol and
triethylorthoformate (51%, Scheme 6.1B). Likely due to the greater oxophilicity of
selenium compared to sulfur, complex 6 is the most air-sensitive of the three iron(II)
compounds, decomposing in air within 2 min in the solid state and 60 s in solution.
Treating ZnCl2 with 1 equivalent of (mimMe)2 in a mixture of methanol and
triethylorthoformate yields [(κ2-mimMe)2]ZnCl2 (7, 53% Scheme 6.1B), analogous to the
Fe(II) complex 5. Zn(II) complex 7 is air-stable in the solid state and in solution.
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NMR spectroscopy. The paramagnetic 1H NMR spectrum of Fe(methimazole)2Cl2
(1) acquired in deuterated acetonitrile shows a large downfield shift of the methyl proton
resonance (δ 13.16) and large upfield shifts of the olefinic resonances (δ 0.87 and 5.42)
and the N-H resonance (δ 3.69) compared to unbound methimazole (Table 6.1). The large
shifts observed and broadening for all proton resonances upon iron coordination are
attributed to the paramagnetic effects of Fe2+.
In contrast, the diamagnetic 1H NMR spectrum of Zn(methimazole)2Cl2 (2)
acquired in deuterated dimethylsulfoxide shows no significant shifts of the methyl, two
olefinic, and N-H proton resonances (δ 3.42, 6.87, 7.06, and 12.07, respectively)
compared to unbound methimazole (Table 6.1).

The

1

H NMR spectrum of

Zn(2-mercaptoimidazole)2Cl2 (3) shows slight downfield shifts for both imidazole and NH proton resonances (δ 6.83 and 11.97, respectively) compared to unbound
2-mercaptoimidazole (δ 6.81 and 11.92, respectively). The slight downfield shift for all
proton resonances of Zn-thione complexes 2 and 3 demonstrate that bound methimazole
and 2-mercaptoinidazole slightly favor their zwitterionic resonance structures compared
to the unbound thiones.
The 13C{1H} NMR spectrum of iron complex 1 could not be obtained due to the
large paramagnetic effects of Fe2+. The

13

C{1H} NMR spectrum of the analogous zinc

complex 2 shows slight upfield resonance shifts for the methyl carbon (δ 33.6), the
olefinic carbons (δ 114.2 and 119.6), and the C=S carbon (δ 160.9) compared to unbound
methimazole (δ 33.9, 114.4, 119.8, and 191.5, respectively). The 13C{1H} NMR spectrum
of 3 shows no significant shifts of the olefinic carbon resonances (δ 116.0), and the C=S
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carbon (δ 160.8) compared to unbound 2-mercaptoimidazole.
The paramagnetic 1H NMR spectrum of [(κ2-mimH)2]FeCl2 (4) shows broad N-H
and imidazole proton resonances with significant shifting (δ 2.57, 1.99, and 2.10,
respectively) compared to the unbound disulfide (Table 6.1). Similar upfield shifts are
observed for the 1H NMR methyl and imidazole proton resonances of [(κ2-mimMe)2]FeCl2
(5) compared to unbound methimazole (Table 6.1). The 1H NMR spectrum of [(κ2seimMe)2]FeCl2 (6) is similar to its sulfur analog 5, in that both the methyl and imidazole
proton resonances are broadened and shifted upfield (δ 2.58, 1.26, and 1.25, respectively)
compared to that of unbound (seimMe)2 (δ 3.66, 7.05, and 7.15, respectively).
The 1H NMR spectrum for [(κ2-mimMe)2]ZnCl2 (7) is similar of that of the zincimidazole complex 2 in that the methyl and imidazole proton resonances are slightly
shifted downfield (δ 3.42, 6.87, and 7.06, respectively) compared to unbound (mimMe)2
Table 6.1. 1H NMR resonances for iron and zinc complexes 1 - 7.
Compound

δ CH3

δ CH

δ NH

Methimazole*
Fe(methimazole)2Cl2 (1)*

3.42
13.16

6.87, 7.05
0.87, 5.42

12.06
3.69

methimazole**

3.41

6.59, 7.05

12.05

Zn(methimazole)2Cl2 (2)**

3.42

6.87, 7.06

12.07

2-mercaptoimidazole**

-

6.81

11.92

Zn(2-mercaptoimidazole)2Cl2 (3)**

-

6.83

11.95

-

6.81

-

1.99, 2.10

3.42

6.87, 7.05

[(κ -mim )2]FeCl2 (5)*

2.26

0.87, 1.25

(seimMe)2*

3.66

7.05, 7.15

1.13

3.43,8.00

-

3.42

6.87, 7.05

-

[κ -mim )2]ZnCl2 (7)**
3.42
* 1H NMR spectrum acquired in CD3CN
** 1H NMR spectrum acquired in DMSO-d6

6.87, 7.06

-

H

(mim )2 *
2

H

[(κ -mim )2]FeCl2 (4)*
Me

(mim )2*
2

Me

2

Me 2

[(κ -seim ) ]FeCl2 (6)*
Me

(mim )2**
2

Me
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2.57
-

(Table 6.1).
13

C{1H} NMR for Fe(II) complexes 1, 4, 5, and 6 could not be obtained due to

the paramagnetic effects of the Fe(II) center. However, the

13

C{1H} NMR spectrum of

the zinc complex 7 shows very slight downfield shifts for the methyl (δ 34.0), imidazole
(δ 114.35 and 120.0), and quaternary (δ 161.4) carbon resonances compared to unbound
(mimMe)2 (δ 33.8, 114.1, 119.8 and 160.3, respectively).
Because NMR spectra of Fe(II)-thione complexes 1, 4, 5, and 6 show
paramagnetic contributions from the iron(II) center, it is not possible to evaluate thione or
selone ligand binding using this method. However, the 1H NMR and {1H}13C NMR
spectra of zinc complexes 2, 3, and 7 display little to no significant differences in the
resonance shifts of the bound thione ligands compared to the free thiones, indicating that
the zinc-bound thiones, while favoring their zwitterionic forms, do not significantly
increase in zwitterionic resonance character compared to the unbound thiones.
Infrared spectroscopy. Infrared spectroscopy was performed on iron and zinc
complexes 1-3 to determine the effects of metal binding on the C=S/Se bond strength.
The IR spectrum of Fe(methimazole)2Cl2 (1) shows a S=C stretching vibration at 1155
cm-1, slightly shifted to higher energy from unbound methimazole (1150 cm-1 35). Similar
to complex 1, the IR spectrum of Zn(methimazole)2Cl2 (2) also shows a slight shift of the
C=S stretching vibration to higher energy (1156 cm-1). In contrast, no significant shift is
observed for the C=S stretch of Zn(2-mercaptoimidazole)2Cl2 (3, 1153 cm-1) compared to
unbound 2-mercaptoimidazole (1151 cm-1). For the diselenide and disulfide complexes 4
– 7 the S-S stretching vibrations occur at 512 cm-1, typical for S-S bond vibrations
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(500-540 cm-1).
The slight increase in C=S stretching vibrations for complexes 1 and 2 is opposite
to that observed previously for Fe(dmit)2Cl2, [Fe(dmit)2(NCCH3)]2+, and [Fe(dmit)4]2+
complexes16 that have C=S stretching vibrations that shift to lower energy (1176 – 1178
cm-1) compared to unbound dmit (1181 cm-136). The IR data for complexes 1 - 3 suggest
that the thiones bind through primarily σ and π donation as previously observed for iron
(Chapter 2) and zinc (Chapter 4) binding.
Structural analysis of thione,disulfide, and diselenide complexes with iron and
zinc. Crystals of Fe(methimazole)2Cl2 (1), Zn(methimazole)2Cl2 (2) were grown via slow
diffusion of ether into acetonitrile solution, and crystals of [(κ2-mimH)2]FeCl2 (4),
[(κ2-mimMe)2]FeCl2 (5), and [(κ2-seimMe)2]FeCl2 (6) were grown via diffusion of ether
into methanolic solution. Single-crystal X-ray diffraction data were collected by Dr.
Collin McMillen (Department of Chemistry, Clemson University).

Selected bond

distances and angles for 1, 2, 4, 5, and 6 are summarized in Tables 6.2 and 6.3, and their
structures are shown in Figures 6.2 and 6.3.
The Fe(II) center in complex 1 adopts a distorted tetrahedral coordination
geometry with bond angles ranging from 112.89(3)° to 110.50(4)°. The Fe(II) center is
bound through the sulfur atoms of the thione, rather than through the available nitrogen
atom of the imidazole ring. The Fe-S bond distances of 2.344(2) Å, are similar to those of
reported Fe(II)-thione complexes (2.298(1) – 2.474(1) Å).15 Although 1 is similar in iron
coordination environment to Fe(dmit)2Cl2 (Chapter 2), the imidazole ring orientations are
different. The Fe(methimazole)2Cl2 (1) complex, when looking down the FeCl2 plane
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Figure 6.2. Crystal structure diagrams with 50% probability density ellipsoids for Fe(methimazole) 2Cl2 (1)
A) looking down the S-Fe-S plane and B) looking down the Fe-Cl plane and Zn(methimazole)2Cl2 (2) C)
looking down S-Zn-S plane and D) looking down Zn-Cl plane. Hydrogen atoms are omitted for clarity.
Table 6.2. Selected bond lengths and angles for complexes 1 and 2.
1
Fe1—S1

2
2.3442 (8)

Zn1—S1

2.3353 (13)

2.3442 (8)

Zn1—S2

2.3450 (14)

Fe1—Cl1

2.2856 (8)

Zn1—Cl2

2.2530 (13)

Fe1—Cl1i

2.2856 (8)

Zn1—Cl1

2.2602 (14)

S1—C1

1.718 (3)

S1—C1

1.709 (5)

1.718 (3)

S2—C5

1.714 (5)

Cl1—Fe1—Cl1i

110.50 (4)

Cl2—Zn1—Cl1

109.89 (5)

Cl1—Fe1—S1

112.89 (3)

Cl2—Zn1—S1

102.63 (5)

Cl1 —Fe1—S1

111.19 (3)

Cl1—Zn1—S1

115.24 (5)

i

111.19 (3)

Cl2—Zn1—S2

118.47 (5)

Cl1i—Fe1—S1i

112.89 (3)

Cl1—Zn1—S2

106.92 (5)

97.65 (4)

S1—Zn1—S2

103.90 (5)

Fe1—S1

i

S1 —C1

i

i

i

Cl1—Fe1—S1

S1—Fe1—S1

i

i symmetry operator for symmetrically equivalent atoms: -x, y, -z+2/3

(Figure 6.2B), is in the shape a “w” with the imidazole rings cis to one another, while
Fe(dmit)2Cl2 complex is in the shape of a “hook” with the imidazole rings trans to each
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other. For 1, the imidazole ring planes are inclined at 76.07°, and the ring centroids are
twisted at 12.79° to one another (measuring the centroid-S-S-centroid torsion angle).
Both rings are inclined at 53.54° relative to the FeCl2 group (the rings are related by
symmetry, so the angle is the same). For Fe(dmit)2Cl2 the ring planes are inclined at
65.59° to one another, and the ring centroids are twisted at 97.95° to one another.
Similarly to complex 1, its zinc counterpart 2 also crystallizes in a distorted
tetrahedral coordination geometry with bond angles ranging from 102.63(5)° to
118.47(5)°. The Zn-S bond distances of 2.335(1) Å and 2.345(1) Å are slightly shorter
compared to the previously synthesized Zn-thione complex Zn(dmit)2Cl2 (2.354(1) Å and
2.377(1) Å (Chapter 4) but similar to [Zn(dmit)4]2+ (2.339(1) Å and 2.357(1) Å.37
Changing the metal center from iron to zinc changes the solid state packing of the
complexes. Complex 1 packs in space group P2n which contains an inversion center,
whereas complex 2 packs in space group P212121 that does not contain an inversion
center. Unlike complex 1, complex 2 is in the shape of a “lightning bolt” with the
imidazole rings trans to each other when viewed down the FeCl2 plane, a packing effect
possibly caused by the methyl groups on the imidazole rings being cis to one another
(Figure 6.2C). In contrast, its iron counterpart 1 has the methyl groups trans to one
another (Figure 6.2A). This difference in the orientation of the imidazole rings when
compared to Zn(dmit)2Cl2 (Chapter 4) is the result of the absent methyl group on the
nitrogen atoms of the imidazole ring.
X-ray diffraction structures of the iron and zinc complexes with oxidized
methimazole and seleno-methimazole ligands (4 - 6) were also obtained (Figure 6.3), and
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selected bond lengths and angles are provided in Table 6.2. The iron(II) metal center in
[(κ2-mimMe)2]FeCl2 (4; Figure 6.3A) adopts a distorted tetrahedral geometry, with bond
angles ranging from 104.6(1)° to 123.96(6)° and is bound by two chloride atoms and two
nitrogen atoms within the imidazole rings of the [(κ2-mimMe)2] ligand. The Fe-N bond
distances are 2.074(4) Å and 2.075(4) Å, similar to the M-N bond lengths of
[(κ2-mimBut)2]MCl2 (M = Fe(II), Co(II), Zn(II), and Ni(II)) complexes (1.980(3) to
2.060(4) Å26) [(κ2-seimMes)2]MCl2 (M = Fe, Co, and Ni) complexes (2.004(4) to
2.0985(3) Å26). The S-S bond length of 2.066(2) Å is similar to the previously reported
[(κ2-mimMe)2]ZnCl2 complex and the unbound (κ2-mimMe)2 compound (2.069(1) Å38 and
2.085(2) Å,39 respectively).
The iron(II) center of [(κ2-mimH)2]FeCl2 (5; Figure 6.3B) also adopts a distorted
tetrahedral geometry with bond angles ranging from 104.00(9)° to 115.87(4)°. The S-S
bond length of 2.069(1) Å is similar to 4, previously reported [(κ2-mimBut)2]MCl2 (M =

A

B

C

Figure 6.3. Crystal structure diagrams with 50% probability density ellipsoids for A)

[(κ2-

mimH)2]FeCl2 (4), B) [(κ2-mimMe)2]FeCl2 (5), and C) [(κ2-seimMe)2]FeCl2 (6). Hydrogen atoms are
omitted for clarity.
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Table 6.3. Selected bond lengths and angles for complexes 4, 5, and 6.
4
5
Fe1—N3
2.076 (3)
Fe1—N3
2.074 (4)
Fe1—N1

6
2.073 (4)

Fe1—N1

2.082 (3)

Fe1—N1

2.075 (4)

Fe1—N3

2.075 (4)

Fe1—Cl1

2.2764 (11)

Fe1—Cl1

2.2647 (15)

Fe1—Cl1

2.2720 (16)

Fe1—Cl2

2.2809 (10)

Fe1—Cl2

2.2829 (15)

Fe1—Cl2

2.2922 (16)

S1—C1

1.755 (4)

S1—C1

1.756 (5)

Se1—C1

1.893 (5)

S2—C4

1.748 (4)

S2—C5

1.741 (5)

Se2—C5

1.887 (5)

S1—S2

2.0699 (14)

S1—S2

2.066 (2)

Se1—Se2

2.3433 (9)

N3—Fe1—N1

114.47 (12)

N3—Fe1—N1

109.87 (17)

N1—Fe1—N3

114.12 (16)

N3—Fe1—Cl1

108.42 (9)

N3—Fe1—Cl1

106.50 (13)

N1—Fe1—Cl1

104.10 (12)

N1—Fe1—Cl1

104.00 (9)

N1—Fe1—Cl1

104.64 (12)

N3—Fe1—Cl1

104.82 (13)

N3—Fe1—Cl2

105.24 (8)

N3—Fe1—Cl2

106.21 (12)

N1—Fe1—Cl2

104.15 (13)

N1—Fe1—Cl2

109.17 (9)

N1—Fe1—Cl2

105.26 (12)

N3—Fe1—Cl2

106.42 (13)

Cl1—Fe1—Cl2

115.87 (4)

Cl1—Fe1—Cl2

123.96 (6)

Cl1—Fe1—Cl2

123.65 (7)

C1—S1—S2

101.48 (12)

C1—S1—S2

101.59 (16)

C1—Se1—Se2

97.80 (14)

C4—S2—S1

102.33 (12)

C5—S2—S1

100.83 (18)

C5—Se2—Se1

97.70 (16)

Fe(II), Co(II), Zn(II), and Ni(II)) complexes (1.980(3) - 2.060(4) Å26), and the free
disulfide (mimMe)2 (2.085 (2) Å39). Although complexes 4 and 5 are similar in structure,
their space groups are different (Pbca and P21/c, respectively) due to the methylated
nitrogen within the imidazole rings of 4 altering the packing in the crystal system.
For the iron-selenide complex [(κ2-seimMe)2]FeCl2 (6; Figure 6.3C), the iron(II)
center also adopts a distorted tetrahedral geometry with bond angles ranging from
104.10(13)° to 123.64(6)°. The average Fe-N bond length of 2.074(4) Å is similar to the
average M-N bond lengths of [(κ2-seimMes)2]MCl2 (M = Fe(II), Co(II), and Ni(II))
complexes (2.004(4) to 2.0985(3) Å26). In addition, the Se-Se bond length of 2.343(1) Å
is similar to reported [(κ2-seimMes)2]MCl2 (M = Fe(II), Co(II), and Ni(II)) complexes
averaging Se-Se bond lengths of 2.312(1) to 2.3284(6) Å.26
Complexes 4 - 6 are isomorphous with each other and published [(κ2-
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mimBut)2]MCl2 complexes (M = Fe(II), Co(II), Ni(II), Zn(II)) and [(κ2-seimMes)2]MCl2 (M
= Fe(II), Co(II), Ni(II)) where (κ2-mimBut)2 and (κ2-seimMes)2 are bis(1-R-imidazol-2yl)disulfides (R = butyl) and diselenides (R = Mes). For complexes 4, 5, and 6, the [(κ2mimMe)2], [(κ2-mimH)2], and [(κ2-seimMe)2] ligands bind iron through the nitrogen atoms,
creating a seven-membered chelate ring. The disulfide or diselenide bond twists from one
imidazole ring to the other, intersecting the FeCl2 or ZnCl2 plane.
It is interesting to note that methimazole and 2-mercaptoimidazole bind to iron
and zinc through the sulfur atom rather than through the nitrogen atom in the imidazole
ring; this exclusive sulfur binding is also observed for other metal complexes.15 It is not
until the thiones become oxidized to the disulfide dimers that they bind to iron and zinc
through the imidazole nitrogens. This may be attributed to the tendency of the thiones to
exist in their zwitterionic resonance structures rather than their thione resonance
structures,16 increasing the partial negative charge on the sulfur atom and increasing their
metal binding affinity.

6.3 Conclusions
We have synthesized several novel Fe2+ and Zn2+-methimazole and 2mercaptoimidazole complexes to examine the metal binding properties of the current
thyroid drug methimazole and its derivatives. When bound to Zn2+, the thiones
methimazole and 2-meraptoimidazole show no significant increase or decrease intheir
zwitterionic character using 1H NMR spectroscopy. These thiones readily oxidize to form
their disulfide and diselenide dimers that coordinate readily through the available
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imidazole nitrogens to form seven-atom ring systems. However, Fe(II) and Zn(II)
complexes of methimazole and 2-mercaptoimidazole ligands bind solely through the
sulfur atoms rather than through these imidazole nitrogen atoms. Infrared spectroscopy of
the iron- and zinc-thione complexes 1 – 3 suggest metal coordination of the thiones is
primarily through σ and π donation as observed for M(dmit/dmise)2Cl2 and
[M(dmit/dmise)4]2+ (M = Fe(II) or Zn(II)) complexes (Chapters 2 and 4). Further
characterizationand reactivity studies of these complexes including electrochemical
studies and oxidation by H2O2, will aid in understanding the mechanisms by which
methimazole and its derivatives prevent metal-mediated oxidative DNA damage.

6.4 Experimental Methods
General procedures. The synthesis and handling of all iron complexes were
carried out under an inert atmosphere of nitrogen or argon using standard glove-box and
Schlenk techniques. The following reagents were used as received: diethyl ether (Acros),
hydrated iron(II) chloride (Acros), zinc(II) chloride (Alfa Aesar), methimazole (Acros),
and 2-mercaptoimidazole (Acros).
Instrumentation.

1

H and

13

C{1H} NMR spectra were obtained on Bruker-

AVANCE 300 MHz and 500 MHz NMR spectrometers. 1H and 13C{1H} NMR chemical
shifts are reported in δ relative to tetramethylsilane (δ 0) and referenced to solvent.
Infrared spectra were obtained using Nujol mulls on KBr salt plates with a Magna 550 IR
spectrometer. Abbreviations used in the description of vibrational data are as follows: vs,
very strong; s, strong; m, medium; w, weak; b, broad. MALDI mass spectrometry

197

experiments were performed using a Bruker Microflex MALDI-TOF mass spectrometer
with trans-2-3-(4-tert-butylphenyl)-2-methyl-2-propenyldiene (m/z 250.3) as the matrix.
Synthesis of Fe(methimazole)2Cl2 (1). FeCl2·4H2O (168 mg, 0.845 mmol) was
dissolved in triethylorthoformate/dichloromethane 1:1 (10 mL), and to this solution was
added a solution of methimazole (192 mg, 1.68 mmol) in dichloromethane (10 mL) via
cannula. The reaction mixture was stirred for 2 h, the solvent was reduced to ~5 mL, and
diethyl ether (20 mL) was added to precipitate Fe(methimazole)2Cl2 (1) from solution.
The mixture was filtered, washed with diethyl ether (10 mL × 3), and dried under
vacuum to afford Fe(methimazole)2Cl2 (1) as a beige solid. Crystals for X-ray analysis
were grown via slow vapor diffusion of ether into acetonitrile yielding colorless crystals.
Yield: 225 mg, 75%. 1H NMR (CD3CN): δ 13.16 (s, 3H, CH3), 5.42 (s, 1H, CH) 0.87 (s,
1H, CH), and 3.69 (s, 1H, NH). IR (cm-1): 3338 (b), 3156 (s), 3128 (s), 2926 (b), 1707
(w), 1611 (w), 1506 (s), 1456 (s,b), 1377 (s), 1346 (s), 1279 (s), 1243 (w), 1154 (s), 1096
(s), 1081 (s), 1017 (w), 919 (m), 859 (w), 750 (s), 687 (w), 668 (s), 605 (w), 512 (s).
MALDI-MS (m/z): [Fe(C4H6N2)Cl2]H+ 239.9, [Fe(C4H6N2)2Cl2]H+ 354.8. Anal. Calcd.
For C8H12Cl2FeN4S2: C, 27.06; N, 15.78; H, 3.41. Found: C, 27.12; N, 15.74; H, 3.39.
Melting point: 160 ˚C (dec).
Synthesis of Zn(methimazole)2Cl2 (2). ZnCl2 (112 mg, 0.823 mmol) was dissolved
in acetonitrile (20 mL), and to this solution was added a solution of methimazole (186
mg, 1.64 mmol) in acetonitrile (10 mL) via cannula. The reaction mixture was stirred for
2 h, the solvent was reduced to ~5 mL, and diethyl ether (20 mL) was added to
precipitate Zn(methimazole)2Cl2 (2) from solution. The mixture was filtered, washed with
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diethyl ether (10 mL × 3), and dried under vacuum to afford Zn(methimazole)2Cl2 (2) as
a white solid. Crystals for X-ray analysis were grown via diffusion of ether into
acetonitrile. Yield: 249 mg, 83%. 1H NMR ((CD3)2SO): δ 3.42 (s, 3H, CH3), 6.87 (d, J HH
= 2.4 MHz, 1H, CH), 7.06 (d, J

HH

= 2.4 MHz, 1H, CH), 12.09 (s, 1H, NH).

13

C{1H}

NMR ((CD3)2SO): δ 33.5 (CH3), 114.2 (CH), 119.6 (CH), 160.9 (C=S). IR (cm-1): 3233
(b), 3136 (w), 2926 (s,b), 2855 (s), 1675 (w), 1575 (s), 1463 (s), 1405 (w), 1377 (m),
1282 (w), 1254 (w), 1156 (m), 1086 (m), 1017 (w), 920 (w), 839 (w), 750 (w), 730 (s),
685 (w), 669 (w), 517 (w). MALDI-MS (m/z) = [Zn(C4H6N2S)Cl2]H+ 249.9,
[Zn(C4H6N2S)2Cl2]H+ 364.1. Anal. Calcd. For C8H12Cl2N4S2Zn: C, 26.35; N, 15.37; H,
3.32. Found: C, 26.23; N, 15.42; H, 3.28. Melting point: 160-163°C.
Synthesis of Zn(2-mercaptoimidazole)2Cl2 (3). ZnCl2 (112 mg, 0.823 mmol) was
dissolved in acetonitrile (20 mL) and to this solution was added a solution of 2mercaptoimidazole (186 mg, 1.64 mmol) in acetonitrile (10 mL) via cannula. The
reaction mixture was stirred for 12 h, and the volume was reduced to ~5 ml in vacuo.
Zn(2-mercaptoimidazole)2Cl2 (3) was precipitated from solution by addition of diethyl
ether (20 mL). The mixture was filtered, washed with diethyl ether (10 mL × 2), and
dried under vacuum to afford Zn(2-mercaptoimidazole)2Cl2 (3) as a beige solid. Crystals
for X-ray analysis were grown via diffusion of ether into acetonitrile. Yield: 83%. 1H
NMR ((CD3)2SO): δ 6.83 (s, 2H, CH), 11.95 (s, 1H, NH).

13

C{1H} NMR ((CD3)2SO):

116.0 (CH), 160.8 (C=S). IR (cm-1): 3233 (b), 3136 (w), 2926 (s,b), 2855 (s), 1675 (w),
1575 (s), 1463 (s), 1405 (w), 1377 (m), 1282 (w), 1254 (w), 1156 (m), 1086 (m), 1017
(w), 920 (w), 839 (w), 750 (w), 730 (s), 685 (w), 669 (w), 517 (w). MALDI-MS (m/z):
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[Zn(C3H4N2S)2Cl]H+

299.9,

[Zn(C3H4N2S)2Cl2]H+

334.9.

Anal.

Calcd.

For

C6H8Cl2N4S2Zn: C, 21.41; N, 16.65; H, 2.40. Found: C, 21.38; N, 16.58; H, 2.37.
Melting point: 156-158°C.
Synthesis of [(κ2-mimH)2]FeCl2 (4). FeCl2·4H2O (182 mg, 0.845 mmol) was
dissolved in triethylorthoformate/methanol 1:1 (10 mL) and to this was added a solution
of (mimH)2 (192 mg, 0.845 mmol) in methanol (10 mL) via cannula. The reaction mixture
was stirred for 2 h, the solvent was evaporated under vacuum to ~5 mL, and the product
was precipitated from solution by addition of diethyl ether (20 mL). The mixture was
filtered, washed with diethyl ether (10 mL x 3), and dried under vacuum to afford [(κ2mimH)2]FeCl2 (4) as a beige solid. Crystals for X-ray analysis were grown via slow vapor
diffusion of dichloromethane into acetonitrile solution. Yield: 60%. 1H NMR (CD3CN): δ
6.83 (s, 2H, CH), 11.95 (s, 1H, NH). IR (cm-1): 3306 (m), 3197 (s), 3171 (w), 3137 (w),
2926 (b), 2361 (w), 2342 (w), 1710 (w), 1691 (w), 1580 (s), 1466 (s), 1407 (s), 1377 (s),
1276 (w), 1220 (m), 1155 (w), 1116 (w), 1066 (m), 954 (w), 913 (w), 844 (w), 759 (s),
736 (s), 688 (w), 671 (s), 512 (w), 492 (m). MALDI-MS (m/z) = [Fe(C6H6N4S2)Cl2]H+
324.9. Anal. Calcd. For C6H6Cl2FeN4S2: C, 22.17; N, 17.24; H, 1.86. Found: C, 22.09; N,
17.17; H, 1.92. Melting point: 168 °C (dec.).
Synthesis of [(κ2-mimMe)2]FeCl2 (5). FeCl2·4H2O (168 mg, 0.845 mmol) was
dissolved in triethylorthoformate/methanol 1:1 (10 mL) and to this was added (mim Me)2
(191 mg, 0.845 mmol) in methanol (10 mL) via cannula. The reaction mixture was stirred
for 12 h, the solvent was evaporated under vacuum to ~5 mL, and the product was
precipitated from solution by addition of diethyl ether (20 mL). The mixture was filtered,
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washed with diethyl ether (10 mL × 2), and dried under vacuum to afford [(κ2mimMe)2]FeCl2 (5) as a beige solid. Crystals for X-ray analysis were grown via slow
vapor diffusion of ether into methanol yielding yellow/olive green crystals. Yield: 56%
1

H NMR (CD3CN): δ 2.26 (s, 3H, CH3), 1.25 (s, 1H, CH), 0.87 (s, 1H, CH). IR (cm-1):

3338 (b), 3156 (s), 3128 (s), 2926 (b), 1707 (w), 1611 (w), 1506 (s), 1456 (s,b), 1377 (s),
1346 (s), 1279 (s), 1243 (w), 1154 (s), 1096 (s), 1081 (s), 1017 (w), 919 (m), 859 (w),
750 (s), 687 (w), 668 (s), 605 (w), 512 (s). MALDI-MS (m/z): [Fe(C8H11N4S2)Cl]+ 317.1
and [Fe(C8H11N4S2)Cl2]H+ 352.0. Anal. Calcd. For C8H10Cl2FeN4S2: C, 27.21; N, 15.87;
H, 2.85. Found: C, 27.19; N, 15.92; H, 2.91. Melting point: 170°C (dec).
Synthesis of [(κ2-seimMe)2]FeCl2 (6). FeCl2·4H2O (168 mg, 0.845 mmol) was
dissolved in triethylorthoformate/methanol 1:1 (10 mL) and to this was added (seimMe)2
(270 mg, 0.845 mmol) in methanol (10 mL) via cannula. The reaction mixture was stirred
for 2 h, the solvent was reduced under vacuum to ~5 mL, and the product was
precipitated from solution by addition of diethyl ether (20 mL). The mixture was filtered,
washed with diethyl ether (10 mL × 2), and dried under vacuum to afford [(κ2seimMe)2]FeCl2 (6) as a beige solid. Crystals for X-ray analysis were grown via slow
vapor diffusion of ether into methanol yielding yellow-green crystals. Yield: 51% 1H
NMR (CD3CN): δ 1.13 (s, 3H, CH3), 3.43 (s, 1H, CH), 8.00 (s, 1H, CH). IR (cm-1): 3338
(b), 3156 (s), 3128 (s), 2926 (b), 1707 (w), 1611 (w), 1506 (s), 1456 (s,b), 1377 (s), 1346
(s), 1279 (s), 1243 (w), 1154 (s), 1096 (s), 1081 (s), 1017 (w), 919 (m), 859 (w), 750 (s),
687 (w), 668 (s), 605 (w), 512 (s). MALDI-MS (m/z): [Fe(C8H11N4Se2)Cl]+ 412.9 and
[Fe(C8H11N4Se2)Cl2]H+ 448.6. Anal. Calcd. For C8H10Cl2FeN4S2: C, 27.21; N, 15.87; H,
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2.85. Found: C, 27.19; N, 15.92; H, 2.91. Melting point: 162°C (dec).
Synthesis of [(κ2-mimMe)2]ZnCl2 (7). ZnCl2 (168 mg, 0.845 mmol) was dissolved
in triethylorthoformate/methanol 1:1 (10 mL) and to this was added (κ2-mimMe)2 (191
mg, 0.845 mmol) in methanol (10 mL) via cannula. The reaction mixture was stirred for 2
h, the solvent was reduced under vaccum to ~5 mL, and [(κ2-mimMe)2]ZnCl2 (7) was
precipitated from solution by addition of diethyl ether (20 mL). The mixture was filtered,
washed with diethyl ether (10 mL x 2), and dried under vacuum to afford [(κ2mimMe)2]ZnCl2 (7) as a beige solid (52%). Crystals for X-ray analysis were grown via
slow vapor diffusion of ether into ethanol yielding yellow/olive green crystals. 1H NMR
((CD3)2SO): δ 3.17 (s, 3H, CH3), 6.86 (s, 1H, CH), 7.05 (s, 1H, CH). IR (cm-1): 3338 (b),
3156 (s), 3128 (s), 2926 (b), 1707 (w), 1611 (w), 1506 (s), 1456 (s,b), 1377 (s), 1346 (s),
1279 (s), 1243 (w), 1154 (s), 1096 (s), 1081 (s), 1017 (w), 919 (m), 859 (w), 750 (s), 687
(w), 668 (s), 605 (w), 512 (s). MALDI-MS (m/z): [Zn(C8H11N4S2)Cl2]H+ 360.1. Anal.
Calcd. For C8H10Cl2ZnN4S2: C, 27.21; N, 15.87; H, 2.85. Found: C, 27.19; N, 15.92; H,
2.91. Melting point: 160°C.
Single crystal X-ray data collection. Crystals of Fe(methimazole)2Cl2 (1),
Zn(methimazole)2Cl2 (2) were grown via slow diffusion of ether into acetonitrile
solution, and [(κ2-mimH)2]FeCl2 (4), [(κ2-mimMe)2]FeCl2 (5), and [(κ2-seimMe)2]FeCl2 (6)
were grown via diffusion of ether into methanol solution. Single crystal X-ray diffraction
data were collected for Fe(methimazole)2Cl2 (1), which crystallized as colorless plates
Zn(methimazole)2Cl2 (2), which crystallized as colorless prisms, [(κ2-mimH)2]FeCl2 (4),
which crystallized as yellow plates, [(κ2-mimMe)2]FeCl2 (5), which crystallized as yellow
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plates, and [(κ2-seimMe)2]FeCl2 (6), which crystallizes as orange plates. The crystals were
mounted on a glass filament with epoxy glue, and immediately placed on the
diffractometer in a room-temperature nitrogen gas stream. Intensity data were collected
using a Rigaku Mercury CCD detector and an AFC8S diffractometer. The space groups
P2n, P212121, and Pbca were determined from the systematic absences for complexes 1,
2, and 4 respectively (Table 6.4). The space groups Pbca and Pbca were determined from
the systematic absences for complexes 5 and 6 (Table 6.5). Data reduction including the
application of Lorentz and polarization effects and absorption corrections was performed
using the CrystalClear program. The structures were solved by direct methods and
subsequent Fourier difference techniques, and refined anisotropically, by full-matrix least
squares, on F2 using SHELXTL 6.10.40 The quantity minimized by the least squares
program was Σw = (Fo2 - Fc2)2 where w = {[σ2(Fo2)] + (0.0307P)2 + 1.57P} where P =
(Fo2)+2Fc2)/3. In the final cycle of least squares, independent anisotropic displacement
factors were refined for the non-hydrogen atoms, and hydrogen atoms were fixed in
idealized positions with C—H = 0.96 Å. Isotropic hydrogen atom displacement
parameters were set equal to 1.5 times Ueq of the attached carbon atom.
For 1 the largest peak in the final Fourier difference map (0.46 e A-3) was located
1.85 Å from H4C and the lowest peak (-0.33 e∙A-3) was located at a distance of 1.11 Å
from N1. For 2 the largest peak in the final Fourier difference map (0.44 e∙A-3) was
located 1.47 Å from Zn1 and the lowest peak (-0.39 e∙A-3) was located at a distance of
0.94 Å from Zn1. For 3 the largest peak in the final Fourier difference map (0.51 e A-3)
was located 0.92 Å from Cl1 and the lowest peak (-0.42 e∙A-3) was located at a distance
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of 0.85 Å from Zn1. For 4 the largest peak in the final Fourier difference map (0.51 e∙A-3)
was located 0.92 Å from Cl1 and the lowest peak (-0.42 e∙A-3) was located at a distance
of 0.85 Å from Fe1. For 5 the largest peak in the final Fourier difference map (0.51 e∙A-3)
was located 0.92 Å from Cl1 and the lowest peak (-0.42 e∙A-3) was located at a distance
of 0.85 Å from Fe1. For 6 the largest peak in the final Fourier difference map (0.51 e∙A-3)
was located 0.92 Å from Cl1 and the lowest peak (-0.42 e∙A-3) was located at a distance
of 0.85 Å from Fe1.
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Table 6.4. Summary of crystallographic data for complexes 1, 2, and 4.
1

2

4

C8H12Cl2FeN4S2

C8H12Cl2N4S2Zn

C6H6N4S2Cl2Fe

F.W. (g/mol )

355.09

364.61

325.02

Space group

P21/n

P21/c

Pbca

Crystal system

Monoclinic

Orthorhombic

Monoclinic

a,Å

6.6906 (13)

7.7787 (16)

6.8467 (14)

b,Å

8.5246 (17)

13.415 (3)

12.133 (2)

c,Å

12.896 (3)

13.649 (3)

15.242 (4)

α, deg

90

90

90

β, deg

95.42(3)

90

116.68 (2)

γ, deg

90

90

90

V,Å-3

732.2 (3)

1424.3 (5)

1131.4 (4)

2

4

4

Dcal, mg/m

1.611

1.7

1.908

indices (min)

[-6, -10, -15]

[-9, -16, -16]

[-7, -14, -18]

indices (max)

[8, 10, 15]

[9, 16, 16]

[8, 14, 18]

parameters

79

156

137

F(000)

360

736

648

μ, mm-1

1.663

2.375

2.143

2θ range, deg

2.39 - 25.24

2.13 - 25.25

2.25 - 25.23

collected reflections

5665

11529

9306

unique reflections

1320

2579

2044

Final R(obs. data) , R1

0.0316

0.036

0.0289

wR2

0.0786

0.0846

0.0777

final R(all data), R1

0.0355

0.0421

0.0308

0.0827

0.0888

0.0799

goodness of fit (S)

1.108

1.162

1.157

largest diff. peak

0.459

0.438

0.506

Chemical formula
-1

Z
3

a

wR

2

largest diff. hole
-0.334
-0.39
a
R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR2 = {Σw(F02 - Fc2)2}1/2.
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-0.401

Table 6.5. Summary of crystallographic data for complexes 5 and 6.
5

6

C8H10Cl2FeN4S2

C8H10Cl2FeN4Se2

F.W. (g/mol )

353.04

446.87

Space group
Crystal system

Pbca
Orthorhombic

Pbca
Orthorhombic

a,Å

8.5009 (17)

8.2950 (17)

b,Å

13.183 (3)

13.646 (3)

c,Å

24.812 (5)

25.385 (5)

α, deg

90

90

β, deg

90

90

γ, deg

90

90

V,Å-3

2778.5 (10)

2873.5 (10)

8

8

Dcal, mg/m

1.688

2.066

indices (min)

[-10, -15, -29]

[-9, -16, -28]

indices (max)

[10, 15, 29]

[9, 16, 30]

parameters

156

157

F(000)

1424

1712

μ, mm-1

1.752

6.471

2θ range, deg

2.90 - 25.15

2.93 - 25.25

collected reflections

20889

20137

unique reflections

2485

2583

Final R(obs. data) , R1

0.0524

0.03394

wR2

0.1225

0.0964

final R(all data), R1

0.0681

0.0431

wR2

0.1338

0.0997

goodness of fit (S)
largest diff. peak

1.113
0.577

1.124
0.513

Chemical formula
-1

Z
3

a

largest diff. hole
-0.463
-0.558
a
2
2 2 1/2
R1 = Σ ǁ F0| - |Fcǁ/Σ|F0|; wR2 = {Σw(F0 - Fc ) }
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CHAPTER SEVEN
SYNTHESIS, CHARACTERIZATION, AND REACTIVITY OF IRON(II)AND ZINC(II) COMPLEXES OF IMIDAZOLE THIONE AND SELONE
LIGANDS: INVESTIGATIONS INTO OXIDATION MECHANISMS
7.1 Conclusions
Metal-mediated oxidative DNA damage is an underlying cause of many diseases
and becomes very prevalent under oxidative stress conditions.1-5 During oxidative stress,
reactive oxygen species (ROS) production increases such that cellular antioxidants cannot
scavenge them effectively, leading to increased oxidative DNA damage.1-5 To protect
cells from increased ROS production, multifunctional antioxidants have become a topic
of particular interest. Studies have determined that sulfur- and selenium-containing amino
acids and their derivatives effectively prevent Fe(II)- and Cu(I)-mediated oxidative DNA
damage primarily by metal coordination rather than hydroxyl radical scavenging.6-10
Initial interest in antioxidant thiones and selones and their derivatives has arisen from the
discovery of the antioxidant properties of naturally occurring ergothioneine and
selenoneine.11-17 ROS scavenging as well as iron and copper coordination by thione and
selone compounds are responsible for their prevention of DNA damage, but
understanding this novel multifunctional antioxidant activity is lacking, since few iron(II)
complexes with thione and selone ligands are reported.18
N,N’-dimethylimidazole thione (dmit), N,N’-dimethylimidazole selone (dmise),
ethyl-bis(imidazole) thione (ebit), and ethyl-bis(imidazole) selone (ebis) readily bind
Fe(II) in a variety of coordination environments (Chapter 2).19 DFT calculations and 1H
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and

13

C{1H} NMR results demonstrate an increase in zwitterionic character when these

thione and selone ligands are bound to Fe(II). Electrochemical studies revealed that
although Fe(III/II) redox potentials of these iron-thione and -selone complexes fall within
the ability of biological reductants to reduce Fe(III) to Fe(II) (-0.32 V vs. NHE)20 the
thione and selone ligands in these Fe(II) complexes have significantly higher oxidation
potentials than the corresponding Fe(II/II)-derived potentials as well as their unbound
thione and selone compounds.19 These higher ligand-based oxidation potentials suggest
that the bound thiones and selones should undergo sacrificial oxidation and protect Fe(II)
from oxidation to Fe(III).
Since these electrochemical studies of Fe(II)-dmit and –dmise complexes suggest
the ligands would undergo sacrificial oxidation prior to Fe(II) oxidation to Fe(III)
(Chapter 2),19 Fe(dmit)2Cl2 and Fe(dmise)2Cl2 complexes were treated with multiple
equivalents of H2O2 (Chapter 3). 1H NMR specteroscopic examination of Fe(dmit)2Cl2
and Fe(dmise)2Cl2 after H2O2 oxidation identified sacrificial oxidation of dmit and dmise
ligands to afford the imidazolium cation. Similar reactivity of dmit and dmise and
formation of imidazolium was also observed upon treating [Tpm*Cu(dmit/dmise)]+ with
H2O2, demonstrating similar metal-coordination antioxidant mechanisms for dmit and
dmise. Mass spectrometry examination of the oxidized products indicate formation of the
imidazolium cation and oxidized sulfur or selenium species. The major iron-containing
products of Fe(dmit)2Cl2 oxidation by H2O2 is the Fe(III) species [FeCl4]- (m/z 197.91),
demonstrating that dmit does not protect Fe(II) from oxidation. However, when
Fe(dmise)2Cl2 is treated with H2O2, the Fe2+ is protected from oxidation by sacrificial
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oxidation of the selone ligand. Thus, dmit and dmise undergo facile oxidation when
bound to iron(II), but presence of dmise ligands protects Fe(II) from oxidation more than
dmit coordination.
Since zinc does not participate in production of metal-mediated ROS,
Zn(dmit/dmise)2Cl2

[Zn(dmit/dmise)4]2+

and

complexes

were

synthesized

and

characterized. Zn(dmit/dmise)2Cl2 complexes were also treated with H2O2 and these
results compared to oxidation of the analogous Fe(II) complexes to investigate the role of
redox-active metal centers in metal-binding thione and selone antioxidant activity
(Chapter 4). The 1H and

13

C{1H} NMR spectra of zinc(II)-dmit and -dmise complexes

show very slight downfield shifts for both methyl and olefinic proton resonances
compared to unbound dmit and dmise, indicating a very slight increase in zwitterionic
character when bound to Zn(II), similar to that observed for analogous Fe(II)complexes.19
Electrochemical studies of Zn(II)-thione and –selone complexes demonstrate that when
bound to Zn(II), the dmit- and dmise-based oxidation potentials become more negative
by an average of 0.06 V compared to free dmit and dmise. This decrease in ligand
oxidation potential indicates that dmit and dmise are less readily oxidizable when bound
to Zn(II), a trend opposite to that observed for analogous Fe(II)-dmit and dmise
complexes.19 The 1H NMR spectrum of Zn(dmise)2Cl2 upon treatment with H2O2
indicates imidazolium formation similar to that observed for oxidation of Fe(II)-dmise
complexes (Chapter 3). However, after treatment of Zn(dmit)2Cl2 with H2O2,
imidazolium is observed in addition to oxidized [dmit(OH)]H+ and [dmit(OH)3]- species
and sulfur oxide species as determined by mass spectrometry. Mass spectrometry also
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indicates formation of the Zn(II)-containing species, [ZnCl3]-, for both Zn(dmit)2Cl2 and
Zn(dmise)2Cl2 oxidation by H2O2. These results indicate that C-S cleavage does not
always occur upon zinc-bound dmit oxidation, in contrast to the results observed upon
hydrogen peroxide oxidation of the analogous Fe(II) complex.
Since dmit, dmise, methimazole, and 2-mercaptoimidazole are potent antioxidants
that prevent iron- and copper-mediated DNA damage,10 we have synthesized novel
thione- and selone-containing derivatives (Chapter 5). The newly synthesized
4,5-dichloro-1,3-dimethylimidazole thione and selone compounds have S/Se=C bond
lengths on average 0.021 Å shorter than the C=S/Se bonds of dmit and dmise, indicating
a decrease in zwitterionic character as compared to dmit and dmise. This decrease in
zwitterionic character may decrease their metal-binding affinity. We have also discovered
a novel synthetic route for the addition of substituents onto the protonated nitrogen of
methimazole to affording novel thione compounds. Use of trityl as a thione protecting
group enables non-air sensitive synthetic techniques to be utilized as well as a simple
purification route for the synthesis of novel thione derivatives. In addition,
trityl-protected methimazole allows addition of aliphatic substituents not previously
achievable by nucleophilic methods and also blocks metal coordination to the sulfur
atom, forcing coordination through the nitrogen atom of the imidazole ring, a binding
mode not observed for methimazole. The novel synthetic route utilizing trityl protection
of thiones as well as the synthesis of novel thione and selone derivatives has allow us to
expand our catalog of imidazaole thione and selone compounds and future derivatives
that previous synthetic methods would not afford.
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Methimazole, a current drug for treating hyperthyroidism,22 is a potent antioxidant
that prevents iron- and copper-mediated oxidative DNA damage.10,23,24 We have
synthesized Fe(II) and Zn(II) complexes of methimazole and and its derivatives to
understand how metal coordination may affect their potential biological activity (Chapter
6).

X-ray crystallographic structures show that methimazole coordinates Fe(II) and

Zn(II) through its S atom rather than through the N atom of the imidazole ring. NMR and
IR results indicate that metal coordination of these ligands primarily occurs through
sigma- and pi-donor interactions and results in an increase in zwitterionic ligand
character, as reported for dmit (Chapter 2). Since methimazole and its selenium analog
oxidize to their respective disulfide and diselenide compounds, Fe(II) complexes of these
oxidized (mimH)2, (mimMe)2, and (seimMe)2 ligands and Zn(II) complexes of (mimMe)2
were synthesized. Upon zinc coordination, these oxidized disulfide and diselenide ligands
bind through their N atoms, forming seven membered ring systems. Studies of these iron
and zinc complexes of methimazole and related ligands provide insight into the possible
metal coordination of these biologically relevant thione and selone antioxidants.
Thiones and selones coordinate solely through the sulfur or selenium atoms via σ
and π bond donation and favor their zwitterionic resonance forms when coordinated to
Fe(II) and Zn(II). The mechanism of dmit oxidation is dependent upon metal
coordination; however, the mechanism of dmise oxidation is not, and dmise undergoes
sacrificial oxidation with cleavage of the C=Se bond when bound to Cu(I), Fe(II), and
Zn(II). A new synthetic route utilizing trityl protection of thiones may enable synthesis of
novel thione derivatives unachievable using previous methods. This work has expanded
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our understanding of thione and selone antioxidant mechanisms and their ability to
coordinate the biologically relevant metals iron and zinc.
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